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ABSTRACT 
The presence of memory B cells may contribute to graft damage. In fact, pre-transplant B 
cell sensitization in the absence of circulating antibody represents a risk factor, since 
grafts transplanted into recipients with historical positive but current negative direct 
crossmatch do less well than patients with no evidence of B cell sensitisation. This 
definition of ‘negative’ is based on conventional complement-dependent cytotoxicity 
(CDC) assays and, more recently, on flow cytometry. In this study, I have analysed the 
significance of antibodies undetectable by these conventional techniques but found to be 
present using the more sensitive novel Luminex technology which has now become 
available to detect class I and class II HLA-specific antibodies present in pre-transplant 
patients’ sera at the time of transplantation. Even in the absence of low level antibodies, 
there may still be undetected B cell sensitization. An ELISpot assay has previously been 
developed to quantitate B cell responses. In this study, I have developed the ELISpot 
assay in an attempt to determine B cell allosensitization.  
 
This project aims were:  
1. To evaluate the relationship between renal transplant outcome and the presence of 
low grade HLA-specific IgG-antibodies pre-transplant, both non-donor-specific as 
well as donor-specific antibodies detected using Luminex technology. 
2. To develop ELISpot assays that detect the potential responses of the various cells of 
the B cell compartment, reflecting naive allo-reactivity as well as that which has 
been induced by historical sensitisation events. 
3. To detect the presence of post-transplant HLA-specific IgG antibodies (both donor-
specific and non-donor specific) in tolerant drug-free patient and determine their 
significance in defining the state of tolerance. 
 
Summary of the results: 
 
1. Luminex technology is a more sensitive technique than flow cytometry and CDC in 
detecting low-level donor-HLA-specific antibodies which were present in pre-
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transplant patients’ sera at the time of transplantation and is associated with a higher 
incidence of rejection episodes. 
2. IgM- and IgG-detecting ELISpot assays were developed to determine the frequency 
of antibody-secreting cells. I have begun to apply these methods to determine the 
humoral reactivity against alloantigen in sensitised patients. 
3. Tolerant drug-free patients had no detectable donor-specific antibodies (DSA). In the 
non-tolerant patients, DSA-positive patients had worse graft function than DSA-
negative patients. 
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1.1.  Introduction  
Transplantation has become the treatment of choice for many patients with end-stage 
organ failure (Wolfe et al. 1999; Valderrabano et al. 2001; Liem et al. 2007) while the 
number of individuals on the waiting list to receive an organ donation has increased 
exponentially, the demand has not been met due to difficulties with organ procurement 
and the immunological rejection response. Those individuals who are lucky enough to 
undergo organ transplantation are still faced with many challenges, such as graft rejection 
and a chronically suppressed immune system associated with an increased rate of 
infection and malignant disorders (Zhang et al. 2004). 
 
Graft rejection may develop when the transplant recipient's immune system attacks a 
transplanted organ or tissue. The host's immune system regards the graft as foreign and 
launches cell-mediated and humoral responses against specific antigens present in the 
donor tissue.   
1.2.  Histocompatibility antigens 
It is useful to divide the antigens that are the targets of a graft rejection response into 
three broad categories: antigens derived from the major histocompatibility complex 
(MHC), minor histocompatibility antigens and ABO-blood group antigens.   
1.2.1.  Major Histocompatibility Complex (MHC) antigens 
In humans, the genes that code for MHC proteins are found on chromosome 6 and are 
known as the HLA antigens (HLA was originally an acronym for ‘human leukocyte 
antigen’) (Klein and Sato 2000a; Klein and Sato 2000b). The MHC encodes a group of 
highly diverse cell surface proteins; these are the principal determinants of graft rejection. 
The MHC can be divided into 3 regions I, II, and III. The MHC or HLA class I molecules 
are heterodimers of an α chain and a non-polymorphic molecule (not encoded in the 
MHC) β2 micro-globulin. The α chain forms a peptide-binding cleft in its membrane-
distal domain, where the walls consist of two α-helices and the floor is a β-pleated sheet. 
The class II molecules are heterodimers of an α and a β polypeptide chain, but here both 
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the α and the β chains contribute to the peptide-binding cleft (Klein and Sato 2000a) (See 
Figure 1). 
Class I Class II
Peptide‐binding  groove
α1 β1
β2α2β2mα3
Cytoplasmic tail
Cytoplasmic tail
Plasma membrane
α2 α1
 
Figure 1.  Structure of the “classical” HLA class I and II peptide-presenting 
molecules.    
The HLA class I molecule is a transmembrane protein made up of the class I alpha chain 
(α), encoded by the HLA locus and the β2 microglobulin (β2m) molecule, which is not 
encoded in the HLA region. HLA class II is a transmembrane heterodimer made up of an 
alpha and beta chain, both encoded in the HLA region. The α chain of the class I 
molecule has two peptide-binding domains (α1 and α2), an immunoglobulin-like domains 
(α3) the transmembrane region and the cytoplasmic tail. Each of class II α and β chaims 
has four domains: the peptide-binding domain (α1 or β1), the immunoglobulin-like 
domain (α2 or β2), the transmembrane region, and the cytoplasmic tail. The peptide-
binding groove is formed by the α1 and α2 domains in the case of HLA class I, whereas 
the α1 and β1 domains form this structure in HLA class II molecules.  Figure drawn using 
Microsoft Office PowerPoint. 
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The three classical class I gene products are HLA-A, -B, & -C, while class II molecules 
are HLA-DR, DQ and DP. Whereas class I molecules are present on all nucleated cells 
(of which graft endothelial cells are of particular significance in transplantation) the 
constitutive expression of class II molecules is restricted to antigen-presenting cells 
(APC), such as dendritic cells, macrophages and B cells. However, they are also 
expressed on microvascular endothelial cells and can be expressed on other cells in the 
correct inflammatory context (Rose 1997; Valujskikh and Heeger 2003). In the context of 
transplantation, the graft itself contains a significant number of “passenger” donor APCs 
that express high levels of the MHC class II (as well as MHC class I molecules).  Of note, 
APCs also express costimulatory molecules required for T cell activation; this will be 
discussed in more detail later.   
 
Typically, MHC class I molecules present peptides from intracellular, endogenous 
proteins while MHC class II molecules present peptides derived from exogenous and 
membrane proteins that have been taken up by the cell by endocytosis (Rotzschke and 
Falk 1991; Rudensky et al. 1991). Cross-priming is a mechanism by which CD8+ T cells 
are primed. Non-infectious material could be 'taken up' by APC and then be processed 
and presented on MHC class I molecules to cytotoxic CD8+ T cells. This phenomenon is 
reflected in the two major pathways of protein degradation: proteasomal degradation, 
particularly relevant to the generation of MHC class I peptides, and degradation by the 
endosomal lysosomal system, which is responsible for the processing of MHC class II 
peptides (Klein and Sato 2000a).  
 
In man, peptides of foreign and self proteins are presented on MHC class I and MHC 
class II molecules at the cell surface and can be recognized by CD8+ and CD4+ T 
lymphocytes, respectively. 
The peptides that bind to the MHC class I peptide-binding groove mainly stem from 
proteins that have been endogenously synthesized in the cell in its cytosol, and which are 
degraded by the action of proteasomes.  The peptides are transported from the cytosol 
into the endoplasmic reticulum (ER) by the Transporter Associated with Processing 
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(TAP) (Cresswell et al. 1999). Binding of a peptide to a class I molecule in the ER 
stabilizes the class I molecule. Together they then travel to the cell membrane where they 
may be recognized by the T cell receptor (TCR) of CD8+ T cells (See Figure 2).  The 
CD8 molecules of these T cells, by binding to the MHC class I molecules, at a site distant 
to the peptide-binding cleft, participate in binding of the peptide/MHC class I complex to 
the T cell.  
The MHC class II molecules are also synthesized in the ER. Their peptide-binding cleft 
is, however, prevented from binding peptides in the ER by the so-called invariant chain 
(Ii), part of which, the MHC class II-associated invariant-chain peptide (CLIP), binds to 
the cleft of the MHC class II molecules.  As well as blocking the peptide-binding cleft, Ii 
also participates in directing the class II molecules to the endosomes.  In the endosomes 
MHC-DM molecules participate in the process of exchanging Ii, more specifically the 
CLIP, with peptides that mainly stem from exogenous or membrane-bound proteins taken 
up by the cell by endocytosis. The peptide/MHC class II complexes then travel to the cell 
membrane of the APC, where they may be recognized by the TCR of CD4+ T cells. 
Similarly to the CD8 molecule of CD8+ cells, the CD4 molecules of these CD4+ T cells, 
by combining with the MHC class II molecules at a site distant from the peptide- binding 
groove, participate in binding of the peptide/MHC class II complex to the T cell (Klein 
and Sato 2000a) (See Figure 2).  
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Figure 2.  Schematic representation of the pathways by which peptides derived   
from intracellular and extracellular protein bind to HLA class I and II molecules, 
respectively.   Figure drawn using Microsoft Office PowerPoint. 
 
The debate about HLA matching remains focused on its effect on the outcome of  
transplantation.  Overall, the fewer HLA mismatches between donor and recipient, the 
better the long-term graft survival (Held et al. 1994; Smith et al. 1995; Taylor et al. 1997; 
Morris et al. 1999; Kaczmarek et al. 2006):  HLA matching is known to improve the 
outcome of renal (Opelz et al. 1992) and heart transplantation (Smith et al. 1995; 
Hosenpud et al. 1996; Hornick et al. 1997; Sheldon and Poulton 2006). In renal 
transplantation, the benefits of HLA-A, -B and -DR matching are evident both in the 
early post-transplant period and in the long-term (Fuggle et al. 2004; Su et al. 2004). 
However, in liver transplantation, the adverse effect of HLA-A, -B, -DR incompatibility 
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on survival of grafts or recipients is still controversial (Meyer et al. 1997; Navarro et al. 
2006).  Certain studies, including those by UK Transplant, have found that mismatch at 
the DR locus has the most negative effect (Doxiadis et al. 2007).  One study observed 
that HLA-DR mismatches and the number of rejection episodes correlated with poor 
long-term survival (Kaczmarek et al. 2006).   
 
The main problem with analysing the influence of HLA on graft survival is that the level 
of HLA matching is associated with other factors that independently have an impact on 
graft outcome or waiting time and are difficult to separate from the apparent influence of 
HLA matching (Roberts et al. 2004). For example, previous graft failure, presensitization 
to HLA antigens, the recipient's race (Kasiske et al. 1991), organ-preservation time, the 
amount and type of immunosuppression used, and the use of regionally or nationally 
shared organs (Sanfilippo et al. 1988; Su et al. 2004) can all have an impact on graft 
survival.  Furthermore, the quality of HLA typing has not always been high, an analysis 
of data from the 1990s showed that when donors, in zero mismatched transplants, were 
retyped, there was a 30% discrepancy rate (Hata et al. 1996). Studies from Europe 
indicated a 25% discrepancy rate between HLA types defined by serology and retyped 
using DNA methods (Hsia et al. 1993; Poli et al. 1993).  Most of the discrepancies were 
due to differences in reporting broad and split antigens.   Increased utilization of broad 
antigens increases the probability of identifying an HLA matched recipient for a donor 
(Takemoto et al. 1992; Takemoto et al. 1994) and this strategy has the potential for 
increasing the percentage of transplants that are HLA matched.  However, split antigen 
matching may be important for HLA-A and HLA-B (more so than for HLA-DR) and thus 
broad antigen reporting may not be sufficient.  Zero HLA-A-B-DR mismatched, first 
transplant recipients, with split HLA-DR mismatches had survival similar to those with 
no split DR mismatches; but those with split HLA-A or HLA-B antigen mismatches had 
poorer survival (Opelz 1988).  Of note, recipients with a previously failed transplant also 
had a poorer outcome with split DR mismatches. The influence of HLA-DQ and DP 
matching is less clear (Tong et al. 1993) and (Rosenberg et al. 1992).   
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Whilst the exact influence of HLA matching may not be clear, as said before, the overall 
picture shows that HLA matching is better for long-term graft survival and the 
association between HLA matching and long-term graft survival is one of the main pieces 
of evidence for an immunologic pathogenesis of chronic allograft nephropathy 
(Takemoto et al. 2000). 
  
1.2.2.  Minor Histocompatibility antigens 
Minor histocompatibility antigens are peptides derived from any polymorphic proteins, 
not encoded by genes within the MHC, presented by recipient HLA molecules. Minor 
histocompatibility antigens provoke T cell immune responses (Simpson et al. 2002). 
Immune responses to these antigens are generally weaker than those directed against 
HLA antigens, but they can still provoke graft rejection. Their dominant clinical effect 
appears to be in chronic rejection. This partially explains why patients with renal grafts 
with “perfect” HLA matches can still suffer from rejection (Goulmy 1997).     
 
1.2.3.  ABO blood group antigens 
The first major immunological barrier identified in transplantation was ABO blood group 
antigen incompatibility. Antibodies responsible for hyperacute rejection include those 
specific for ABO blood group antigens (Rydberg 2001). ABO antigens are expressed in 
most vascular endothelium of the glomerular and peritubular capillaries of the 
transplanted organ the effects of ABO-incompatible.  As transplantation across an ABO 
incompatibility runs the risk of hyperacute rejection, organ transplants should be ABO 
compatible (Tanabe et al. 1998; Kocher et al. 2001). However, the traditional view has 
been given the shortage of organs for donation, there has long been an interest in 
developing techniques for assessments the effects of ABO-incompatible.     
 
In 1970, the first trial of ABO-incompatible transplantation was started but, on account of 
hyperacute rejection, results were discouraging and work stopped. Almost twenty years 
later, Alexandre et al. (1987) published a series of 26 ABO-incompatible kidney 
transplants using splenectomy and an immunosuppressive regimen with steroids, 
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cyclosporine, azathioprine, anti-thymocyte globulin and donor-specific platelet 
transfusion. As a result of this study, 18 of 24 ABO-incompatible renal transplant 
recipients had graft function for more than one year. (Alexandre et al. 1987). Recently 
published data, from the Japanese, demonstrated long-term survival of ABO-
incompatible living donor kidney transplants (Takahashi et al. 2004). Similar successful 
results , albeit short term, have been shown for protocols developed in Europe (Banner et 
al. 2004; Beimler and Zeier 2007) and the United States (Sonnenday et al. 2004). The 
recent development of desensitization protocols has been shown to reduce and maintain 
anti-A/B titres against the donor blood group sufficiently, preventing antibody-mediated 
rejection and allowing successful ABO-incompatible living-donor kidney transplantation. 
The key factor to successful graft outcome is the prevention of hyperacute rejection and 
the promotion of accommodation (Shimmura et al. 2000; Mahesh et al. 2007) (The terms 
hyperacute rejection and accommodation will be explained later). 
 
In renal transplantation, the potential of ABO antibodies to mediate rejection is clear 
(Galili 2004). A1 antigens are the main antigen involved in anti-A responses, because the 
expression of A1 is both quantitatively greater (number of A determinants) and 
qualitatively different (type of core saccharide antigen) than A2 (Breimer and Samuelsson 
1986). However acute antibody-mediated rejection (AMR) of an A2  renal allograft does 
still occur (Hanto et al. 1993).  
 
1.2.4.  The allocation of deceased-donor kidney scheme 
The kidney allocation system, a three-tier system based on a detailed analysis of 6363 
first kidney transplant recipients, was introduced in the United Kingdom in 1998 (Fuggle 
et al. 1998). Initially, when the scheme was introduced, blood group identity was required 
for all allocation, with the exception of 000 mismatched highly sensitized patients (> 85% 
HLA antibody reaction). A point system was used to differentiate between two or more 
equally matched patients in Tiers 1 and Tiers 2. The points score was based on six 
factors: recipient age, donor-recipient age difference, waiting time, matchability, HLA 
sensitization and the import-export balance for each center (Rudge et al. 2007).  
Matchability was used as an estimate of the likelihood of a patient receiving a well-
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matched kidney based on the frequency of the patient’s HLA type in the donor population 
and degree of sensitization to defined HLA antigen. Matchability was calculated based on 
wait-listed patients, by comparing the individual patient’s HLA phenotype with that of all 
blood group-identical deceased donors from the last 10,000 actual donors in the United 
Kingdom. According to blood group, this number was then translated into a matching 
score from 1 to 10. This system represented the donor population but, as a result of the 
biological diversity of different ethnic groups, it did not represent the recipient waiting 
list and data suggested apparent inequalities in access to organs resulting from biological 
disparity (Rudge et al. 2007).  
Potential changes, that would affect all patients regardless of their ethnic origin, were 
considered when reviewing the 1998 Kidney Allocation Scheme. Firstly, a relaxation of 
blood group rules in the allocation was allowed. For example, blood group O kidneys 
could be allocated to both group O and group B recipients. It was hoped that this would 
lead to more equal waiting times for both groups. Secondly the role of HLA matching in 
allocation was reassessed; a review of the 1998 Kidney Allocation Scheme considered 
different ways in which the role of HLA matching could be modified. For instance, the 
system introduced in 1998 used broad HLA specificities, but it was suggested that this 
could be replaced by cross-reactive groups of antigens (McKenna and Takemoto 2000). 
As a result of the review and other studies, a new Kidney Allocation Scheme was 
introduced in 2006.  
The scheme is now based on five Tiers and applies to all kidneys from deceased heart 
beating donors (www.uktransplant.org.uk.  Data accessed 15th June 2010): 
A. 000 mismatched paediatric patients - highly sensitized or HLA-DR homozygous 
B. 000 mismatched paediatric patients – others 
C. 000 mismatched adult patients - highly sensitized or HLA-DR homozygous 
D. 000 mismatched adult patients – others and favorably matched paediatric patients 
(100, 010, 110 mismatches) 
E. All other eligible patients 
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Paediatric patients in Tiers A and B are prioritized according to waiting time. In the 
remaining Tiers, patients are prioritized according to points allocated on the basis of: 
(1) Waiting time  
(2) HLA match & age combined  
(3) Donor-recipient age difference  
(4) Location of patient relative to donor  
(5) HLA-DR homozygosity  
(6) HLA-B homozygosity  
(7) Blood group match  
 
1.3. The molecular basis of allorecognition 
There are three pathways of allorecognition that can initiate T cell-mediated rejection 
mechanisms: direct, indirect, and semi-direct allorecognition.   
1.3.1.  Direct allorecognition 
Direct allorecognition occurs when recipient T cells recognise and respond to intact 
donor MHC molecules complex, expressed on donor cells of the transplanted organ, in 
particular donor APC (Rogers and Lechler 2001).  The subsequent response is a highly 
aggressive and damaging response with a far greater intensity than that seen during the 
classical nominal immune response.  
There are two theories explaining why the response, resulting from direct allo-
recognition, is so intense and damaging: the high determinant density hypothesis 
proposes that alloreactive T cells directly recognise exposed polymorphic residues in the 
allogeneic MHC molecule and that the bound peptide is not significant (Matzinger and 
Bevan 1977; Bevan 1984). Therefore, all the donor MHC molecules expressed act as 
potential targets, as opposed to just a small fraction that would bind and present the 
appropriate peptide in a normal immune response. The multiple binary model suggests 
that an alloreactive T cell recognises both the peptide and MHC molecule of the complex. 
However, it suggests that all donor MHC molecules can be targets because most will 
carry peptides that are perceived as non-self by virtue of the fact that they are being 
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presented on an MHC molecule not expressed by the recipient. Both hypotheses go some 
way to explain why there is such a high frequency of alloreactive T cells. It is likely that 
there is a spectrum of mechanisms between these two extremes that explain the high level 
of alloreactive T cells (Afzali et al. 2008).   
As direct allorecognition depends on the presence of donor APC, which are only present 
for a short time following transplantation, it is thought that direct allorecognition is most 
important in early rejection episodes and diminishes with time post-transplant (Rogers 
and Lechler 2001). This is in contrast to indirect allo-recognition.       
1.3.2.  Indirect allo recognition 
Indirect allorecognition is analogous to the classical immune response, where donor 
alloantigens are processed as exogenous molecules and presented as peptides associated 
with recipient-MHC class II molecules. Therefore the number of T cells with appropriate 
T cell receptors is much smaller; consequently this response is less aggressive 
(Villadangos 2001). However, host APCs replace donor APC within the graft and T cell 
responses through the indirect pathway become the principal mediators of later rejection 
(acute and chronic) (Hernandez-Fuentes et al. 2003).   
1.3.3.  Semi- direct allorecognition  
It has been suggested that recipient dendritic cells (DC) are capable of acquiring intact 
MHC-peptide complexes from donor-derived cells, in particular, DCs and then presenting 
the complexes to alloreactive T cells. Recipient DC that traffic through the transplanted 
tissues may acquire and present intact donor derived MHC class I or class II molecules 
and directly activate CD8+ and CD4+ cells with direct anti-donor allospecificity (Game 
and Lechler 2002; Jiang et al. 2004).     
 
In addition to T cell-mediated alloresponses initiated following recognition of alloantigen 
via the above described direct, indirect and semi-direct pathways, antibody dependent 
immune responses are also important in the overall alloresponse.  
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1.3.4.  Recognition of alloantigens by antibody 
Alloantibodies are produced following recognition of alloantigen (e.g. ABO blood group 
antigens) by B cell surface receptors (which are essentially surface-bound 
immunoglobulin). Binding of antigen to the B cell receptor initiates B cell activation and, 
in the presence of cytokines released by CD4+ T helper-2 (Th2) cells, differentiation into 
antibody-producing plasma cells.  The donor vascular endothelium is the major target of 
alloantibody and consistent with this, data shows that B cells are found among the cells 
infiltrating rejected organs and can be induced to differentiate into plasma cells, leading 
to the production of antibody within the transplant. Alloantibody-dependent responses 
can play a significant role in hyperacute,   (Rifle et al. 2005) acute and chronic rejection 
(Everly and Terasaki 2009): alloantibody may cause graft dysfunction and damage by 
stimulating complement fixation by the classical pathway, or by targeting Fc receptor-
expressing cells, e.g. neutrophils, natural killer cells and macrophages, to the graft.  
  
B cell development and activation will now be discussed in more detail. 
1.4.  B cell biology 
B cells start their life in the bone marrow as pre-B cells. These cells do not have antibody 
on their surface. Then, a maturation step occurs which involves rearrangement of the 
immunoglobulin genes to produce antibodies.    
 
1.4.1.  Antibody structure and function 
Antibody molecules are immunoglobulins (Ig); they are made up of homologous units of 
about 110 amino acids called Ig domains. The basic unit of an antibody includes four 
polypeptide chains, two identical light (L) chains and two identical heavy (H) chains (see 
Figure 3). The light chain is either of kappa or lambda type. Each light chain is bound, by 
disulfide bonds, to a heavy chain to form a heavy-light heterodimer (HL). Each of these 
chains contains either multiple (for heavy chains) or one (for light chains) constant (C) 
region(s) and one variable (V) region, linked by disulfide bonds. These constant and 
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variable regions are Ig domains. Two identical heterodimers are linked to each other by 
disulfide bonds, at a hinge region, to form the basic antibody molecule (H2L2). 
 
 
Figure 3.  Antibody structure and function  
The basic structure of an antibody consists of two identical heavy and two identical light 
chains. Each of these chains contains constant (C) and variable (V) regions can generate. 
Within the latter of which regions, are the complementarity determining regions. The 
antigen- binding sites are comprised mainly of the CDRs.  The antigen-binding domains 
reside at the tip of the variable regions; their effector domains reside in the constant 
regions at the ‘tail’ of the molecule. Proteolytic digestion with papain or pepsin can 
generate Fab and F(ab)’2 fragment respectively.  Figure drawn using Microsoft Office 
PowerPoint.  
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The antibody molecule can be split into two parts, e.g. by the enzyme papain, at the hinge 
region (see Figure 3) to produce the Fab fragment and Fc portion.  The Fab (fragment, 
antigen binding) fragment contains the site that binds antigen and is composed of one 
constant and one variable domain from each heavy and light chain of the antibody  (see 
Figure 3).  The Fc (Fragment, crystallizable) portion is composed of two heavy chains 
that contribute two or three constant domains depending on the class of the antibody. By 
binding to specific proteins, the Fc region of the antibody generates immune responses 
for a given antigen (Huber 1980). The Fc region also binds to various cell receptors, the 
Fc receptors, and complement proteins. By doing this, it mediates different physiological 
effects including opsonization, cell lysis, and degranulation of mast cells, basophils and 
eosinophils (Woof and Burton 2004). 
 
As mentioned above, the Fab fragment and Fc portion are connected by the hinge region.  
This region is rich in proline, threonine, and serine and imparts lateral and rotational 
movement to the antigen-binding domains, providing the antibody with the ability to 
interact with a variety of antigen orientations. This region, which contains the principal 
disulfide linkages between the heavy chains, is susceptible to proteolysis with papain or 
pepsin. Under physiological pH, papain is capable of fragmenting all isotypes, into Fab 
and Fc fragments whereas pepsin cuts the molecule below the hinge linkage, giving rise 
to the F(ab')2 (bivalent for antigen binding) and various fragments of the Fc portion 
(Burton et al. 1986; Lipman et al. 2005).                                         
 
B cell precursors bring together heavy- and light-chain variable region gene segments 
(VH and VL) by means of V (D) J recombination i.e the coming together of the gene 
segments coding for the variable (V), diversity (D) and joining (J) regions. B cells with 
surface, functional antibody are mature naïve cells. After they succeed in generating a 
potential antigen receptor (the B cell receptor), they are released into the circulation and 
travel around in the blood and lymphatics through tissue and lymphoid organs. In primary 
lymphoid organs, such as thymus and bone marrow, B and T lymphocytes differentiate 
from lymphoid stem cells into mature, naïve, antigen-specific cells. In contrast, secondary 
lymphoid organs, such as the spleen, lymph nodes, and Peyer’s patches (PPs), provide an 
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environment that enable T and B lymphocytes to interact with each other, with accessory 
cells, and with antigens, resulting in the initiation of antigen-specific primary immune 
responses (Weih and Caamano 2003) (see Figure 4).  In the lymph nodes, naïve B cells 
may encounter antigen which they recognize by engagement with their surface antibodies 
which can lead to their activation. Activated B cells migrate to the T cell zones of local 
secondary lymphoid tissues, and then move, within the same secondary lymphoid tissue, 
either to extrafollicular foci or to follicles in which they form germinal centres.  Here, 
activated naïve B cells undergo vigorous proliferation, somatic hypermutation of 
immunoglobulin V-region genes, isotype switching, interaction with antigens, antigen-
driven selection, and differentiation into memory B cells and plasma cells, the majority of 
which are short-lived (Moser et al. 2006; Klein and Dalla-Favera 2008).   
 
Figure 4.  B cell activation 
When naïve B cells recognize antigen, they may become activated and present antigen to 
T helper cells which, if activated upon recognition of the presented antigen, secrete 
cytokines. The release of cytokines from the activated T cells provides an important 
second signal to the B cells. The contact and the cytokine signals are both required for the 
B cell clonal expansion, proliferation and differentiation into antibody-secreting cells 
(ASC) and memory B cells.  Figure drawn using Microsoft Office PowerPoint.   
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1.4.2. B cell activation 
B cell activation can occur in two ways. The first way depends upon T-helper cells, not 
just exposure to T-helper derived cytokines, and is called thymus-dependent (TD) 
activation. The second way can activate B cells in the absence of direct participation by 
T-helper cells and is referred to as thymus-independent (TI) activation.  Antigens which 
activate the TD route are usually soluble proteins whereas such antigens that use the TI 
route are usually bacterial cell wall components.  
1.4.2.1. T-cell dependent activation 
B cells that are dependent upon T helper cell interactions are consequently dependent on 
the signals that drive T cell activation.  CD4+ and CD8+ T cells require the delivery of 
three signals to be activated: one is derived from the interaction of the T cell receptor 
(TCR) with MHC-peptide complexes, the second involves interaction with one of the 
‘costimulatory molecules’ present on T cells and the third is the signal to proliferate, 
often delivered by IL-2.  The most widely studied co-stimulatory molecules, CD80 (also 
called B7.1) and CD86 (also called B7.2), bind to their co-receptors on the T cell, CD28 
and CTLA-4 (CD152) and determine the activation state of the T cell. CD28 is 
constitutively expressed on the surface of CD4+ T cells and, upon binding CD80/86, 
delivers a co-stimulatory signal that is critical for T cell expansion, expression of CD40L 
on the T cell and cytokine production (Figure 5). 
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Figure 5. T cell dependent activation of B cells.  
Costimulatory molecules are important for both B and T cell activation. Upon interaction 
with antigen, antigen-presentation cells (APC), such as B cells and macrophages, are 
stimulated to express specific surface molecules. Among these, the costimulatory 
molecules (CD80 and CD86) play an important role in T cell activation. The interaction 
of CD80/86 on APC with CD28 on T cells provides an important second signal for T cell 
activationt―the first being interaction of antigen with the T cell receptor complex. While 
CD80 and 86 are expressed on activated APCs, a molecule known as CD40 ligand 
(CD40L) is expressed on activated but not resting helper T cells. CD40L binds to its 
complementary receptor, CD40, on B cells and ligation of these molecules is responsible 
for the activation of B cells.  Abbreviations:  TCR; T cell receptor, Ag; Antigen.  Figure 
drawn using Microsoft Office PowerPoint. 
 
Upon interaction with antigen, B cells are stimulated to express specific surface 
molecules. Among these, the interaction of B7.1/2 on B cells and CD28 on T cells 
provides an important second signal for T cell activation (the first signal being interaction 
of antigen with the T cell receptor complex). CD40 ligand (CD40L), expressed on 
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activated but not resting helper T cells, binds to its cognate receptor, CD40, on B cells 
providing key stimulatory signals that are crucial for the production of antibodies. The 
CD40-CD40L pathway is an important mediator of humoral immune function, in 
particular, differentiation, antibody class switching and apoptosis of B cells. CD40L is a 
transmembrane cell surface glycoprotein of 39 kDa, expressed mainly on CD4+ T cells, 
that interacts with CD40 on antigen-presenting cells.  CD40L activation stimulates B cell 
proliferation and differentiation. Indeed, ligation of CD40 on B cells is crucial for 
antibody production and for the generation of memory B cell (van Kooten and 
Banchereau 2000). Thus, defective expression of CD40L on T cells leads to low levels of 
IgG in blood (Kroczek et al. 1994). Furthermore, CD40L signals tune T helper cell 
cytokine production, especially of the Th2 cell (Poudrier et al. 1998). Cytokines that play 
an important role in B cell proliferation and differentiation to antibody-secreting cells are 
IL-4, IL-10 and IL-13. IL-4, secreted from T-helper cells, binds to the IL-4 receptor 
found on resting and activated B cells. IL-4 has multiple effects on B cells, including 
increasing expression of MHC class II, costimulation of B cell proliferation, induction of 
class switching to IgG, IgA, and IgE and memory cell generation (Kirk et al. 2001).  
1.4.2.2.  T cell independent activation 
Some antigens are TI, meaning that a responding B cell is activated in the absence of T 
cells. TI antigens are all large polymeric molecules with repeating antigenic determinants 
(Figure 6). They are classed as one of two types; TI-1, which are polyclonal activators 
(mitogens) of B cell proliferation, e.g bacterial lipopolysaccharide (LPS), and TI-2, which 
are generally repetitive polysaccharide or polymeric protein antigens e.g. bacterial 
flagellin. Many bacteria have repeating carbohydrate epitopes that stimulate B cells by 
cross-linking the Ig antigen-receptors on the B cell. The result is Ig synthesis in the 
absence of T cell help. 
 
B cell activation in response to TI-1 and TI-2 antigens differs accordingly; B cell 
activation in response to TI-1 antigens occurs when macrophages present several of the 
same antigens in a way that causes cross-linking of B cells surface immunoglobulin. This 
B cell activation requires signalling through endotoxin or other substances binding to toll-
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like receptor 4 (TLR 4). It gives rise to polyclonal B cell activation and thus it is not 
antigen-specific (Lanzavecchia and Sallusto 2007).  
TI-2 antigens directly activate B lymphocytes by their ability to extensively cross-link 
membrane immunoglobulin. Activation of B cells by TI-2 antigens requires functional 
expression of Bruton’s tyrosine kinase (BTK), a molecule involved in the surface 
immunoglobulin receptor-mediated signaling cascade (Vos et al. 2000). 
 
Figure 6.  B cell Activation by Thymus-Independent and Dependent Antigens 
(a)-Several antigens can activate B cells independently of T helper cells. T-independent 
type 1 (TI-1) antigens activate B cells without the need of second signal.  (b)- B cell 
activation in response to T cell-dependent (TD) antigens requires two signals: an antigen-
specific first signal delivered via cross-linking of surface immunoglobulin receptors and a 
second signal normally delivered by T helper cells.  Figure drawn using Microsoft Office 
PowerPoint.  
1.4.3. Affinity maturation and Somatic hypermaturation 
Affinity maturation is the process by which B cells produce antibodies with increased 
affinity for antigen during the course of an immune response. With repeated exposures to 
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the same antigen, a host will produce antibodies of ever greater affinity. A secondary 
response can elicit antibodies with several log-fold greater affinity than a primary 
response. The process involves two interrelated processes, somatic hyper maturation and 
clonal selection and they occur in the germinal centres of lymph nodes (Figure 7). 
 
Once naïve B cells are activated by TD antigens, they migrate to follicles in the spleen or 
lymph node. Immunoglobulin genes in germinal centre (GC) centroblasts mutate to 
increase antibody affinity to antigens. This process is known as somatic hypermutation 
(SHM) (Figure 7). This is the process that modifies the immunoglobulin variable region 
(IgV) of the rearranged antibody genes, after the whole gene segment has been generated 
by the process of V (D) J joining. In this process the DNA strand breaks and a number of 
changes occur. These include the introduction of (mostly single) nucleotide exchanges, 
small deletions and duplications, into the rearranged IgV region at a rate of 3–10 per base 
pair per generation. This process is initiated by activation-induced cytosine deaminase 
(AID) which changes cytosine to uracil in DNA, and mutations are generated by DNA 
polymerases during replication or repair of the uracil residue. SHM, as well as acting on 
the kappa (κ)- and lambda (λ)-coding loci, also affects some non-immunoglobulin genes, 
most notably the BCL6 (B cell lymphoma 6) proto-oncogene, in the 5′ regulatory region 
(Muramatsu et al. 2000) B cells which have acquired a higher affinity to antigen are 
selected and differentiate into plasma cells or memory B cells (Dorner and Radbruch 
2005). 
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Figure 7.  The germinal centre microenvironment.   
Antigen-activated B cells differentiate into centroblasts that undergo clonal expansion in 
the dark zone of the germinal centre. During proliferation, the process of SHM introduces 
base-pair changes into the V(D)J region of the rearranged genes encoding the 
immunoglobulin variable region (IgV) of the heavy chain and light chain; some of these 
base-pair mutations lead to a change in the amino-acid sequence. Centroblasts then 
differentiate into centrocytes and move to the light zone, where the modified antigen 
receptor, with help from T cells and follicular dendritic cells (FDCs), is selected for 
improved binding to the immunizing antigen. Newly generated centrocytes that produce 
an unfavorable antibody undergo apoptosis and are removed. A subset of centrocytes 
undergoes immunoglobulin class-switch recombination (CSR). Cycling of centroblasts 
and centrocytes between dark and light zones seems to be mediated by a chemokine 
gradient, presumably established by stromal cells in the respective zones. Antigen-
selected centrocytes eventually differentiate into memory B cells or plasma cells.  Figure 
drawn using Microsoft Office PowerPoint.  
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1.4.4. Class switching 
Antibodies can be divided into five different isotypes, IgG, IgM, IgA, IgD and IgE, and 
several subclasses. This is based on differences in the amino acid sequences in the 
constant region of the heavy chains: γ, μ, α, δ, and ε, respectively.  Naïve mature B cells 
produce both IgM and IgD, which are the first two heavy chain segments in the 
immunoglobulin locus. If these activated B cells are also activated via their CD40 and IL-
4 receptors, they undergo antibody class-switching to produce IgG, IgA or IgE 
antibodies. Class switching generates different classes/isotypes of antibody, all with the 
same variable domains as the original antibody, but possessing different constant 
immunoglobulin heavy chain changes but the variable regions, and therefore antigen 
specificity, stay the same (Dickerson et al. 2003).  Class-switch recombination (CSR) is 
the DNA-level mechanism that mediates class switching. It occurs by DNA 
recombination involving non-homologous end-joining processes between specific 
repetitive regions of several hundred base pairs (known as switch regions) that precede 
the immunoglobulin constant region genes (Kenter 2003). The process occurs within 
GCs, but also extensively outside of GCs in both TD and TI responses (Figure 7). Isotype 
switching alters the effector functions of an antibody thus allowing a particular antigen to 
be cleared by different mechanisms (Storb and Stavnezer 2002). 
1.4.4.1.  IgG 
IgG is the most common Ig isotype in serum; approximately 75% of serum Ig is IgG. In 
humans there are four different IgG subclasses, IgG1, IgG2, IgG3 and IgG4. All of them 
are monomers. However, of all the isotypes, the four IgG subclasses show the most 
conspicuous differences in the number of disulfide bonds and length of the hinge region 
(Colman et al. 1976). IgG2 has a shorter hinge region than IgG1, with 12 amino acid 
residues and four disulfide bridges. The hinge region of IgG2 lacks a glycine residue, and 
it is relatively short (Abramov et al. 1983) . IgG3 differs from the other subclasses by its 
unique extended hinge region about four times as long as the IgG1 hinge (Saluk and 
Clem 1971).  This confers IgG3 with a greater flexibility than the other IgG subclasses. 
The elongated hinge in IgG3 is also responsible for its higher molecular weight compared 
to the other subclasses. The hinge region of IgG4 is shorter than that of IgG1 and its 
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flexibility is intermediate between that of IgG1 and IgG2. The flexibility of the hinge 
region decreases in the order IgG3>IgG1>IgG4>IgG2. This probably explains, in part, 
the higher activity of IgG3 in triggering effector functions such as antigen-binding and 
complement-fixation compared to the other subclasses (van de Winkel and Anderson 
1991).  
 
The capacity of the four human IgG subclasses to bind the complement molecule C1q, 
decreases in the order: IgG3>IgG1>IgG2>IgG4. IgG4 does not activate complement. 
Hinge-dependent Fab-Fab and Fab-Fc flexibility determines the accessibility of the 
complement binding site to C1q. IgG3, the human IgG subclass with the longest hinge, is 
the most effective complement activator. The inability of IgG4 to activate complement is 
caused by the structure of the Fc fragment as well as the steric hindrance of the 
complement-binding sites by the Fab arms (Tao et al. 1993). Most micro-organisms are 
by themselves incapable of activating complement or of binding phagocytes cells such as 
macrophages and monocytes. Antibodies act as flexible adapters mediating the adherence 
of infectious agents to phagocytes. The antibody forms a bridge to attach the microbe to 
the Fc receptor on the phagocyte membrane. This is the process of opsonisation. Again, 
not all subclasses bind equally well to Fc receptors and thus not all mediate opsonisation 
through this route; IgG2 and IgG4 do not bind to Fc receptors (van de Winkel and Capel 
1993). 
1.4.4.2.  IgA 
IgA is the second most common Ig in serum. There are two subclasses of IgA antibodies: 
IgA1 and IgA2 (Almogren et al. 2007). Both subclasses display the typical antibody 
configuration of H2L2 and, like IgG, the Fc region mediates the effector function of the 
antibody (Woof 2002). Plasma IgA is produced in the bone marrow and is predominantly 
monomeric, whereas IgA present in external secretions is a product of the local immune 
system and is produced by plasma cells as a dimer that includes a J chain - a polypeptide 
synthesized by antibody-secreting cells. Dimeric IgA binds to the poly-immunoglobulin 
receptor expressed on the basal surface of epithelial cells and the complex is transported 
to the apical surface where the receptor is cleaved to release the IgA dimer attached to a 
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portion of the receptor, referred to as secretory piece; this process is termed transcytosis. 
These forms of IgA are referred to as sIgA and are relatively resistant to cleavage by 
enzymes present in secretions and produced by some pathogenic organisms (Diebel et al. 
2004). IgA is the primary immunoglobulin present in secretions, where it acts as the first 
line of defence against pathogens at mucosal sites. IgA also plays an important role in 
maintaning gut homeostasis by ensuring that the resident microflora does not invade the 
intestine (Takahashi 2007).   
1.4.4.3.  IgM 
IgM is the third most common serum Ig isotype. It is found as a pentamer or monomer. 
The pentamer form is composed of five antibodies linked by disulfide bonds whereas 
monomeric IgM functions as a receptor for antigen on B cells. IgM is the first isotype 
class to be produced in an immune response, as well as the first antibody synthesized in 
neonates. IgM is very effective at fixing complement (Schreiber and Frank 1972) 
1.4.5.  Fc receptors 
The Fc receptors are a family of proteins found on the surface of certain cells including 
natural killer cells, macrophages, neutrophils, and mast cells, all of which contribute to 
the protective functions of the immune system. Fc receptors bind to antibodies in serum; 
including those that are attached to infected cells or invading pathogens such bacteria and 
viruses. Binding of antibody to Fc receptors can stimulate phagocytic or cytotoxic cells to 
destroy infected cells. There are several different types of Fc receptors, which are 
classified based on the type of antibody that they recognize. For instance, those that bind 
IgG are Fc-gamma receptors (FcγR), those that bind IgA are called Fc-alpha receptors 
(FcαR) and those that bind IgE are called Fc-epsilon receptors (FcεR).  
 
Three different types of FcγR have been identified on human blood cells. These receptors 
have different affinities for their ligands, whereby affinity describes the strength of the 
interaction between the receptor and its ligand.  FcγR I is found on monocytes and 
macrophages and is a high affinity receptor for monomeric IgG (Unkeless et al. 1988). 
FcRγ II (CDw32), a lower affinity receptor, is found on monocytes, platelets, neutrophils, 
and B cells (Looney et al. 1986). FcγR III (CD16), which has the lowest affinity (of 
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FcγRs) for its ligand, is present on neutrophils, eosinophils, NK cells (Gopinath and 
Nutman 1997; Moulding et al. 1999; Mavilio et al. 2005). 
  
Two different types of IgE FcR have been described. The high affinity FcεR I, is present 
on mast cells and basophils (Kinet 1989). The low affinity FcεR II (CD23), is present on 
monocytes, eosinophils, T cells, and B cells (Spiegelberg 1984). 
 
Only one Fc receptor has been described in the FcαR subgroup FcαRI (or CD89). FcαR I 
is found on the surface of eosinophils, monocytes, Kupffer cells, and some dendritic cells 
(Yin et al. 2007).                                             
 
1.4.6.  Kinetics of a B cell immune response  
The primary response, occurring following the first interaction of the immune system 
with a particular antigen, has a characteristic lag phase, during which naïve B cells 
proliferate and differentiate into antibody-secreting plasmablasts and memory cells in 
extracellular foci. Following this, serum antibody levels increase logarithmically, 
reaching a peak at about day 14, plateau for some time, and then decrease as the plasma 
cells begin to die (Smith et al. 1996). The memory cells remain in G0 phase, and have a 
much longer life than plasma cells; some memory cells persist for the life of the 
individual. Therefore, when a person encounters the same antigen for a second time, the 
population of memory cells responds rapidly to begin antibody secretion. In the primary 
response, the first antibodies generated are usually IgM.  
 
The secondary response is not only much quicker but it is also more efficient due to affinity 
maturation (Figure 8 and Table 1 
   Table 1). Most antibody-secreting cells (ASCs) generated during the secondary 
(memory) immune response leave the follicles of the secondary lymphoid tissues and are 
later found in the bone marrow (BM), inflamed tissues, or in the red pulp of the spleens 
with the phenotype of mature plasma cells and a potentially long lifespan (McHeyzer-
Williams and Ahmed 1999; Manz et al. 2002). 
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In the secondary response, the antibody levels peak at about 7 days, and the level of 
antibody is about 100 to 1,000-fold higher than that reached in a primary response. 
Indeed, specific antibodies titres, mostly of IgG and IgA subclasses, can be stable for 
years and are produced mainly by resident plasma cells of the BM. Because IgG 
antibodies only have a half-life of 3 weeks, the survival of plasma cells in the BM is a 
prerequisite for the maintenance of antibody titres over long time periods (Odendahl et al. 
2005). 
 
Immune response 
        Feature Primary Secondary 
Type of B cells involved 
                 
Naïve Memory 
Time to onset 4-7 days 
                
1-3 days 
Time to peak response            10-14 days 
                 
5-7 days 
Magnitude of peak 
response Depends on the antigen 
100 to 1,000 times higher 
than the primary response 
Predominant antibody 
type produced IgM IgG 
Affinity of antibodies Lower Higher 
 
   Table 1.  Comparison of primary and secondary antibody responses 
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Figure 8.  The primary and secondary antibody responses differ significantly. 
The primary response has a characteristic lag phase, during which naïve B cells 
proliferate and differentiate into plasma cells and memory cells. Following this, serum 
antibody level increases logarithmically, reaches the peak at about day 14, remains at a 
plateau for some time, then begins to drop off as the plasma cells begin to die. The 
memory cells have longer life than plasma cells and persist for the life of individual. In 
second exposure to the same antigen, the population of memory cells responds rapidly to 
begin antibody secretion. The antibody levels peak in about 7 days, and the level of 
antibody is about 100 to 1000 fold higher than that in the primary response.  Figure 
drawn using Microsoft Office PowerPoint. 
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1.4.7.  Subtypes of B cells  
B cell development begins as lymphoid stem cells which differentiate into progenitor B 
cells (pro-B cells) which express a transmembrane tyrosine phosphatise called CD45RO. 
Proliferation and differentiation of these pro-B cells into precursor B cells (pre-B cells) 
requires bone-marrow stromal cells which secrete various cytokines, like IL-7, that 
support the developmental process. A receptor on the pro-B cell called c-Kit (a receptor 
tyrosine kinase) interacts with a stromal cell surface molecule causing the pro-B cell to i) 
divide and differentiate into the pre-B cells and ii) start expressing a receptor for IL-7. IL-
7 induces down-regulation of adhesion molecules on the pre-B cells so that they can 
detach from the stromal cells.  
 
As mentioned before, B lymphocytes express antibody molecules during early 
development. The first classification of B cells into different development stages was 
made according to whether they expressed no immunoglobulin chains, the 
immunoglobulin heavy chain (H-chain) only, or both heavy and light chains (L-chain).  
As B cells develop from pro-B cells to mature B cells, they express surface proteins other 
than immunoglobulin that are characteristic of each stage. Subsequently, the B cell 
different stages can be identified by the expression of surface proteins as shown in Figure 
9.  
 
Another protein that is expressed throughout B cell development is CD19. CD19 is 
transmembrane glycoprotein that is expressed from the pro–B cell until the plasma cell 
stage. CD19 is involved in the regulation of B cell proliferation and also participates in B 
cell receptor signalling (Sen et al. 2002). CD20 is also expressed on cells of the B cell 
lineage. CD20 is a regulator of transmembrane calcium conductance and thought to play 
a role in B cell activation and proliferation (Tedder and Engel 1994). Its expression in 
human B cells is seen first in bone marrow pre-B cells and persists until plasma cell 
differentiation (Anolik et al. 2003). Figure 9 summarizes the patterns of expression of 
these antigens in this cell lineage.  
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Figure 9.  B cell development stages. 
Stages of B cell maturation are indicated by their anatomical site and the expression of cell-
surface markers.  Figure drawn using Microsoft Office PowerPoint. 
Development up to the immature B cell stage takes place in the bone marrow and is 
independent of antigen. Prior to release into the periphery, immature B cells undergo 
selection for self tolerance and subsequently for the ability to survive in the peripheral 
lymphoid tissue. B cells that survive these selection processes are released into the 
periphery where they undergo further differentiation to become naïve B cells. These cells 
recirculate through secondary lymphoid organs, where they may encounter and be 
activated by appropriate foreign antigen. 
1.4.7.1.  Naïve B cells 
All naïve B cells express cell-surface IgM and IgD, yet IgM makes up less than 10% of 
the immunoglobulin found in plasma; as mentioned previously, the most abundant 
isotype in plasma is IgG. Much of the antibody in plasma has therefore been produced by 
B cells that have undergone isotype-switching (Warnatz et al. 2002). Little IgD antibody 
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is produced at any time, so the early stages of the antibody response are dominated by 
IgM antibodies (Han et al. 2004). Later, IgG and IgA are the predominant isotypes, with 
IgE contributing a small but biologically important part of the response (Avery et al. 
2008). The overall predominance of IgG results, in part, from its longer half life in the 
plasma (Kelly et al. 2005). 
1.4.7.2.  Memory B cells 
Memory B cells can exist for long periods of time and provide the basis of the enhanced 
secondary response, both by their increased number following the primary response and 
the lower threshold required for their activation in contrast to naïve B cells (Kelly et al. 
2005). Proliferation and differentiation of memory B cells may be spontaneous or result 
from irregular antigen exposure, such as through a microbial carrier state, or from 
exposure to cytokines produced by nearby T cells in response to unrelated antigens.  
 
It is possible to distinguish between naïve and memory B cells by the presence or absence 
of the surface molecule CD27; naïve B cells are CD27- whereas memory B cells are 
CD27+. Moreover, naïve B cells are IgD+ IgM + CD27- whereas; memory B cells can be 
IgD+ IgM + CD27+, or IgD – IgM+ CD27+ or IgG + IgA + CD27+ (Chong et al. 2005).  
CD27 is a type I transmembrane glycoprotein expressed by the majority of peripheral 
blood T lymphocytes and B cells. It is a member of the nerve growth factor receptor 
(NGFR)/tumour necrosis factor receptor (TNFR) family. The CD27 ligand, CD70, is a 
type II transmembrane glycoprotein with homology to TNF (Held-Feindt and Mentlein 
2002). The ligation of CD27 yields crucial signals that positively control the entry of B 
cells into the pathway to plasma cells. 
1.4.6.2.1 Memory B cells subsets 
Memory B cells are characterized by the rapid production of high-affinity Abs in 
response to secondary Ag response.  This accelerated humoral recall response is due to 
the expansion of affinity-matured memory response precursors and their rapid 
differentiation into plasma cells (McHeyzer-Williams and Ahmed 1999).  There are two 
distinct subsets of isotype-switched (IgM-IgD-IgG+) and somatically mutated memory B 
cells that do not secrete antibody but, can give rise to plasma cells upon adoptive transfer 
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with antigen (McHeyzer-Williams et al. 2000). Based on the expression B220 and CD19, 
there are mainly two subtypes of memory B cells. One of these subsets expresses high 
levels of the B lineage marker B220 and CD19.These B220+ memory B cells expand to 
peak levels by day 4 following secondary antigen challenge and they persist in the spleen 
for at least 6 weeks. The second memory subset however, does not express the B cell 
isoform B220 or CD19. These B220- memory responders emerge in the spleen with 
kinetics similar to those of the B220+ subset, but they persist long term at much higher 
frequencies. This B220- memory subset also comprises more than 95% of the antigen-
specific B cells in the bone marrow. Thus, the B220- memory B cell subset emerges, 
following secondary challenge, as a major cellular component of the antigen-specific 
memory B cell response and contributes significantly to the rapid appearance of high-
affinity antibody. Since both memory B cell subsets express somatically mutated 
immunoglobulin, it is likely that their precursors originate in the germinal centre (GC) 
reaction during the primary response (McHeyzer-Williams et al. 2000; Driver et al. 2001; 
Tarlinton 2006) 
1.4.7.3.  Plasma cells   
Activated B cells differentiate into non-proliferating, mature plasma cells under the 
control of chemokines that are essential for lymphocyte trafficking (Acosta-Rodriguez et 
al. 2007). Early plasma cells leave the secondary lymphoid organs to migrate into the 
bone marrow or into inflamed tissues. In secondary lymphoid tissue, plasma cells are 
short-lived; however, bone marrow plasma cells can live for extended period; for months 
to years (Manz et al. 1997). Their survival is dependent on a complex molecular 
microenvironment called the “plasma cell survival niche”. Secondary lymphoid organs 
apparently provide only a few survival niches for plasma cells hence few plasma cells 
remain in the secondary lymphoid organs; after immunization, <5% of antigen-specific 
plasma cells persist in the spleen compared with 95% in the BM (Hoyer et al. 2004). IL-
5, IL-6, tumour necrotic factor-α (TNF-α), stromal cell-derived factor-1 (SDF-1), and 
CD44-mediated signalling have been described as survival factors for plasma cells. These 
long lived plasma cells do not divide and no longer react to antigen or antigen-antibody 
complexes.  In the resting state, the majority of plasma cells are in the bone marrow and 
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antigen-specific plasma cells are found in the peripheral blood only at low frequency 
(around 1:10 million peripheral blood mononuclear cells) (Traggiai et al. 2003). After 
vaccination, a large but temporary increase in antigen-specific cell numbers is detected 
within the peripheral blood. This increase probably reflects newly generated cells moving 
from the lymphoid tissues to the bone marrow and is associated with an increase in serum 
antibody level (Kelly et al. 2005).  
 
Plasma cells can been identified by the increased expression of CD38 (Avery et al. 2005). 
CD38 is a glycoprotein found on the surface of many immune cells, including CD4+ and 
CD8+ T cells, B and natural killer cells. It is a marker of cell activation, adhesion and 
signal transduction (Lee 2000). Ligation of CD40L maintains memory B cell populations 
that are expanded by IL-2 and IL-4. The differentiation of memory B cells into CD38-
expressing cells is IL-10 dependent. IL-10 interrupts memory B cell expansion and 
appears to be crucial for the differentiation of germinal centre B cells into plasma cells 
secreting IgG and IgA; in its absence, germinal centre B cells differentiate into 
CD20+CD38− cells (Arpin et al. 1997). CD38+ B cells appear in cultures of memory B 
cells stimulated with CD40L and IL-10 (Choe et al. 1996). Additional cytokines such as 
IL-2, IL-4, IL-5, and IL-6 are also known to stimulate B cells to become plasma cells, 
secreting different classes of antibodies such as IgG, IgA or IgM (Nagumo et al. 2002).   
 
Studies of normal plasma cells isolated from tonsils, blood, and bone marrow showed 
plasma cells expressing high levels of CD38 but heterogeneous levels of other surface 
molecules (Brieva et al. 1991). Although early plasma cells and their precursors are 
found in tonsils, more mature plasma cells are present in the bone marrow. This reflects 
the different functions of these tissues in inducing and maintaining plasma cell responses 
(Brieva et al. 1991). It has been indicated that most IgG-secreting cells present in the 
tonsils are proliferating cells (B cell/plasmablasts); however, IgG-secreting cells in the 
bone marrow are non-proliferating cells (plasma cells) (Arce et al. 2004).  
 
 
 
 
Introduction 
 50
1.4.7.4.  B-1 and B-2 cells 
B-1 and B-2 cells are lymphocyte populations that differ in development, surface marker 
expression, tissue localization, and function. B-1 cells are the major source of natural 
antibody, polyreactive, weakly autoreactive Ig that is present in the sera of pre-immune 
animals. In contrast, B-2 cells produce high affinity, somatically mutated Ig only after 
immunization. Antibodies from both cell types have been shown to be necessary for 
protection from influenza virus. 
1.4.7.4.1.  B-1 cells 
In mice B-1 cells arise early in life from foetal and neonatal progenitors.  They are 
enriched in the peritoneal and pleural cavities of mice, and can be distinguished by the 
expression of several surface markers such as CD5, Mac-1, and CD43, as well as by a 
B220low, IgMhigh, IgDlow, CD23low or high phenotype (Tung and Herzenberg 2007). 
Peritoneal B-1 cells consist of two different sub-populations, B-1a and B-1b, which are 
CD5+ and CD5–, respectively, but are otherwise similar in their surface marker phenotype 
(Sen et al. 2002). 
1.4.7.4.2.  B-2 cells  
B-2 cells, also known as follicular B cells, are the predominant B cells in the spleen, 
lymph nodes, and peripheral blood of mice. These are the cells which cooperate with T 
cells in the germinal centre and undergo somatic hypermutation of their Ig genes to 
produce high-affinity antibody in the humoral immune response. They are also B220+ 
IgMlow, IgDhigh, CD23high (Schneider et al. 2001; Vinuesa et al. 2005). 
 
1.5.  B cell sensitisation in transplantation 
As mentioned previously, alloantibodies can contribute to transplant rejection via 
recruitment of phagocytes and activation of complement dependent cytotoxicity 
mechanisms.  Allograft rejection can be divided into three main categories; these were 
initially based on the length of time required for rejection to develop but are now known 
to be associated with different mechanisms, some of which involve alloantibodies. 
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1.5.1.  Categories of solid organ allograft rejection  
1.5.1.1.  Hyperacute rejection 
Hyperacute rejection is an antibody-mediated response that occurs immediately, within 
minutes to hours of vascularisation of the transplanted graft, and is caused by pre-formed 
complement-fixing antibodies in the recipient’s serum.  These antibodies are usually 
specific for blood group antigens or donor MHC molecules expressed on the vascular 
endothelium of the graft (Pescovitz 2006). The presence of HLA-specific antibodies has 
been reported to cause hyperacute rejection of kidney (Patel and Terasaki 1969; Terasaki 
et al. 1971; Gebel et al. 2003),  heart (Smith et al. 1993), lung (Lau et al. 2000; 
Reinsmoen et al. 2004), and pancreas grafts (Hawthorne et al. 1996; Pelletier et al. 2002)  
sensitisation events such as blood transfusions, pregnancy and previous transplants can be 
responsible for the development of HLA-specific antibodies (Vaidya 2005).  
 
When preformed antibodies bind to donor antigens on vascular endothelium, complement 
activation is rapidly initiated and platelets and endothelial cells are activated. The 
immediate effect of endothelial cell activation, by antibody binding, is the retraction of 
the plasma membrane from the underlying substrate (Saadi et al. 1995), and release of 
preformed von Willebrand factor and P-selectin to the cell surface (Tedesco et al. 1997). 
Activated endothelial cells produce IL-1, IL-8 and monocyte chemotactic protein 1 
(MCP-1) which recruit neutrophils and monocytes to the site of injury (Torzewski et al. 
1996). These events are followed by entrapment of blood elements and activation of 
clotting factors in the microvasculature of the graft. The result is massive intravascular 
coagulation, occlusion of afferent vessels and subsequent lack of tissue perfusion and 
graft necrosis. During this process the endothelium is transformed from a protective 
barrier, between the blood and extravascular tissues, into a procoagulant and adhesive 
interface that promotes inflammation. This can result in cortical necrosis in the kidney 
and myocardial infarction in the heart. This process is essentially untreatable. 
1.5.1.2.  Acute rejection 
Most acute rejection occurs within days to weeks post-transplantation but episodes of  
acute rejection may occur years after transplantation. There are two types of acute graft 
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rejection; acute cellular and acute humoral. These types of rejection are distinguished by 
their underlying mechanisms, although there is often significant overlap.  
 
For the purposes of standardised comparison, acute rejection has been categorised 
according to the Banff classification (other pathological schemes have also been 
developed) (Racusen et al. 1999; Solez et al. 2008) (Table 2). The Banff schema was first 
developed by a group of pathologists, nephrologists, and transplant surgeons at a meeting 
in Banff, Canada, in 1991. It has continued to evolve through meetings every two years 
and has become the worldwide standard for interpretation of transplant biopsies. The 
Banff criteria were designed to guide therapy in transplant patients and to help establish 
an objective rejection endpoint in clinical trials. It contains detailed definitions of grades 
(or criteria) for each histological feature, together with instructions on how these grades 
should be assembled into a clinically meaningful assessment.  In summary; biopsies are 
taken at regular time intervals post-transplant, starting at the time of transplantation 
(‘zerotime’).  For a biopsy specimen to be considered adequate for analysis (in the case of 
kidney transplantation) more than seven glomeruli and at least one artery must be present 
in the specimen (Schwarz et al. 2005).  The histology of the biopsy speciments is then 
analysed.  The novel features of the Banff classification system include the introduction 
of the categories 'Borderline Changes' and the separation of 'acute rejection' into mild, 
moderate, and severe.  The Banff classification scheme also introduced a numerical 
grading system for each of the renal compartments - interstitium (i), tubules (t), vessels 
(v), and glomeruli (g) as: 0- absent, 1- mild, 2- moderate, and 3- severe (Solez et al. 
2008) (See Table 2 for more details).  Analysis of biopsies according to the Banff 
classification is now almost universal in all studies involving renal transplant biopsies.  
These analyses can influence clinical management and are the standard of care in most 
centers today (Nankivell and Chapman 2006). 
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1. Normal 
2. Antibody-mediated changes (may coincide with categorised 3,4,5 and 6) 
Due to documentation of circulating anti-donor antibody, and C4d or allograft pathology C4d deposition without 
morphologic evidence of active rejection 
C4d+, presence of circulating anti-donor antibodies, no signs of acute or chronic TCMR or ABMR (i.e. g0, cg0, ptc0, no 
ptc lamination). Cases with simultaneous borderline changes or ATN are considered as indeterminate 
Acute antibody-mediated rejection 
C4d+, presence of circulating anti-donor antibodies, morphologic evidence of acute tissue injury, such as (Type/Grade): 
I. ATN-like minimal inflammation 
II. Capillary and or glomerular inflammation (ptc/g >0) and/or thromboses 
III. Arterial—v3  
Chronic active antibody-mediated rejection 
C4d+, presence of circulating anti-donor antibodies, morphologic evidence of chronic tissue injury, such as glomerular 
double contours and/or peritubular capillary basement membrane multilayering and/or interstitial fibrosis/tubular atrophy 
and/or fibrous intimal thickening in arteries 
3. Borderline changes 
‘Suspicious’ for acute T-cell-mediated rejection (may coincide with categories 2, 5 and 6) 
This category is used when no intimal arteritis is present, but there are foci of tubulitis (t1, t2 or t3) with minor interstitial 
infiltration (i0 or i1) or interstitial infiltration (i2, i3) with mild (t1) Tubulitis 
4. T-cell-mediated rejection (TCMR, may coincide with categories 2, 5 and 6) 
Acute T-cell-mediated rejection (Type/Grade:) 
IA. Cases with significant interstitial infiltration (>25% of parenchyma affected, i2 or i3) and foci of moderate tubulitis (t2) 
IB. Cases with significant interstitial infiltration (>25% of parenchyma affected, i2 or i3) and foci of severe tubulitis (t3) 
IIA. Cases with mild-to-moderate intimal arteritis (v1) 
IIB. Cases with severe intimal arteritis comprising >25% of the luminal area (v2) 
III. Cases with ‘transmural’ arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with 
accompanying lymphocytic inflammation (v3) 
Chronic active T-cell-mediated rejection  
‘chronic allograft arteriopathy’ (arterial intimal fibrosis with mononuclear cell infiltration in fibrosis, formation of neo-intima) 
5. Interstitial fibrosis and tubular atrophy, no evidence of any specific aetiology 
(may include nonspecific vascular and glomerular sclerosis, but severity graded by tubulointerstitial features) 
Grade 
I. Mild interstitial fibrosis and tubular atrophy (<25% of cortical area) 
II. Moderate interstitial fibrosis and tubular atrophy (26–50% of cortical area) 
III. Severe interstitial fibrosis and tubular atrophy/ loss (>50% of cortical area) 
6. Other 
Changes not considered to be due to rejection; may include isolated g, t, i, cg, ct, ci, cv lesions and considered with the 
categories 2, 3 ,4  and 5.   
Table 2.  Banff 97 diagnostic categories for renal allograft biopsies -  Banff’07 
update 1,2 
Abbreviation: Tubulitis (t); intimal arteritis (v), mononuclear cell interstitial infiltrate (i); 
glomerulitis (g); interstitial fibrosis (ci); glomerulopathy (cg); tubular atrophy (ct) ; 
mesangial matrix increase (mm); vascular fibrous intimal thickening (cv); arteriolar 
hyaline (ah); T cell-mediated rejection (TCMR);  antibody-mediated rejection  (ABMR); 
Peritubular capillaries (ptc) ; acute tubular necrosis (ATN); no significant cortical ptc, or 
<10% of PTCs with inflammation (PTC0); no glomerulitis (g0); no glomerulopathy-
double contours in <10% of peripheral capillary loops in most severely affected 
glomerulus. This table is adapted from (Solez et al. 2008).  
Introduction 
 54
1.5.1.3.  Acute cellular rejection (ACR) 
ACR results from the development of alloantigen-specific cytotoxic T lymphocytes and 
delayed hypersensitivity. Inflammatory mediators produced by T cells, macrophages and 
donor tissue have all been implicated as having an important role in the rejection process 
observed in murine allograft models and human transplants. The role and expression of 
cytokines during ACR in mice models and human allografts have been studied 
extensively (Kamoun 2001).  
 
ACR  in renal transplants is characterised by the accumulation of mononuclear cells in 
the interstitium accompanied by inflammation of the tubules and sometimes of the 
arteries. Mononuclear cells permeate the interstitial space around tubules and are 
composed mostly of CD4+ and CD8+ T cells (Robertson et al. 1996). Tubulitis is the 
principal lesion used for the diagnosis of ACR in the Banff criteria. Tubulitis is diagnosed 
as invasion of the tubular epithelium by infiltrating T cells and macrophages. However, 
glomerulitis is occasionally a feature of ACR and in this case the glomeruli are largely 
infiltrated with T cells and macrophages (Magil 2005) . 
 
Many recent studies have suggested that monocytes play a more important role in 
allograft rejection than had previously been thought. For instance, when human renal 
allograft patients are T cell-depleted using monoclonal antibody preparations, rejection 
still occurs and is characterized by intense infiltration of the allograft by activated 
monocytes (Tinckam et al. 2005). Graft dysfunction occurs upon the arrival, in the graft, 
of such activated monocytes, even without a T cell infiltrate. Monocytes have also been 
shown to be among the first cells infiltrating human renal allografts immediately upon 
reperfusion (McLean et al. 1997). Thus, monocytes could be envisioned as interacting 
with graft cells such as the vascular endothelium and conveying alloantigen and 
costimulation to T cells (Xu et al. 2006). 
 
In glomeruli, monocytes differentiate into macrophages. Activated macrophages can be 
recognized by over-expression of HLA class II antigens, and production of 
proinflammatory products, such as TNF-α and interleukin-1 (IL-1)  (Rastaldi et al. 2000). 
The presence of large numbers of interstitial HLA DR+ cells and the highly significant 
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correlation with the numbers of T cells, monocytes and macrophages, suggest that these 
cells are activated. It has been suggested that upregulation of HLA-DR expression is a 
good marker of rejection because, in immunosuppressed human patients,  HLA-DR 
expression was more prominent in tubules encircled by the heaviest infiltrate of activated 
mononuclear cells.  In addition, it has been suggested that cytokines, secreted by the 
inflammatory cells, induced tubular cells to express HLA-DR antigens and act as APC 
(Ozdemir et al. 2004).  
1.5.1.4.  Acute humoral rejection (AHR) 
AHR occurs in sensitized patients or in those with a history of previously failed 
allografts. AHR is due to the indirect recognition of alloantigen by recipient CD4+ T 
helper cells and B cells. These cells produce effector molecules that support the de novo 
production of antibodies directed against allo-MHC expressed in the graft. The clinical 
features of graft rejection caused by de novo alloantibodies include neutrophil infiltration 
into capillaries in the graft, inflammation of the vascular system, fibrosis, and necrosis of 
blood vessel walls (Moll and Pascual 2005). This is reflected in the Banff criteria, which 
says that the pathological features associated with AHR are the presence of 
polymorphonuclear cells (PMN) in the peritubular capillaries, severe vasculitis, 
glomerulitis, and fibrinoid necrosis (Solez et al. 2008). In kidney grafts, the damage 
caused by AHR causes a rapid decrease in renal function with a resultant decrease in 
urine output, rise in serum creatinine levels, and the presence of protein and blood in the 
urine.  
Most alloantibodies are directed against HLA antigens. In humans, the arterial 
endothelium expresses HLA class I antigens, whereas the capillary endothelium can 
express both HLA class I and II antigens (Fuggle et al. 1986; Suitters et al. 1987). Recent 
studies have shown that donor-class I HLA-specific and donor-class II HLA-specific 
alloantibodies (detectable by sensitive assays before transplantation) when present at low 
levels, can be associated with severe AHR after transplantation (Gibney et al. 2006).  
An important step in alloantibody-mediated rejection is the initiation of the complement 
cascade. As described previously this involves the binding and activation of the 
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complement protein C1q and subsequent deposition of C4d on the surface of the cell to 
which the antibody bound (Feucht et al. 1991). C4d is a relatively stable molecule that 
can be identified by immunohistochemistry in graft biopsies. Thus, the detection of C4d 
is indicative of an antibody response (Bohmig et al. 2002). The detection of C4d in a 
graft biopsy is often associated with circulating DSA against HLA in patients’ sera 
(Ionescu et al. 2005; Worthington et al. 2007) and C4d deposition is associated with the 
presence of DSA and is considered a marker of antibody-mediated rejection (Feucht et al. 
1991; Howie 2007). However, C4d can also be activated by an alternative, antibody-
independent mechanism (Schaapherder et al. 1995). Thus, C4d may also be potentially 
deposited without prior antibody binding in the setting of solid-organ transplantation, for 
example, after ischemia-reperfusion injury (Park et al. 2002). It is not confirmed whether 
the lectin pathway plays any role in the activation of C4 in transplantation (Sacks et al. 
2003; Sund et al. 2003) but, the potential for this has to be taken into consideration when 
interpreting C4d data. This said, the detection of C4d is useful in the diagnosis of AHR 
and thus is being investigated as a diagnostic marker of AHR.  Its usefulness for this 
purpose differs between the organs studied.   
1.5.1.5. Complement and rejection 
Transplantation has a strong effect on the activation of the innate immune response 
because of the presence of multiple harmful stimuli, including organ donor brain damage, 
heat and cold shock, and ischaemia-reperfusion insult. The complement system forms an 
important link between the innate and adaptive immune responses. It is helpful to regard 
the immune system as having reparative functions, as well as being  a host defence 
system, facilitating the clearance of damaged, necrotic or apoptotic cells following a 
harmful incident (Walport 2001). 
 
There are three pathways of complement activation; the classical pathway, mannose- 
binding lectin pathway and alternative pathways. The pathway of particular, but not 
exclusive interest in transplantation is the classical pathway in which antibodies are 
linked to the activation of the complement pathway. The classical pathway of 
complement activation can be triggered by antibody bound to an antigen on the cell 
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surface (e.g. foreign particle, immune complex, cell or other material). Antibody bound 
particles of this type interact directly with the complement molecule, C1q. This activates 
C1 which then cleaves the C4 molecule. Further degradation of C4 results in the 
fragmentation of C4 to C4a, C4b, C4c and C4d. C4b and C4d can be produced in fluid 
phase or on a target surface e.g. allograft tissue. C4b molecule is short-lived but C4d is 
present for longer surface-bound or free and circulating in serum (Fujita et al. 1978) As 
such C4d is an excellent marker for classical complement activation in vivo or in vitro. 
 
Complement activation in the post-ischaemic kidney occurs by the alternative pathway. 
Proximal renal tubular cells are rich in proteolytic enzymes and can secrete complement 
proteins, which leads to complement activation (Pratt et al. 2002). T cells, B cells and 
APCs express complement receptors that respond to stimulation by splitting complement 
products. These cells also express on their surface complement control proteins such as 
CD46 and CD55 which recognise covalently bound fragments of C3 and C4, and are able 
to transduce signals to the interior of the cell as well as inhibit complement. These 
complement receptor-ligand-interactions are thought to mediate B cell and T cell 
interactions in transplantation (Sacks and Zhou 2005). In addition to regulating the 
function of effector CD4 + T cells and CD8 + T cells lineages, it seems that complement 
receptors on APCs and T cells can mediate counter-regulatory activity, reducing the 
inflammatory and immune response (Lalli et al. 2008). 
1.5.1.5.1. C4d in Kidney Transplantation 
Capillary C4d deposition was recognized as a specific and independent prognostic marker 
of antibody-mediated rejection (AMR) in renal allograft biopsies (Crespo et al. 2001) and 
recently it was included in the Banff classification as a criterion for the diagnosis of acute 
and chronic AMR (Solez et al. 2008). The clinicopathological descripton of AHR 
associates the presence of C4d in peritubular capillaries (PTCs) (Trpkov et al. 1996), the 
presence of neutrophils in PTCs and the fibrinoid necrosis of arteries (Collins et al. 
1999), with circulating class I HLA-specific antibody (Collins et al. 1999) (Figure 10). In 
the early post-transplant renal biopsy, detecting C4d can be diagnostic of acute humoral 
rejection even in the absence of detectable donor-specific antibodies (DSA), specific for 
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HLA, in serum (Nickeleit et al. 2002). C4d deposits in peritubular capillaries are found in 
some biopsy samples from patients with rejection, suggesting an antibody-mediated 
process (Feucht et al. 1991; Watschinger and Pascual 2002). Consequently, the detection 
of C4d fragment is increasingly being used to diagnose humoral rejection caused by 
HLA-specific alloantibodies in renal transplantation.  C4d deposition may be used as a 
marker of active immunological rejection; C4d deposited within days or weeks of a 
transplant operation (Haas et al. 2002) remains in situ only a few days after the antibody 
has been removed from the circulation: for instance, 8 days in human renal allografts 
(Sund et al. 2003). Therefore, if C4d deposition is demonstrable, antibody has fixed 
complement in the endothelium within the previous week, and the process is 
immunologically active.   
 
Figure 10.  C4d staining in kidney allograft biopsies with AMR. 
(A) Frozen-immunofluorescence: intense C4d expression in PTC and glomeruli. (B) 
Frozen-immunohistochemistry: similar expression of C4d in PTC and glomeruli. (C) 
Paraffin-IF: the expression of C4d in PTC displayed lower fluorescence intensity. (D) 
Paraffin-IHC: C4d expression in PTC (no C4d stained in glomeruli). A–D: ×200. This 
figure was taken from (Ludovico-Martins et al. 2009).  
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However, as mentioned above, in some cases, C4d deposition can be due to non-
antibody-mediated endothelial injury, for example ischaemia- reperfusion injury and non-
HLA endothelial antigens have also been suggested to contribute to some episodes of 
AHR (Alvarez-Marquez et al. 2009). Therefore C4d deposition must be interpreted with 
caution.  
1.5.1.5.2. C4d in Heart Transplantation  
In order to diagnose a patient with a heart transplant AMR, a patient needs to have 
clinical evidence of cardiac dysfunction or heart failure and immunopathological 
evidence of complement activation in the endomyocardial biopsy (deposition of C4d 
and/or C3d). However, the finding of complement deposition in an endomyocardial 
biopsy per se does not mean that the patient has AMR, (Rodriguez et al. 2005). The 
diagnosis of AMR, as defined by the Banff classification, requires three features, (a) 
functional evidence of allograft dysfunction, (b) morphological evidence of acute tissue 
injury and (c) evidence of antibody-dependent activation of the classical pathway of the 
complement system (C4d deposition in the peritubular capillaries), and detection of 
circulating DSA (Solez et al. 2008), and not C4d deposition alone. 
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Figure 11.  Immunofluorescence microscopy of a heart biopsy from a patient in the 
months after heart transplant, during an episode of AMR.  
IgM deposits (3+) are present in a granular pattern around capillaries (60x). C1q deposits 
are barely detectable in the capillaries (60x). C4d staining shows intense linear deposits 
in the capillary endothelium (cross sections as well as longitudinally oriented capillaries 
are shown) (60x). C3d deposition is clearly positive in the same linear pattern around 
capillaries, identical to that shown for the C4d deposits (60x) .This figure was taken from 
(Rodriguez et al. 2005).  
 
1.5.1.5.3. C4d in Liver Transplantation 
The significance of AMR in liver allograft remains uncertain. In clinical practice, 
hyperacute rejection is very rare, and some initial reports suggested that liver allografts 
were much more resistant to humoral rejection than other solid organ allograft 
(Donaldson et al. 1995) . It is natural for the liver to be considered an ‘immunologically 
privileged organ’, and cadaveric donor liver transplantation is usually performed without 
considering HLA matching (Wang-Rodriguez and Rearden 1995).  The role of C4d in the 
evaluation of humoral rejection in liver allografts has not been clearly described (Racusen 
et al. 2003). Recent papers reported the demonstration of C4d in liver allografts, 
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especially in allografts showing cellular or apparent humoral rejection, but the status of 
anti-donor antibodies was not described in most cases (Krukemeyer et al. 2004; Sawada 
et al. 2005). The most important factor in liver transplation is ABO compatibility rather 
than HLA.  In ABO-incompatible transplantation, the portal stromal C4d immunostaining 
was associated with a high postoperative titer of anti-A/B antibody and reduced graft 
survival, suggesting the association of C4d deposition and ABO-incompatible humoral 
rejection (Haga et al. 2006). 
 
 
Figure 12.  Representative C4d staining in the liver in crossmatch-negative patients. 
Capillary staining of C4d in the portal area of the liver, showing; (a) acute rejection; (b) 
the internal lamina of the hepatic artery (noted by the authors to be typically low 
intensity); (c) acute rejection with portal stromal staining surrounding blood vessels or 
bile ducts and; (d) faint capsular staining in time-zero biopsy. This figure was adapted 
from (Sakashita et al. 2007).  
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1.5.1.5.4. C4d in Lung Transplantation 
In lung transplantation, there are limited and conflicting studies on C4d and other 
components of complement activation as markers of AMR in the lung allograft (Magro et 
al. 2002; Magro et al. 2003). Although a number of studies have demonstrated an 
association between complement deposition and graft dysfunction after lung 
transplantation, this has not been a universal finding (Wallace et al. 2005). Another study 
showed that the development of HLA-specific antibody was associated with high-grade 
and refractory ACR, lymphocytic bronchiolitis, and increased use of cytolytics and 
immunosuppressive therapy (Girnita et al. 2005). 80% of specific C4d staining was 
detected at the same time as circulating DSA (Westall et al. 2008).  
 
 
 
 
 
 
 
 
 
 
Figure 13.  Histological and immunoperoxidase findings suggestive of AMR in the 
absence of ACR.   
The patient did not have either ACR or significant airway infection early post-transplant. 
(A) Endoluminal C4d staining throughout the septal capillaries. (B) Endoluminal C3d 
deposition within the septal capillaries. (C) Biopsy from the same patient showing 
persistent C3d deposition within the septal capillaries. (D) Light microscopy of same 
biopsy showing expansion of the septa by collagen defining septal fibroplasia, a 
presumptive sequela of prior episodes of AMR. This figure has been adapted from  
(Westall et al. 2008).  
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1.5.1.6. Chronic rejection 
Chronic rejection is defined as an alloimmune response resulting in slow deterioration of 
organ function. Progressive chronic graft dysfunction is the progressive loss of allograft 
function, often with hypertension and proteinuria, several months or years after 
transplantation (Mauiyyedi et al. 2001). The mechanisms of chronic graft dysfunction can 
be immunological or non-immunological: immunological mechanisms comprise 
antibody- and/or T cell- mediated responses to the allograft (Jindal and Hariharan 1999). 
Chronic active alloimmune rejection is associated with slow, progressive cortical 
scarring, thought to be caused by immunological mechanisms. Non-immunological 
factors that contribute to chronic graft rejection include ischaemic-reperfusion injury, 
chronic cytomegalovirus and polyomavirus infection, chronic toxic effects of 
immunosuppressive drugs (in particular, calcineurin-inhibitors), hypertension, 
hyperlipidaemia and chronic vesicoureteral reflux recipient age and race (Gill et al. 
2002).  
 
In 1975, Pierce et al. reported that HLA-specific DSA might be related to chronic 
rejection. He showed that such antibodies, detected by reactivity to donor cells, were 
highly correlated with renal allograft loss and chronic allograft arteriopathy (Pierce et al. 
1975). Subsequent studies in renal and cardiac allograft patients have also indicated a 
strong correlation between circulating HLA-specific DSA antibodies and acute and 
chronic rejection (Davenport et al. 1994; Tambur et al. 2005; Ho et al. 2009). 
Corroboration of antibody participation in chronic rejection comes from allograft elution 
studies, in which antibodies with donor class I and class II specificities, have been eluted 
from chronically rejected human kidneys (Bocrie et al. 2007). 
 
Cardarelli et al. determined the prevalence and significance of HLA-specific DSA in post 
transplant patients’ sera using ELISA. He concluded that HLA-specific antibodies were 
associated with worse allograft function and in situ evidence of anti-donor humoral 
alloreactivity. In addition, he suggested that long-term renal transplant patients, with an 
increase creatinine level, should be screened for HLA-specific antibodies and C4d in 
biopsy (Cardarelli et al. 2005). Theruvath and his colleges reported that the development 
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of post-transplant class II HLA-specific antibodies is associated with chronic rejection. 
The alloantibodies detected in these patients proved to be IgG directed against HLA class 
I or class II specificities, with serum titres ranging from 1:8 to 1:128 (Theruvath et al. 
2001). 
 
Vareesangthip et al. studied the correlation of post-transplant class I and class II, HLA-
specific antibodies with glomerular filtration rate (GFR) and he concluded that class II 
HLA-specific antibody had a negative correlation with GFR, in contrast to class I HLA-
specific antibody, which showed no significant correlation (Vareesangthip et al. 2004).  
 
The term ‘chronic rejection’ should now be used only in those cases of late allograft 
dysfunction where an alloimmune mechanism of injury can be identified (cellular and/or 
humoral component to the injury process). This is superseding the term “chronic allograft 
nephropathy”.  
 
The most important risk factor for chronic rejection is the incidence of one or more 
previous acute rejection episodes (Tejani et al. 2002). However, not all acute rejection 
episodes lead to chronic rejection; the type, severity, number and timing of rejection 
episodes determine the final outcome (Libby and Pober 2001):  Acute vascular rejection 
is a more pronounced adverse prognostic feature compared with tubulointerstitial cellular 
rejection (Lindholm et al. 1993). Acute rejection episodes, followed by partial loss of 
graft function, have a more harmful effect on long term graft outcome than acute 
rejection episodes with complete functional recovery (Shoskes and Halloran 1996). 
Recipients with repeated acute rejection episodes have lower graft survival rates than 
those with no or only one acute rejection episode (Humar et al. 2000). Finally, timing of 
the first acute rejection episode has an impact on the long-term outcome; acute rejection 
episodes within the first three months have much less effect on chronic rejection 
(Sijpkens et al. 2003) whereas episodes of acute rejection that occur after the first 3 
months, significantly impair the long-term prospects of the transplant.   
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1.5.2.  Diagnostic criteria for chronic rejection 
Histopathologic examination of rejected grafts shows varying combinations of lesions 
such as chronic transplant glomerulopathy, chronic transplant arteriopathy, interstitial 
fibrosis, and tubular atrophy. Diagnostic criteria for active chronic antibody-mediated 
rejection include the following: transplant glomerulopathy (TG), peritubular capillary 
basement membrane layering, tubulointerstitial fibrosis with or without peritubular 
capillary loss, arterial intimal fibrosis without duplication of the internal elastica lamina, 
diffuse C4d positive staining in the peritubular capillaries and detection of donor-specific 
antibody (Racusen 2004). Recent data suggest that anti-donor humoral immunity 
contributes to the development of histopathological lesions and to the progressive 
deterioration of allograft function in a subset of kidney transplant recipients (Moll and 
Pascual 2005). In particular, transplant glomerulopathy was found to be associated with 
C4d glomerular deposits and with peritubular capillary basement membrane 
multilayering. Najafian and his group reported that 61% of ‘typical’ chronic rejection 
cases with arterial and/or glomerular pathological changes had capillary C4d deposition 
(Najafian and Kasiske 2008). In contrast, chronic allograft arteriopathy, is characterized 
by the presence of disruption of the internal elastica lamina, inflammatory cells in the 
fibrotic intima and proliferation of myofibroblasts in the intima. These criteria are 
indicative of chronic T cell-mediated rejection (Solez et al. 2008). Chronic endothelial 
injury may manifest as new basement membrane formation in glomerular or peritubular 
capillaries, or it may lead to chronic ischaemic injury manifest by tubulointerstitial or 
intimal fibrosis (Najafian and Kasiske 2008). 
1.5.3.  Transplant glomerulopathy (TG )  
The presence of HLA-specific antibodies, pre-and/or post-transplantation, is a key factor 
in the development of transplant glomerulopathy (TG) and chronic allograft rejection 
(Cosio et al. 2008). The risk of TG is further increased in patients with a history of acute 
rejection; approximately 45% of patients with acute rejection develop TG compared to 
6% of recipients without acute rejection (Cosio et al. 2008).  
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TG, when accompanied by C4d deposition in peritubular capillaries and by circulating 
DSA, is diagnostic of chronic humoral rejection (Sis et al. 2007). Demirci et al. showed 
proteinuria, decreased allograft function, and impaired survival were strongly correlated 
with the development of HLA-specific antibodies, deposition of C4d, and TG (Demirci et 
al. 2008). However, the significance of the association between class II HLA-specific 
antibodies and C4d deposition at the time of diagnosis of TG is still controversial; only in 
some cases do the peritubular capillaries stain positive for C4d at TG diagnosis (Colvin 
2007). One explanation is that there are two types of TG: C4d-positive, antibody-
mediated and C4d-negative, antibody-independent. Another hypothesis suggests that 
alloantibody-mediated injury is not always associated with detectable C4d deposition. 
This hypothesis was supported by one study in which 87% of patients with TG had class 
II HLA-specific antibodies, but only 23% of cases were C4d-positive (Cosio et al. 2008). 
In another study, only 36% of TG cases were C4d-positive, but 70% had HLA-specific 
antibodies that in 85% of the cases were donor-specific (Sis et al. 2007). 
1.5.4.  Transplant arteriopathy 
The development of transplant arteriopathy is mediated by leukocytes, particularly 
macrophages and platelets, which release cytokines that instigate endothelial cell 
activation, increased expression of proinflammatory molecules in the endothelium, 
increased leukocyte extravasation and increased inflammation. Smooth muscle cells 
respond to the growth factors and vasoactive peptides, produced by endothelial and 
inflammatory cells, via the expression of classical growth factors and their receptor 
genes, such as insulin-like growth factor-1 and platelet-derived growth factor. These 
growth factors and receptors work in a paracrine- and autocrine- manner to stimulate 
proliferation. As a result, the arteries affected by the proliferative arteriopathy begin to 
occlude, leading to anoxic and fibrotic changes in the transplant (Hayry et al. 1999). 
1.5.5.  The effect of antibody in the absence of complement fixation 
Antibody can cause an effect on endothelial cells that is independent of complement 
which might still contribute to the pathogenesis of graft rejection (Jin et al. 2005). 
Complement fixation is required for acute antibody-mediated rejection, but the picture is 
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not so clear for chronic antibody-mediated rejection. In the absence of complement or 
inflammatory cells, antibody can induce endothelial-cell activation (Smith et al. 1998). 
These antibodies can activate endothelial cells directly by cross-linking MHC molecules. 
Activation of endothelial cells by this mechanism leads to proliferation, increased 
phosphorylation of tyrosine proteins, production of growth factors and their receptors 
(transforming growth factor-β (TGF-β), platelet-derived growth factor (PDGF) and 
fibroblast growth factor (FGF)), cytokines and adhesion molecules (Bian et al. 1997; 
Bian et al. 1998; Presta et al. 2005). 
 
This process might be related to the arterial intimal proliferation that is characteristic of 
chronic rejection. In addition, antibody can lyse target cells by complement-independent 
pathways, through the low-affinity Fc receptor for IgG FcγRIII (CD16) at the surface of 
natural killer cells and macrophages by the process known as antibody-dependent cell-
mediated cytotoxicity (ADCC). The action of antibody on endothelial cells in the absence 
of complement activation also may have a role in allograft rejection, particularly chronic 
allograft rejection (Tinckam and Chandraker 2006). Even in the absence of complement, 
endothelial cells demonstrate activation and proliferation in the presence of MHC class I 
antibodies in vitro (Jindra et al. 2008).  
1.5.6.  Accommodation 
Patients may have circulating anti-donor antibody without graft dysfunction, a condition 
known as ‘accommodation’ (Koch et al. 2004). Accommodation reflects a biological 
change or a coordinated series of changes that enable cells and tissues to persist in the 
face of noxious agonists, cells, or other factors directed against them. Accommodation 
may originate from a single mechanism or from multiple mechanisms encompassing 
changes to both the graft and the recipient (Koch et al. 2004). Chronic antibody-mediated 
rejection may result from partial accommodation concurrent with incomplete inhibition 
of the complement pathway, thus preventing cell lysis but allowing chronic endothelial 
cell damage (Colvin and Smith 2005). Protocol biopsies have revealed that 2 to 17% of 
normally functioning grafts have C4d deposition without graft pathology, a combination 
found in over half of all ABO-incompatible grafts (Haas et al. 2006). Whether this is 
stable accommodation, without long-term consequences, remains to be determined: 
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Animal studies argue that C4d deposition combined with donor reactive HLA-specific 
antibodies lead to chronic rejection, at least in the absence of immunosuppression (Smith 
et al. 2006), but, it is well established that accommodation can occur in ABO-
incompatible grafts which then persist without obvious ill effects. Evidence for further 
activation of the complement system, notably C3d, is correlated with signs of 
inflammation and may be useful in this setting (Haas et al. 2006). Unfortunately, C3d is 
difficult to evaluate in the kidney due to the common presence of C3 along the tubular 
basement membrane.   
1.5.7.  Stages of antibody-mediated rejection  
As described above, antibodies against antigens that are expressed on renal and other 
solid-organ allografts are a real barrier to successful transplantation. However, it is only 
in the past 15 years that researchers have started to understand the full spectrum of 
antibody effects on the allograft. At a National Institutes of Health (United States) 
Consensus Conference, four stages of antibody-mediated rejection were described as 
follows: 
Stage I: The first evidence of an antibody-mediated response is the de novo generation of 
donor-reactive antibodies. In many situations and for unknown reasons, donor-reactive 
antibodies do not elicit acute antibody-mediated rejection. Many reports have highlighted 
the impact of pre-transplant humoral allosensitization on organ transplant outcome 
(Terasaki 2003). Preformed HLA-specific antibodies have been associated with 
hyperacute rejection, humoral rejection, and increased incidence of acute cellular 
rejection (Terasaki and Cai 2005). Transplanted organs, especially the kidney and heart, 
are at risk of hyperacute rejection if the patient has preformed donor-specific 
alloantibodies (Moll and Pascual 2005). The primary target of donor-specific antibodies 
is the vascular endothelium of the transplanted organ. The most common target antigens 
are HLA class-I and ABO blood group antigens but other, less-well defined antigens, 
have also been identified as targets of pre-formed antibodies. 
 
Stage II: shows evidence of antibody reactivity and complement activation in the graft, 
with C4d deposition in peritubular or glomerular capillary endothelium. At this stage, 
there is no evidence of pathological or clinical injury in the graft. Both stage I and II fit 
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the criteria for accommodation that is, graft resistance to antibody, therefore graft injury 
is not necessarily predestined to occur.  
 
Stage III: In addition to positive staining for C4d, morphological abnormalities are now 
observed, but graft function is still normal. This is known as sub-clinical rejection. 
 
Stage IV: In addition to positive staining for C4d and pathological changes, graft 
dysfunction and/or proteinuria occurs. 
 
The interval between these stages can be long or short, and it is not known whether 
progression is inexorable (Colvin and Smith 2005). 
 
The targets of DSA and NDSA are varied and the antibodies themselves vary in isotype 
and time of production.  These issues will be discussed below. 
1.5.8.  HLA-specific antibodies 
The presence of DSA before and after transplantation has been associated with rejection 
episodes and the loss of renal allografts (Patel et al. 2007; Marrari and Duquesnoy 2009). 
In humoral rejection, the endothelium of a donor organ is targeted by alloantibody 
binding to antigens on endothelial cells (Jindra et al. 2006), specifically HLA class I 
antigen expressed by these cells (Jindra et al. 2008). If the level of HLA-specific 
antibodies is high enough and the antibodies possess appropriate immunological 
characteristics, HLA-specific antibodies can cause acute rejection, directed against the 
vasculature of the graft (Feucht et al. 1993). Consistent with this, acute rejection after 
renal transplantation is associated with DSA and transplant recipients who develop HLA-
specific antibodies post-transplant, experience more rejection (Panigrahi et al. 2007). 
Conversely, patients without HLA-specific antibodies post-transplant have better graft 
function (Piazza et al. 2000). In some studies, circulating antibodies were detected only 
after graft dysfunction had developed and sometimes only after the transplant had been 
removed. The suggested explanation for this was that the graft may absorb DSA (Martin 
et al. 2003; Adeyi et al. 2005), making measuring circulating antibodies in the serum 
difficult, potentially leading to under-estimatation of their frequency (Rifle et al. 2005). 
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Similarly, some investigators have reported that in some cases, both DSA and non-donor 
specific antibodies (NDSA) against HLA may develop but, because DSA are bound and 
absorbed by the graft, the presence of NDSA against HLA in post-transplant patient sera 
is apparently more frequent than DSA (Terasaki and Ozawa 2005; Seveso et al. 2009).  
Using complement-dependent lymphocytotoxicity (CDC) assays, enzyme linked 
immunosorbent assays (ELISA), and X-MAP technology assays (also known as Luminex 
bead-dependent assays) (these methods will be discussed in more detail later), Hourmant 
et al. evaluated and correlated with transplant outcome, the percentage of patients with 
post-transplant DSA and NDSA, who had a functioning kidney at one-year post-
transplant. The presence of either DSA or NDSA significantly correlated with lower graft 
survival, poor transplant function, and proteinuria (Hourmant et al. 2005). However, a 
previous study by Gibney et al. had conflicting findings; similarly to Hourmant’s study, 
Gibney et al. found that the detection of DSAs was associated with significantly higher 
rates of graft dysfunction but, in contrast with Hourmant et al., the presence of NDSA 
was associated with excellent outcomes. Gibney et al. highlighted that the occurrence of 
low-level DSA (detected using X-MAP Technology but not by other tests) could be used 
to help identify patients who required more aggressive immune monitoring or 
immunosuppressive strategies (Gibney et al. 2006). Later, Moe and his colleagues agreed 
with Hourmant, finding that NDSAs are associated with kidney failure; almost half of the 
failures in his study group occurred after development of NDSA (Mao et al. 2007a).   
In the past, the conventional standard methods used to measure antibodies in serum did 
not have the specificity needed to identify properly all antibodies present in a given 
serum. It is now possible to identify both DSA and NDSA using the sensitive and specific 
X-MAP technology. As a result, more HLA-specific antibodies specificities are now 
being detected, e.g. by single-antigen X-MAP technology beads (Billen et al. 2008) and 
NDSA can be detected, on some occasions, due to sharing epitopes with DSA.  
The type of de novo HLA-specific antibody (against class I or II HLA) and its 
relationship to the development of acute or chronic rejection have been studied by various 
investigators.  Kidney transplant recipients who have rejected a kidney have been shown 
to have HLA-specific antibodies. Non-sensitized kidney transplant recipients may 
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develop de novo HLA-specific antibodies, both DSA and NDSA, as well as non-HLA-
specific antibodies after transplantation. The development of de novo antibodies increases 
the risk of acute rejection and reduces allograft survival (Li et al. 2008): various 
investigators have reported the relationship between the development of acute rejection 
and the presence of de novo HLA-specific antibodies, of both classes, in patient’s sera 
(Akalin and Pascual 2006) and thus post transplant de novo development of HLA-specific 
antibodies is thought to represent an important risk factor for poorer outcome (Reinsmoen 
et al. 2004). Martin et al. observed that most de novo HLA-specific antibodies were class 
I HLA-specific antibodies (50 % anti-class I alone, 36% both class I and class II) (Martin 
et al. 2003). 
 
It is important to remember that the generation of alloantibodies after transplantation may 
be the result of T cell sensitisation during or after an acute rejection episode. In fact, 
many studies have confirmed that T cell recognition of processed alloantigen, by the 
indirect pathway, is the main factor that begins and sustains the progression of chronic 
allograft rejection (van Besouw et al. 2005). When investigating alloantibody production 
therefore, it should be highlighted that the detection of Ig class-switched alloantibody is 
certainly associated with the expansion of T cells with indirect allospecificity; only 
indirect pathway T cells can provide help for allospecific B cells (Steele et al. 1996).  
 
To detect de novo HLA-specific antibody production, a patient’s pre-transplant 
alloantibody status should be studied by the most sensitive assays such as flow beads and 
X-MAP technology (Cai and Terasaki 2005).  
 
The following facts suggest advantages of further/more extensive post transplantation 
monitoring: 
1.  Post transplantation monitoring of HLA-specific antibody production would allow the 
identification of kidney transplant recipients who might be at increased risk of late 
allograft failure.  
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2.  Knowledge of alloantibody status after transplantation may help to guide the 
appropriate use of immunomodulatory agents to downregulate HLA-specific 
antibody production (Lachmann et al. 2009). 
 
Bearing in mind the strength of evidence for the roles of pre-existing and de novo HLA-
specific antibodies in graft rejection, it is necessary to improve methods for the detection 
and monitoring of both types of antibodies to continue improving allograft and patient 
survival. 
1.5.8.1.  Class I HLA-specific and class II HLA-specific antibodies 
It is well established that not all HLA-specific antibodies have the same effect on graft 
loss.  Class I HLA-specific antibodies are a high risk factor for rejection (Vasilescu et al. 
2006). The presence of IgG class I  HLA-specific antibodies, regardless of the presence 
or absence of class II HLA-specific antibodies, is associated with decreased graft survival 
during the first year post-transplantation (Vasilescu et al. 2006) and class I HLA-specific 
DSA are associated with early graft loss. By comparison, class II HLA-specific DSA are 
associated with the steady deterioration in renal allograft function which leads to chronic 
rejection (Lachmann et al. 2009). Campos et al. showed that the presence of class II 
HLA-specific antibodies increases the risk of graft failure in patients who already had 
declining graft function (Campos et al. 2006).  Pollinger et al. reported that in post-
transplant samples, the detection of class II HLA-specific DSA is an indication of renal 
acute rejection (Pollinger et al. 2007). With these data in mind it makes sense that post-
transplant monitoring of classII HLA-specific antibodies now represents an essential tool 
in the clinical management of kidney transplants (Campos et al. 2006).  
 
The differing roles of class I and class II HLA-specific antibodies in rejection can be 
explained by the different distribution of HLA antigens among the cells. HLA class I 
antigens are found on all cells of the transplanted organ thus making all cells of the organ 
a target for the HLA class I antibodies.  In contrast, the source of allo-HLA class II 
antigens is more restricted; donor APCs and the graft endothelium are the main sources 
of these antigens and thus represent a smaller number of cells (and thus a smaller number 
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of targets) than cells expressing HLA class I.  Furthermore, the supply of HLA class II 
antigens changes with time after transplant; donor DCs which are present in the graft at 
the time of transplantation die in the days and weeks after transplantation and 
consequently this source of HLA class II antigens decreases post-transplantation.  The 
source of HLA class II does not disappear completely because Human kidney endothelial 
cells constitutively express HLA class II antigen (Markus et al. 1988) and in 
inflammatory or stress-inducing conditions can upregulate HLA class II antigen, 
providing more targets for the class II HLA-specific antibodies (Ahern et al. 1982). The 
induction of high levels of HLA class II expression on kidney endothelial cells, the 
primary target of antibody-mediated cytotoxicity, is due to an increase of cytokines, e.g. 
interferon-γ, which promote the transcription of HLA class II genes (Muczynski et al. 
2003). Another important characteristic of HLA class II expression on endothelial cells is 
that the level of HLA-DQ and HLA-DP expression is less than HLA-DR and varies from 
one donor to another. This is a very important fact to take into consideration when 
determining the potential risk factors associated with class II HLA-specific antibodies 
responsible for positive B-cell FCXM, since patients with DSA against donor HLA-DR 
antigens may have a higher risk for developing adverse effects compared to those with 
HLA-DQ-specific and/or HLA-DP-specific antibodies (Delgado and Eckels 2008). 
1.5.8.2.  HLA-DP-specific antibodies 
HLA-DP antigens can function as classical restriction elements for antigen presentation 
yet neither HLA-DP typing, nor HLA-DP-specific antibody analysis are included in 
routine compatibility testing because the information available on the structure and 
specific function of HLA-DP and the clinical implications of these antigens acting in 
antigen presentation, is still limited (Diaz et al. 2003).  Several years ago, detection of 
HLA-DP-specific antibodies was performed using an HLA class II panel that was typed 
for HLA-DP as well as HLA-DR and HLA-DQ however, HLA-DP-specific antibodies 
were only identified in the absence of DR and DQ antibodies, as the individual members 
of the screening panel expressed DR and DQ, as well as DP antigens. Recently, the 
company One Lambda, has advanced this area by producing single antigen HLA class II 
Flow PRA beads. These beads are coated with six DP antigens (Qiu et al. 2005) and are 
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used to help identify DP antibodies regardless of any other HLA antibodies a patient 
might have. 
 
The presence of HLA-DP-specific antibodies has been reported to occur more frequently 
in patients who reject their graft. Consequently, it has been suggested that HLA-DP-
specific antibodies are involved in the process of chronic graft rejection (Scornik et al. 
2007). The presence of pre-formed donor HLA-DP-specific alloantibodies in sensitized 
patients’ sera may cause acute allograft rejection via a memory alloresponse to a repeat 
HLA-DP antigen mismatch e.g. donor HLA-DP-specific antibodies directed towards an 
epitope in the beta chain (Goral et al. 2008).  
1.5.8.3.  The role of HLA-specific IgG and IgG subclass 
The role of different IgG subclasses of alloantibodies in graft survival is still 
controversial. Karuppan et al. suggested that non-complement fixing IgG2 and IgG4 
alloantibodies contribute to the risk of developing early acute kidney rejection after 
kidney transplantation (Karuppan et al. 1992). Consistent with this, Nanni-Costa and his 
colleagues analysed a patient serum sample, by ELISA, and found early acute vascular 
graft rejection due to the presence of a pre-transplant donor-specific antibody of  IgG2 
subclass (Nanni-Costa et al. 1996).  However, in the same year, Kerman and his group 
tested random post-transplant sera for IgG subclass (IgG1, IgG2, IgG3, IgG4) using the 
PRA-STAT (ELISA kit). They found a significant correlation between the presence of 
IgG1 and graft rejection but not IgG2, IgG3, IgG4 (Kerman et al. 1996). Monterio 
investigated the presence of IgG1 in both pre-transplant and post-transplant sera using 
PRA-STAT and also found that class I HLA-specific IgG1 antibodies were the major 
isotype correlated with poor graft outcome (Monteiro et al. 1997). Arnold and his 
colleagues, using a modified ELISA kit, observed a large number of IgG4 antibodies 
against HLA class II antigen (Arnold et al. 2004). Warrens and his team used flow 
cytometry to study the effect of IgG subclasses in sensitised renal transplant recipients 
with class I HLA-specific antibodies. They concluded that a subclass pattern of HLA-
specific antibodies that was skewed towards the IgG1 subclass represented a risk factor 
for graft loss (Griffiths et al. 2004).  
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Gao and his group used flow cytometry to study the presence of anti-donor IgG subclass 
antibodies before and after liver transplantation. They reported that the presence of IgG3 
donor-specific-antibodies was associated with increased risk of hyperacute rejection 
because IgG3 is the strongest complement-fixing IgG subclass (Gao et al. 2004). 
Heinemann and his team disagreed with the previous finding showing that non-
complement-activating antibodies (IgG2, IgG4) may be of relevance for the allograft 
function by modulating the rejection processes. These antibodies can be detected, using 
ELISA and X-MAP Technology, in the eluted antibodies from explanted kidneys 
(Heinemann et al. 2007). 
1.5.8.4.  HLA-specific IgA  
There is increasing evidence that antibodies of the IgA isotype play an important role in 
kidney transplantation. In one study, the presence of HLA-specific IgA antibody in pre-
transplant patient serum was associated with improved allograft survival, the proposed 
mechanism for this was that HLA-specific IgA antibodies compete with and inhibit the 
harmful HLA-specific IgG antibodies binding to allograft HLA (Kerman et al. 1996). 
However, Heinemann et al. could not reproduce this result (Heinemann et al. 2007).  
 
Susal et al. reported that pre-sensitized patients with high serum IgA content had better 
graft survival rate. In contrast, graft survival rates in pre-sensitized patients with low 
serum IgA content or with low IgA autoantibody activity were extremely poor (Susal et 
al. 2000). In patients with high pre-transplant alloantibody and high serum IgA, it has 
been suggested that low-dose immunosuppression may be sufficient to manage rejection. 
This would have the advantage of decreasing drug side effects, such as toxicity, infection, 
and cancer (Susal et al. 1995). 
1.5.8.5.  HLA-specific IgM  
In 1997, McCalmon and his group used CDC assays to identify the presence of IgM 
antibodies (IgM autoantibodies, non-donor-specific-IgM lymphocytotoxic antibodies and 
IgM anti-allogeneic HLA antibodies). The results suggested that kidney rejection is not 
mediated by any type of IgM antibody (McCalmon et al. 1997). In addition, McAlister et 
al. studied the effect of the presence of IgM and IgG donor-specific antibodies in patient 
Introduction 
 76
serum using flow cytometry and concluded that the presence of the former may actually 
be protective of kidney graft survival (McAlister et al. 2004). The presence of HLA-
specific IgM antibodies is correlated with the presence of naïve cytotoxic T lymphocytes 
and successful kidney transplantation (van Kampen et al. 2001). Also, it has been 
suggested that the presence of IgM autoantibodies might improve graft survival rate 
because the epitopes recognized by IgM show a high degree of homology with antigenic 
receptors of the T cells and therefore they could be involved in suppressor or 
immunoregulatory effects (Diaz et al. 2004). Another study reported that IgG antibody 
was much more closely correlated with severe kidney rejection than IgM antibody 
(Khodadadi et al. 2006).  However, a recent study that looked for a correlation between 
HLA-specififc IgM antibodies, or non-HLA-specific IgM antibodies, with patient 
survival, found that the presence of pre-transplant non-HLA-specific IgM antibodies, 
correlated with higher patient mortality, in cardiac graft recipients (Smith et al. 2009).  
Based on their results, the authors suggested that pre-existing cytotoxic IgM antibodies, 
in the recipient, against non-HLAs may be a risk factor in cardiac survival (Smith et al. 
2009).  IgM antibodies therefore, may not be as innocuous as previous studies have 
suggested. 
1.5.9. Non-HLA-specific antibodies 
The role of anti-ABO blood group antibodies in transplantation has been discussed in 
section 1.2.4 above. Here I will focus on other non-HLA-specific antibodies. 
 
Many investigators have suggested that one cause of acute and chronic humoral rejection 
is the presence of non-HLA-specific antibodies. For instance, in more than 10% of cases 
with C4d-positivity on biopsy it proved impossible to detect the presence of complement-
fixing HLA-specific antibodies, suggesting that non-HLA-specific antibodies may be the 
cause, at least in some cases (Mauiyyedi et al. 2002). There is evidence that antibodies to 
antigens present on endothelial cells and monocytes are associated with renal transplant 
failure. Many studies have reported formation of antibodies against non-HLA antigens on 
endothelial cells to be associated with chronic rejection after heart (Jurcevic et al. 1998) 
and kidney transplantation (Zou et al. 2007). Following aortic valve transplantation, the 
presence of post-transplant HLA-specific antibodies caused up-regulation of adhesion 
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molecules on endothelial cells (in the presence of IL-1 cytokines); this may lead to 
endothelial cell activation and contribute to rejection (Smith et al. 1998). Perrey and his 
colleagues studied patient serum by ELISA assay and concluded there was a correlation 
between the renal graft loss and the presence of IgG antibodies against endothelial cells 
(Perrey et al. 1998). Correlations between anti-endothelial antibodies and chronic renal 
allograft rejection have been reported (Ball et al. 2000). 
1.5.9.1.  MICA antibodies 
MHC class I chain-related antigen A (MICA) and B (MICB) belong to a gene family 
located in MHC class I. The MHC class I-related chain (MIC) locus is situated on 
chromosome 6, linked to HLA locus (Zou et al. 2007).  MICA and MICB encode cell-
surface glycoproteins which are expressed on endothelial cells (Zwirner et al. 1998), 
dendritic cells, fibroblasts, epithelial cells, and many tumours, but not on peripheral-
blood lymphocytes (Zou et al. 2007).  
Since MICA antigens are not expressed on lymphocytes, the cells commonly used for 
cross-matching, antibodies directed against MICA are not detected by the conventional 
methods. However, antibodies to the MICA antigens have been found to be cytotoxic in 
the presence of serum complement thus allowing them to be measured (Zou et al. 2007).  
In addition, X-MAP technology can be used to detect anti-MICA antibodies. 
These polymorphic MIC molecules can be targeted by both cellular and humoral immune 
responses. In fact, MICA has been reported to be an important polymorphic alloantigen 
capable of inducing the synthesis of specific alloantibodies in transplanted patients 
(Zwirner et al. 2000) and of being a target for humoral immunity associated with 
irreversible rejection of kidney allografts (Sumitran-Holgersson et al. 2002) Of note, 
MICA and MICB expression have been demonstrated in kidney and pancreas allografts 
with acute and chronic rejection and acute tubular necrosis (Hankey et al. 2002). 
Mizutani et al. reported that antibodies to MIC are produced in the course of 
immunization by pregnancy and kidney transplantation (Mizutani et al. 2006).  Panigrahi 
et al. studied the development of post transplant HLA-specific  and anti-MICA antibodies 
in response to live related donor renal transplantation. He highlighted the importance of 
Introduction 
 78
NDSA antibodies as they could act as surrogate markers of T cell activation. He used X-
MAP technology to detect MICA and observed correlations between the presence of 
MICA antibodies and graft destruction. Interestingly, patients who develop both HLA-
specific  and MICA antibodies reject their grafts more frequently than those having either 
of these classes of antibodies alone (Panigrahi et al. 2007). 
 
It has also been reported that post-transplantation development of alloantibody specific to 
HLA and MICA is correlated with chronic rejection and poor allograft survival (Mizutani 
et al. 2005). Mizutani et al. suggested that final constriction of vessels results from a long 
repeated process of antibody-induced damage to the vessel wall followed by repair and 
hypertrophy of the endothelium. Moreover, a higher frequency of HLA-specific  and anti-
MICA antibodies are found in patients who rejected their grafts compared to those whose 
grafts were still functioning, suggesting that they maybe a major cause of graft failure 
(Mizutani et al. 2006). 
1.5.9.2.  Vimentin antibodies 
It is well recognized that the release of self-antigens to the periphery occurs during and 
after ischemia-reperfusion injury and after rejection episodes (Boros and Bromberg 
2008). This may predispose an individual to rejection by exposing new targets to the 
immunological processes involved in graft rejection. Vimentin is an intermediate filament 
cytoskeletal protein that may act as an autoantigen. It is present within endothelial cells, 
smooth muscle cells, fibroblasts, and leukocytes, as well as renal tubular cells, and renal 
cells (Mahesh et al. 2007; Leong et al. 2008). During transplantation or rejection, 
endothelial damage may occur, which would expose vimentin, allowing this self-protein 
to behave like an alloantigen (Carter et al. 2005). Vimentin antibodies are found in 
autoimmune disease such as rheumatoid arthritis and systemic lupus erythematous (SLE) 
and are formed de novo following cardiac transplantation, where they have been linked to 
chronic rejection (Mahesh et al. 2007). After cardiac and renal transplantation, patients 
make an autoimmune response to vimentin, demonstrated by autoantibodies and self-
restricted vimentin-specific CD8+ T cells (Barber et al. 2004). Carter et al. showed that 
21 of 48 patients with renal failure had antibodies to vimentin when the graft failed. In 
that study, post-transplant samples were tested for the presence of IgM and IgG vimentin 
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antibodies using a newly developed flow cytometric assay in which recombinant 
vimentin was bound to polystyrene microspheres (Carter et al. 2005). 
 
1.5.10. HLA cross matching; methodology and efficiency 
As extensively described above, MHC molecules of the graft are the principal targets of 
the immune response post-transplantation. In 1969, Patel and Terasaki reported that the 
presence of recipient antibodies against antigens (later found to be MHC molecules) 
expressed on donor T and B lymphocytes were a risk factor for early rejection or graft 
loss after renal transplant (Patel and Terasaki 1969). For this reason, end stage renal 
failure patients being considered for renal transplantation are screened for the presence of 
pre-formed HLA-specific antibodies in their historical and current sera to avoid humoral 
rejection. CDC, ELISA, flow cytometry and X-MAP technology assays enable recipient 
sensitisation to be determined (Patel and Terasaki 1969; Fernandez-Fresnedo et al. 2003; 
Monien et al. 2006; Lentine et al. 2008; Gupta and Sinnott 2009). This has allowed 
successful renal transplantation and in patients with pre-existing antibodies to donor 
MHC antigens, thereby providing an avenue to transplantation for highly sensitized 
patients who would otherwise have to remain dialysis-dependent. The above mentioned 
tests each yield different information and have their individual advantages and 
limitations. 
1.5.10.1.  Complement Dependent Cytotoxicity (CDC) 
CDC is used as an initial screening test to identify patients at risk of antibody-mediated 
damage to grafted organs or tissue.  Donor cells are mixed with serum from the proposed 
recipient and incubated.  Following this incubation, complement is added to the cells for 
a period of time (commonly one hour).  At the end of this incubation period, cells that 
have been lysed, due to the action of complement, via antibody binding to cell-surface 
antigens, are detected by viability staining.   
 
CDC was introduced to determine the suitability of an organ and transplant recipient 
combination.  This test detects and identifies only complement-fixing (IgG1, IgG3 and 
Introduction 
 80
IgM) antibodies, which may be directed against HLA or non-HLA antigens, including 
autoantibodies (Smith et al. 2009).  Autoreactive IgM antibodies, which appear, in some 
studies, to be irrelevant to transplant outcome (Worthington et al. 1998) but in others to 
be protective (McAlister et al. 2004), can be differentiated from IgG isotypes by 
performing the test with and without dithiothreitol (DTT).  
 
A negative CDC crossmatch result means proceeding with the transplant and a positive 
crossmatch is considered a contraindication for kidney transplantation; IgG antibodies 
have been shown to be detrimental to the graft (Patel and Terasaki 1969).  However, 
despite a negative direct CDC crossmatch at the time of transplantation, sensitized 
recipients have an increased risk of chronic rejection (Takemoto et al. 1999).  These 
sensitised patients may have produced a negative crossmatch result in part because of the 
limitations of CDC.  For example, the test is not HLA-specific and is unable to detect 
non-complement-fixing antibodies such as those of IgG2 and IgG4 subclasses 
(Worthington et al. 2001).  These factors contribute to the insensitivity of the CDC test.  
Further limitations, of using CDC for screening, include the requirement for large panels 
of viable lymphocytes to cover all HLA specificities and the subjective reading of the 
tests.  
 
To increase the sensitivity of CDC testing, a complement-fixing anti-human globulin 
(AHG) antibody is added prior to the addition of complement. This test has the ability to 
detect low titer antibodies that are not commonly detected by the standard CDC method 
(Johnson et al. 1972).  Unfortunately, as B lymphocytes express large quantities of 
surface immunoglobulin, the augmented AHG-CDC cannot be efficently implemented to 
detect B-cell antibodies. Therefore, to date, serological B cell crossmatches continue to 
be performed using the less sensitive CDC assays.  This is not ideal because there is a 
strong correlation between the presence of anti-class II and hyperacute rejection (Scornik 
et al. 1992) (this can be clearly observed in patients who have only anti-class II antibody 
and no anti-class I antibody) but  assessing the level of anti-class II antibodies using the B 
cell CDC crossmatch assay is unreliable; many sensitized patients have a combination of 
anti-class I and anti-class II antibodies and the B cell crossmatch is sensitive to both 
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antibodies to class I and class II.  Therefore, to solve this problem, B cell crossmatch 
results must interpreted in the context of a comprehensive antibody screening test such as 
ELISA, Flow cytometry (Pelletier et al. 1999; Sagoo et al. 2010) and X-MAP 
Technology (Billen et al. 2009). 
1.5.10.2.  ELISA 
ELISA-based tests use soluble HLA antigens as antibody targets and have certain 
advantages over CDC. First of all, this test has no requirement for viable lymphocytes or 
complement. Secondly, it was designed to detect only HLA-specific antibodies, both 
complement-fixing and non complement-fixing. There are two types of ELISA kits: the 
first is used to screen patients for the presence or absence of any HLA-specific antibody. 
The second type of ELISA defines the specificity at the level of individual alleles. These 
facilitate analysis of sera from sensitized patients. The sensitivity and specificity of 
ELISA techniques are higher than with CDC (Fernandez-Fresnedo et al. 2003). However, 
ELISA is less sensitive than flow cytometry. For example, in one study Gebel 
investigated 264 patients waiting for cardiac or renal transplantation, to detect 
alloantibodies using anti human globulin-enhanced, complement-dependent cytotoxicity 
assays (AHG-CDC), ELISA and flow cytometry. Discordant results occurred in 32 
samples: i.e. antibodies were detected by flow cytometry in 32 patients who were 
negative by CDC. Of these, 20 were positive by ELISA (Gebel and Bray 2000). 
1.5.10.3.  Flow cytometry 
The flow cytometric crossmatching technique (FCXM) is more sensitive than CDC for 
detection of anti-donor antibodies in renal transplantation (Bray et al. 1989). However, 
the clinical relevance of the increased sensitivity of FCXM is controversial because it 
does not differentiate between cytotoxic and non-cytotoxic antibodies. Positive T-cell 
FCXM and negative CDC crossmatching has been proven to help to identify patients at 
risk of rejecting a kidney transplant (Mahoney et al. 1996). However, the clinical 
relevance of a B-cell FCXM positive has not been established. On one hand many 
investigators have reported that a B-cell FCXM positive has damaging effect to the 
outcome of kidney transplantation (El Fettouh et al. 2000; Scornik et al. 2001) but, on the 
other hand, several other studies havs concluded that a B-cell FCXM does not influence 
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graft outcome (Lobashevsky et al. 2000; Le Bas-Bernardet et al. 2003). The clinical 
implication of B-cell FCXM continues to be a matter of debate for several reasons:  
1. Ig-Fc receptors, expressed on the B cell surface, bind anti-IgG antibodies non-
specifically and promote false positive crossmatch results.  
2. Some investigators claim that the FCXM test is too sensitive and detects non-
complement-fixing antibodies that have limited impact in kidney transplantation (Vaidya 
et al. 2001).  
3. A FCXM, positive for B-cells only, is not always related to the presence of DSA 
against the HLA class II antigen; it can be due to the presence of auto-antibodies which 
may or may not influence of transplant outcome (Ettenger et al. 1983; Le Bas-Bernardet 
et al. 2003, McAlister et al. 2004). Alternative explanations for positive B-cell FCXM are 
the presence of low levels of donor-specific class I HLA-specific antibodies (Bishara et 
al. 1988) and the presence of donor-specific-antibodies raised against a variety of minor 
histocompatibility antigens (Zwirner et al. 1998).          
 
Flow cytometry was developed to detect IgG antibody binding to lymphocytes. One of its 
applications is to assess the specificity of weak HLA-specific antibodies that are not 
normally detected by less sensitive methods such as CDC (Cole et al. 2002) . Also it has 
the ability to detect both complement-fixing (IgG3, IgG1) and non-complement-fixing 
subclasses of IgG (IgG2, IgG4) (Wahrmann et al. 2003). Flow cytometry cross matching 
is a more sensitive assay than classical CDC in that it allows the detection of antibodies at 
lower serum concentration as well as detecting both IgG2 and IgG4 (Harmer 1998). One 
limitation of this method, as with CDC, is the need for cell targets which leads to the 
detection of both HLA- and non-HLA- specific antibodies (FCXM). As a result, further 
screening products have been developed. For instance, Flow-PRA beads are 
microparticles coated with purified HLA class I or class II antigen (Crespo et al. 2001) 
the binding of HLA-specific antibodies to which is detected by flow cytometry. Ishida 
and his team compared the results of 125 patients analyzed by both flow PRA beads and 
FCXM in correlation with graft outcome. They found out that 28 patients were positive 
by Flow PRA but negative by FCXM. 16 of those 28 patients developed humoral 
rejection (Ishida et al. 2005). Flow PRA beads consist of a mixture of different coloured 
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beads with different florescent properties. These beads are exited at 488nm, generating 
maximum emission of approximately 580 nm. Each group of beads is incubated 
separately with the test serum and then stained with a FITC-conjugated anti-human IgG 
antibody. Beads stained positively can be compared to the negative control serum and the 
control beads to determine the range of antibodies present in the patient’s serum.  
1.5.10.4.  X-MAP Technology 
X-MAP Technology is a multiplex, flow cytometric-based assay system that involves the 
use of microparticles or polystyrene beads coated with pooled or specific purified HLA 
class I and class II antigens. Up to 100 beads can be combined in a single test. HLA-
specific binding can be detected using a fluorescence-conjugated secondary antibody 
directed against human immunoglobulin and fluorescence is measured in a flow analyzer 
(Vignali 2000). The coated beads are filled with two fluorescent dyes in differing ratios, 
resulting in 100 different bead sets that can be distinguished by their internal “colour”. 
The X-MAP analyzer resembles a flow cytometer with two lasers. One laser allows 
identification of the bead set based on the emission profile of the two internal 
fluorophores, while the other laser is used to excite the reporter fluorophore bound to 
each bead. By loading different bead sets with different antigens and subsequent 
preparation of a bead mix, the antibody response to up to 100 different antigens can be 
measured simultaneously. Finally, high speed digital-signal processors will identify each 
individual microsphere and quantify the results. X-MAP technology is the most sensitive 
technique for detecting HLA-specific antibody (Gibney et al. 2006). It is a time-saving 
analytical system (Martins 2002) but some caution must be exercised in the use of X-
MAP Technology because of a number of limitations of the assay: 
1. HLA extraction and binding to the carrier beads may result in changes of tertiary 
protein structure leading to modification of the structure of the molecules; 
instances of impaired binding of HLA-specific antibodies have subsequently 
resulted in false-positive or false-negative reactions. 
2. The antigen density on beads may not correlate with the natural HLA expression 
on cells in vivo therefore there may be occasions when an antibody in serum may 
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bind to beads whereas it would not have bound to cells and vice versa (Schwartz 
et al. 2004; Gupta and Sinnott 2009).  
3. Another cause of false-positive results is the program analysis when the bead 
default background values are used for calculating the final result. This problem 
can be solved by using an internal negative control and it is necessary to do this 
for each laboratory because of the variation in flow cytometer lasers and 
laboratory conditions.  
4. The mean fluorescent intensity which is chosen by a laboratory as the cut-off 
value for classifying results as positive or negative will vary between laboratories.  
Consequently it is not possible to directly compare results between laboratories 
without using the same beads, same flow cytometer and same cut-off value. 
 
Even with these constraints considered, X-MAP Technology is still a highly useful 
technique for use in transplantation clinics, but it must be used in conjunction with the 
previously described assays, CDC and flow cytometry cross-matching, to ensure the 
combined results can be reliably used to predict patient responses to grafts.  Furthermore, 
these assays are continuously being improved and developed. 
 
X-MAP Technology may be used in the following ways: 
• To detect IgG complement-fixing and non-complement-fixing-antibodies. 
There are two types of commercially available X-MAP technology kits: a 
screening (poly-antigenic) kit that detects the presence of IgG Abs to HLA class I 
and II and a kit that uses oligo-antigenic beads which determines antibody 
specificity and lately single antigen beads. 
• To provide accurate assignment of antibody specificities in highly reactive sera 
(Vaidya et al. 2006) and to monitor patient antibody profiles in relation to donor-
specific antigen pre-transplant following antibody removal and identification of 
DSA post-transplantation (Vignali 2000). The assays that are used for this are the 
recently developed, single antigen (SA) assays. These assays have a single 
recombinant HLA antigen on each bead and therefore are more specific than 
oligo-antigenic assays.     
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• The SA X-MAP assays can be modified to detect other Ig isotypes such as IgM 
and IgA (Gupta and Sinnott 2009).  
• Recent reports indicate that these assays can also be modified to potentially 
identify clinically relevant complement-C4d-fixing antibodies (Jacobson et al. 
2006; Smith et al. 2007). 
 
As I have discussed, antibodies are very important for transplant rejection. Their 
detection and monitoring are invaluable for choosing transplant donors and recipients and 
for tailoring treatment to recipients.  The antibodies themselves are produced by plasma 
cells, differentiated B cells, thus making the B cell lineage a target for anti-rejection 
therapeutics. The activation of the three components of the B cell compartment, plasma 
cells, memory cells and naïve B cells, may lead to graft rejection. Memory B cells do not 
secrete antibodies but their presence implies that the patient would be at increased risk of 
mounting a highly damaging humoral response on secondary exposure to the same 
antigen (Zarkhin et al. 2008).  Later in this thesis, I will describe ways of detecting the 
presence of allospecific cells in each of these compartments. In the next section of this 
introduction, I will review the background literature to that work. 
 
1.6.  B cell culture for the detection of alloantibodies 
Activation of B-lymphocytes in vitro through CD40-engagement (using anti-CD40 
antibodies, CD40L transfectants and soluble trimetric CD40L) has been shown to induce 
proliferation, differentiation and secretion of immunoglobulin in various culture systems 
(Banchereau and Rousset 1991) ; (Armitage et al. 1993). Culture of B-lymphocytes, in 
the presence of the CD40L-expressing mouse thymoma cell line EL4B5 (Wen et al. 
1987) , is used to stimulate B-lymphocytes so that the supernatants can be tested for the 
presence of specific antibodies. The availability of a culture system for B-lymphocytes, 
and the analysis of their secreted products, might allow for a more detailed 
characterization of the humoral compartment of the allo-response. Determination of i) the 
characteristics of HLA-specific antibody specificities, secreted by individual B-
lymphocytes, and ii) of the frequency of B-lymphocytes involved, may be helpful for the 
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determination of unacceptable or high risk mismatched antigens on donor organs for 
highly sensitised patients.  
1.6.1.  B cell quantitation assays  
Many assays, such as the limiting dilution assay (LDA) (Dozmorov et al. 1996), 
haemolytic plaque forming cell assays (PFA) (Kingry and Fauci 1979) and the enzyme-
linked immunosorbent spot (ELISpot) assay (Slifka and Ahmed 1996), have been 
developed to quantitate B cell responses. 
1.6.1.1. Limiting dilution assays 
LDA have been used in many areas of biology. For example, LDA is used in 
immunology, cell biology and bacteriology. In immunology, LDAs have been used to 
determine the frequency of effector cells in a population.In addition, LDAs can be used to 
estimate the proportion of specific T cells, in a mixture, that can respond to an activation 
stimulus. The LDA is superior to other assays that measure the activation of T cells but 
do not give information regarding the frequency of responding cells.  LDAs are based on 
a process of diluting a dose to the point where the response is undetectable or cannot 
occur.  The assay requires only small numbers of biologically active cells (Matthews 
1998) and can be used to detect positive or negative responses generated by biologically 
active cells in individual or in vitro replicate cultures. LDAs can be used to estimate the 
absolute number of activated cells from small samples (Bonnefoix et al. 1996).  
However, the LDA has its limitations:   
1. The LDA can underestimate the true frequency of antigen-specific precursors by 5-
100-fold (Butz and Bevan 1998). 
2. There are inadequate references for designing and setting up LDA experiments. and 
there has been inadequate linear regression, used for the purpose of frequency 
estimation in LDA, in the last 20 years (Chaui-Berlinck and Barbuto 2000). 
3. Statistical and experimental errors can occur and therefore impact on the 
performance and evaluation of LDA. These errors directly affect the interpretation, 
validity, and significance of the LDA results (Sieburg et al. 2002). 
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1.6.1.2.  Haemolytic plaque forming cells assay (PFA) 
The haemolytic PFA is a method that utilises the ability of antibodies, when in the 
presence of complement proteins, to lyse adjacent red blood cells, creating a “haemolytic 
plaque”.  The PFA can be used to show that certain antibodies are secreted following a 
primary or secondary immunization. For example, an antigenic suspension is injected by 
the intravenous or intraperitoneal route into a rodent. The animals are killed 4-5 days 
(direct plaque assay) or 7-10 days (indirect plaque assay) post immunisation to allow for 
IgM and IgG production before killing (Herscowitz et al. 1975). The spleen is removed 
and the splenocyte suspension is incubated on an agrose plate (Jerne’s technique) or over 
a slide (Cunningham’s technique) with sheep red blood cells and guinea-pig serum as a 
source of adequate complement.  The result is the formation of clear zones (plaques) in 
the agar. Located within the center of each plaque is a single antibody-producing plasma 
cell. The number of plaques can be counted with the naked eye or under a microscope 
with low magnification (Golub et al. 1968). 
 
As mentioned above, there are two types of plaque assay: 
1. Direct: Antigen-specific IgM antibodies produced by antibody-forming cells are able 
to directly cause complement-mediated lysis of antigen-sensitised red cells 
because of their complement-fixing ability (Herscowitz et al. 1975). 
2. Indirect: Antigen-specific IgG antibodies do not fix complement as efficiently as IgM 
thus anti-IgG antibodies must be added to enhance the ability of IgG-producing 
cells to lyse the target red cells. By carrying out the assay with or without the 
anti-IgG step, it is possible to distinguish the number of IgM- or IgG-producing 
B cells (Howard and Gowans 1972). 
1.6.1.3.  ELISpot  
The ELISpot technique was first described in 1983 and initially was primarily used for 
the detection of antibody-secreting cells (Czerkinsky et al. 1983). However, in 1988, 
Czerkinsky described the use of the reverse ELISpot technique for the detection of 
cytokines from human T cells (Czerkinsky et al. 1988).  The reverse ELISpot is mainly 
used to establish T cell frequencies secreting a certain cytokine in a certain disease, such 
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as autoimmune and allergic diseases (Kalyuzhny 2005), or to detect antigen-specific T 
cells in infectious or malignant diseases (Gajewski 2000). 
 
Today, the ELISpot assay is applicable to a wide range of immunology research areas, 
including cancer (Janetzki et al. 2005), transplantation (Hernandez-Fuentes et al. 2003; 
Gerrits et al. 2005), infectious diseases (Gray et al. 2009), and vaccine development 
(Carpenter et al. 2006) and is the one of the most commonly used assays for monitoring 
immune responses.  
 
The ELISpot assay employs the sandwich assay approach of the Enzyme Linked 
Immunosorbent Assay (ELISA), with some variation (Clay et al. 2001): the quantitation 
of memory B cell precursors is determined at the level of the antibody-secreting cells 
instead of assaying for the specific antibody that is secreted, by these cells, into the 
culture medium (Slifka and Ahmed 1996). 
 
One of the major problems with the ELISpot is the inconsistency observed when results 
are compared between laboratories (Janetzki et al. 2008). The main cause of 
inconsistencies is the method used to evaluate ELISpot plates: the eye and the magnifying 
glass. This is time consuming and labour-intensive. Furthermore, high spot numbers are 
difficult to enumerate and limited resolution makes it difficult to recognize and exclude 
artefacts as well as to count small and faint spots or spots located close together.  In  1997, 
the first automated ELISpot readers were introduced to the market (Cox et al. 2006). 
Today, there are various readers available differing in resolution, hardware, and software 
packages. Automated readers offer many advantages over manual evaluation methods, 
like faster and more accurate evaluation, lower variability, and prevention of certain 
biases. 
 
The focus today is on standardization of the technique and simplification to enable the 
scientist to run a high number of samples in a short time without compromising quality 
because, whilst there are some limitations with ELISpot, it has several advantages over 
the other methods described above: 
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• The ELISpot assay is more rapid than the LDA (Shata et al. 2003).  Although, the 
ELISpot assay follows the same basic principles as an LDA, it requires 4 to 5 days of 
in vitro mitogen stimulation compared with 10–14 days or 14–21 days (if EBV 
stimulation is used) for the LDA(Shokrgozar et al. 2006). 
• When analysing the results, ELISpot readers count antibody-secreting cells, whereas 
ELISA based LDAs detects the bulk antibody secreted and accumulated in culture 
supernatants (Shokrgozar et al. 2006). 
• The ELISpot is more sensitive  (it can be used to detect target cells at a frequency as 
low as 1:100,000 (Shata et al. 2003)) and practical than PFA because ELISpot plates 
can be stored up to a month before analysing the samples (Lakew et al. 1997). 
• An advantage of ELISpot over the haemolytic PFC assay is its ability to measure low 
frequency events such as IgE immunoglobulin secreting cells (ISC). The technique can 
also detect ISC specific for antigens that are not readily coupled to erythrocytes 
(Sedgwick 2005). 
 
Because of the above-mentioned advantages, I chose to use ELISpot assays in this 
project.   
 
The aim of this thesis was to investigate the implications of different IgG subclasses on 
graft rejection in sensitized individuals.  As previously described, the different subclasses 
interact with different effector mechanisms and therefore may contribute differently to 
graft rejection. Methods that can be used to analyse B cell responses, have been described 
above.  We chose to use the ELISpot method and X-MAP Technology to look at B cell 
activation, IgG subclass production by these activated B cells and the specificity of the 
antibodies produced and correlate them with graft outcome. 
  
Thus far this Introduction has focussed on the immune mechanisms that contribute to 
graft rejection. However, as briefly discussed, there are instances when grafts are not 
attacked by the recipient’s immune system.  This can be the result of accommodation 
and/or the development of tolerance. I shall now briefly describe the role of tolerance in 
transplantation.  
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1.7.  Mechanisms of graft acceptance 
1.7.1.  Accommodation 
Accommodation may develop as an alteration of the host response, for example, through 
changes in antibody titre or Fc functionality. Graft endothelial cells express factors that 
protect against antibody and complement damage to the graft (Bach et al. 1997). In 
addition, in a xenograft model, accommodation has been associated with increased graft 
expression of anti-apoptosis and complement regulatory factors (Salama et al. 2001). In 
human renal allografts, Cornell et al. reported that the expression of the complement 
regulatory factor protectin (CD59), is increased by peritubular capillaries acute and 
chronic rejection and decay-accelerating factor (CD55) in acute humoral rejection 
(Cornell et al. 2008).  Having a greater understanding of accommodation may open up 
therapeutic avenues for treating graft rejection.  
1.7.2.  Tolerance  
Immune tolerance is a state of antigen-specific unresponsiveness, to an antigen that can 
be self or foreign. It occurs in two forms: central tolerance, peripheral tolerance. Central 
tolerance occurs during lymphocyte development and operates in the thymus and bone 
marrow (BM). In order to prevent autoimmunity, T and B lymphocytes that recognize 
self antigens are deleted (in the thymus and BM, respectively) before they develop into 
mature cells. However, because many self-proteins are not expressed in the thymus or 
BM and in some cases are not expressed until a lymphocyte migrates to the secondary 
lymphoid tissues, there needs to be some mechanism to prevent auto reactivity of 
lymphocytes and this is known as peripheral tolerance (Sprent and Kishimoto 2001). 
 
There are four possible ways in which self reactive lymphocytes may be prevented from 
responding to self antigens: clonal deletion (death), induction of a refractory state 
(anergy), inhibition of function by other cells or their products (immune regulation) and 
sequestration of antigen (ignorance) (Abbas et al. 2004). 
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Tolerance mechanisms that control T and B cell responses will now be discussed in more 
detail.  
1.7.2.1.  T cells 
1.7.2.1.1. Central Tolerance 
The most effective mechanism of immunological self-tolerance is central deletion, in 
which self-reactive T cells are deleted in the thymus, during T cell maturation, by 
negative selection (Mondino et al. 1996). T cell receptor (TCR) editing, plays a role in 
controlling the development of self-reactive T cells in the thymus (Nemazee and 
Hogquist 2003).  TCR editing is a mechanism of tolerance in which the binding of self-
antigen during development promotes secondary antigen-receptor gene rearrangement of 
the T-cell receptor -chain coding gene, which usually results in the replacement of the 
autoreactive receptor with a benign one. 
 
TCRs are selected to recognize a composite ligand comprising a peptide fragment of 
antigen bound to a major histocompatibility complex (MHC) molecule. Composites of 
self-peptides and MHC are displayed on the surface of cortical thymic epithelial cells, 
and CD4+CD8+ thymocytes, which express TCRs that bind these ligands, trigger 
maturation signals that inhibit recombination activating gene (RAG) expression, thereby 
closing off the option of editing (Gotter and Kyewski 2004). As a result, thymocytes are 
selected and promoted to survive (positive selection). Thymocytes whose receptors do 
not recognize self-MHC molecules die in a process known as “death by neglect”. As 
positively selected thymocytes move from the cortex toward the medulla, they continue 
the maturation process and further test their TCRs for self-reactivity. TCRs that bind 
strongly to self-peptide/MHC complexes trigger the death of thymocytes (negative 
selection). The medullary cells, of the thymus, express T cell costimulatory molecules, 
such as CD80 and CD86, the ligands for CD28, which play a crucial role in stimulating T 
cell responses and are important for the development and maintenance of self-tolerance 
(Goodnow et al. 2005). 
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1.7.2.1.2. Peripheral tolerance 
Although central tolerance is the most effective mechanism to eliminate self-reactive T 
cells, such deletion is incomplete. Therefore, the immune system has developed the 
mechanisms that generate tolerance in the periphery. The mechanisms responsible for 
peripheral tolerance can be divided into those that regulate the intrinsic state of 
responsiveness of T cells e.g. their internal biochemistry and their pattern of gene-
expression, and those that provide extrinsic controls, e.g. limiting the supply of essential 
growth factors, costimulation, and proinflammatory mediators, and by active suppression 
by regulatory T cells (Mondino et al. 1996). 
1.7.2.1.3. Extrinsic regulation of T cell tolerance 
Naturally occurring regulatory CD4+CD25+ T cells play an important role in autoimmune 
disorders, allergy and the immune response to infections and tumours, allergy and 
transplantation (Sakaguchi 2004). CD4+CD25+ regulatory T cells are derived from the 
thymus and comprise 5-10% of the CD4+ T cell population (Itoh et al. 1999). In 2003, it 
was reported that the transcription factor, forkhead box P3 (FoxP3) is the key regulatory 
product for the development and function of CD4+CD25+ regulatory T cells; indeed, it 
was found that its expression was restricted to CD4+CD25+ regulatory T cells  (Fontenot 
et al. 2003). 
 
CD4+CD25+ regulatory T cells require antigen-specific activation by the T cell receptor 
(Thornton and Shevach 2000) and once activated, they suppress the proliferation and 
cytokine production of effector T cells. The mechanisms by which these cells suppress 
effector cells includes the secretion of cytokines such as transforming growth factor-β 
(TGF-β) and IL-10 and direct cell-cell contact through binding of cell-surface molecules 
such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) (Itoh et al. 1999; Yong et 
al. 2007). In addition to the naturally occurring regulatory T cells, other CD4+ regulatory 
T cells are produced in the periphery. These are known as “adaptive” regulatory T cells. 
It has been shown that stimulation of CD4+CD25−FoxP3− effector T cells through the 
TCR, in the presence of TGF-β, results in FoxP3 upregulation, generating 
Introduction 
 93
CD4+CD25+FoxP3+ T cells with regulatory properties similar to naturally occurring 
regulatory T cells (Chen et al. 2003). 
 
Another type of adaptive regulatory T-cell is the type-1 regulatory T-cell (Tr1). These 
cells can be generated from naïve CD4+ T cells by antigenic stimulation in the presence 
of IL-10 and IFN-α, or in the context of a combination of vitamin D3 and 
dexamethasone. These cells regulate immune responses by producing high levels of IL-
10 and TGF-β (Groux et al. 1997). 
 
Yet another type of regulatory CD4+ T cells, Th3 cells can be generated e.g. after oral 
administration of myelin basic protein or IL-4.  They produce high levels of TGF-β with 
varying amounts of IL-4 and IL-10 (Inobe et al. 1998). 
 
In addition to CD4+ regulatory T cells, there are also regulatory CD8+ T cells; the 
CD8+CD28- suppressor T cells. These cells are capable of suppressing the activation and 
proliferation of CD4+ T cells by preventing the up-regulation of B7 of APC (Liu et al. 
1998). CD8+CD28- suppressor T cells express CTLA-4, FoxP3 and GITR 
(glucocorticoid-induced TNF receptor). They also express high mRNA levels of members 
of the killer cell immunoglobulin-like receptor (KIR) family (Scotto et al. 2004). 
  
1.7.3. Regulatory T cells in transplantation tolerance 
Regulatory T cells can play an important role in both the induction and maintenance of 
tolerance to donor alloantigens (Yong et al. 2007). The roles of  regulatory T cells in the 
induction and maintenance of transplantation tolerance has been studied  extensively in 
experimental transplantation models (Wood and Sakaguchi 2003). It has been 
demonstrated that CD4+CD25+ regulatory T cells play an essential role in transplantation 
tolerance; removal of these cells, from normal mice, enhanced graft rejection (Sakaguchi 
et al. 1995). 
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Regulatory activity specific for donor alloantigens is enriched amongst CD4+CD25+ T 
cells in some settings and can be induced by manipulating the immune system before 
transplantation (Kingsley et al. 2002). Donor alloantigen-specific CD4+CD25+ regulatory 
T cells can control aggressive CD4+ as well as CD8+ T cells thereby preventing rejection 
and can mediate linked unresponsiveness (Wood and Sakaguchi 2003). In vivo, donor 
alloantigen-specific CD4+CD25+ cells are dependent on IL-10 and CTLA4 for functional 
activity. These populations of regulatory cells can be induced by manipulating the adult 
immune system (Roncarolo et al. 2003).  
 
The active regulation or suppression of immune responsiveness to donor alloantigens 
offers a way to silence aggressive alloimmune responses, thereby preventing damage to 
the graft.  The generation of regulatory T cells with defined alloantigen-specificity could 
provide dynamic control of rejection responses and offers a potential route to permanent 
graft survival without the need for life-long non-specific immunosuppression (Wood and 
Sakaguchi 2003). 
 
A CD4+CD25+ regulatory T-cell population has been described in the peripheral blood of 
healthy human volunteers. These cells have the same characteristics as CD4+CD25+ 
regulatory T cells isolated from mice (Stephens et al. 2001). The peripheral CD4+CD25+ 
regulatory T cells in humans display a broad usage of the T-cell receptor Vβ repertoire, 
indicating that they recognize a wide variety of antigens (Taams et al. 2002). There is 
also evidence of a functional role: for example, liver transplant patients who experienced 
an acute rejection episode were shown to have a lower number of CD4+CD25+ T cells in 
the peripheral blood than patients who remained free from rejection (Demirkiran et al. 
2006). In both lung and kidney transplant patients, a relationship between the frequency 
of peripheral CD4+CD25+ regulatory T cells and chronic rejection has been 
demonstrated-: patients with chronic rejection had a lower number of these cells in the 
peripheral blood than stable patients on immunosuppression (Meloni et al. 2004; Louis et 
al. 2006). 
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Besides the frequency of regulatory T cells in the peripheral blood, another parameter 
that may contribute in determining transplant outcome is the suppressive potency of 
peripheral CD4+CD25+ regulatory T cells. Bann et al. reported that depletion of 
CD4+CD25+ regulatory T cells from the peripheral blood significantly increased IL-2 
production and the proliferative response directed to donor antigens, indicating that these 
cells suppressed the anti-donor immune reactivity (Baan et al. 2007). Ciubotaria et al. 
detected the presence of a population of CD8+CD28- suppressor T cells in peripheral 
blood of kidney, heart and liver transplants. Moreover, they observed an inverse 
correlation between the presence of peripheral suppressor T cells and the incidence of 
acute rejection in these patients. Thus, the presence of these suppressor cells in the 
circulation seems to be associated with good graft outcome (Ciubotariu et al. 2001). 
1.7.3.1. B cell tolerance 
A series of checkpoints normally control B cell selection: this occurs centrally in the BM 
by gene rearrangement and there is a second screening process to detect reactivity with 
peripheral self-antigens which results in apoptosis, receptor editing, or anergy in the 
peripheral lymphoid tissue  (Goodnow et al. 1990).  
 
The transition from early immature to immature B cells in the bone marrow is considered 
to be an essential checkpoint that eliminates cells with the potential to produce self-
reactive antibodies. The most likely molecular event underlying this checkpoint of B cell 
central tolerance is receptor editing, a mechanism in which random Ig light-chain 
replacement eliminates self-reactive antibodies. First, antibodies with very high affinity 
for self are removed by clonal deletion in early development. Next, antigen-receptor 
editing by light-chain replacement, results in pairing with the existing Ig heavy chain to 
generate a non-self reactive B cell receptor (BCR). Failing this process, these B cells are 
deleted by apoptosis (Gay et al. 1993). Once immature B cells are released from the bone 
marrow, they are detected in the periphery as new emigrant B cells (CD10+IgM+CD27-) 
that still have a large number of self reactive clones. A second tolerance checkpoint 
occurs in their transition into the mature naïve B cell (CD10-IgM+CD27-) compartment. 
At this point, less than 5% of the peripheral naïve compartment consists of autoreactive B 
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cells. These are silenced by the induction of a state of unresponsiveness; anergy. Anergy 
is the state which B cells may enter after receiving a potentially specific initial stimulus 
but then failing to receive secondary signals that sustain their activation. It is 
characterized by a reduction in both the expression of surface IgM and the signalling 
pathways after ligation of surface immunoglobulin. If an anergized, self-reactive B cell 
encounters a T cell specific for a self peptide from the relevant autoantigen, Fas ligand on 
the T-cell surface binds to Fas on the B cell, inducing apoptosis in the B cell. (Rathmell et 
al. 1995).  Anergic B cells have several features that distinguish them from naïve B cells. 
These features include reduced lifespan, altered migration patterns and anatomical 
location, and an ability to interact productively with helper T cells. These mechanisms 
limit the ability of anergic cells to participate in the immune response (Hodgkin and 
Basten 1995).   
 
Failure of either of these two B cell tolerance checkpoints leads to higher numbers of 
mature autoreactive B cells and the development of autoimmunity. For instance, the naïve 
mature B cell compartments of both systemic lupus erythematosus (SLE) and rheumatoid 
arthritis patients contain high number of autoreactive B cells (Grimaldi et al. 2007).  
In this introduction I have described the cellular and humoral causes of graft rejection and 
the increasing use of markers of AHR as a diagnostic tool, for graft rejection, in the 
clinic. Prof.Warrens’ group has previously carried out preliminary experiments 
characterising HLA-specific antibodies, using flow cytometry, and their effect on graft 
survival.  In this thesis I describe experiments undertaken to further characterise the role 
of antibodies, specifically different istotypes, in graft rejection and clinical outcome.  
These experiments used patient serum samples, B cells and mixed lymphocyte cultures.  
In the next three chapters I describe these experiments. 
 
 
 
 
 
 
 
 
  97
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2.  
Using X-MAP technology to detect 
pre-formed donor HLA-specific 
antibodies in sera negative in both 
Complement-Dependent 
lymphocytotoxicity Crossmatching 
and Flow Cytometry Crossmatching 
 
 
 
 
 
 
 
Chapter 2 
 98
2.1. Introduction 
 
As described in section 1.5.10, HLA-specific antibodies can be detected using various 
techniques including complement dependent lymphocytotoxicity crossmatching (CDC), 
ELISA, Flow cytometry and X-MAP technology.  As described, these techniques have 
been modified and improved over the past fifty years to improve accuracy, sensitivity and 
reliability.  I shall now describe how the results of these tests are interpreted.         
 
Many factors must be considered before interpreting a positive crossmatch as clinically 
relevant. IgM or IgG autoreactive cytotoxic antibodies can cause a positive crossmatch 
but are not regarded as a contraindication to transplantation. Therefore, the performance 
of an auto-crossmatch helps in the interpretation of a positive allo-crossmatch (Gebel et 
al. 2003). 
 
The clinical significance of a positive direct cytotoxic crossmatch as a result of HLA–
specific antibodies is well established; however, there is debate as to the degree of 
clinical relevance of these antibodies under the following circumstances: (1) low titre 
HLA-specific antibodies, (2) non-complement-fixing HLA-specific antibodies, (3) 
antibodies against HLA class II antigens and (4) donor-specific HLA-specific antibodies 
detected in a historical but not a current sample. 
 
A positive CDC T cell crossmatch implies the presence of class I HLA-specific 
antibodies and is currently regarded an absolute contraindication to transplantation. A 
positive B cell crossmatch (in the face of a negative T cell crossmatch) may reflect the 
presence of class II HLA-specific antibodies, or weak class I HLA-specific antibodies 
due to the higher expression of HLA class I antigens on B cells (Eng et al. 2008).  The 
clinical significance of a positive B cell crossmatch and negative T cell crossmatch is 
controversial (Bryan et al. 1993; Lobashevsky et al. 2000). Importantly, a negative pre-
transplant CDC crossmatch significantly reduces the risk of hyperacute rejection (Gebel 
et al. 2003) but, early antibody-mediated rejection may still occur in the presence of a 
negative CDC crossmatch.  This indicates that the CDC crossmatch lacks the sensitivity 
required to detect low-level HLA-specific  antibodies (Gibney et al. 2006).  
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A T cell-negative, B cell-positive crossmatch could be the result of nonspecific antibodies 
(Le Bas-Bernardet et al. 2003). B lymphocytes are very sensitive targets: as mentioned 
above, they express not only HLA class II but also HLA class I antigens on their surface. 
B cells also express Fc receptors, which bind IgG non-specifically-this may also lead to 
an irrelevant positive crossmatch (Delgado and Eckels 2008). To optimize interpretation 
of a B cell crossmatch, key factors are: (1) evaluation of pre-transplant sera using HLA-
specific solid-phase targets such as ELISA and X-MAP technology, (2) elimination of 
non-specific binding of B cell targets using pronase and (3) inclusion of autologous cells 
for crossmatching. 
 
Some groups reported no difference between the 1-year graft survival of recipients 
transplanted with current negative, historic positive, CDC T cell crossmatches and that of 
patients transplanted with current negative, historic negative CDC T cell crossmatch 
(Gebel et al. 2003; Lefaucheur et al. 2009). On the other hand, others have reported that 
40% of current negative, historical positive recipients developed antibody-mediated 
rejection within three months post-transplant (Cardella et al. 1982). Many investigators 
have observed a higher incidence of early graft loss among current negative, historic 
positive recipients (Lefaucheur et al. 2008). Moreover, it has recently been reported that 
early graft loss occurs in current negative, historical positive even if the latter is based 
solely on a positive flow cytometric crossmatch (Karpinski et al. 2001). It has been 
suggested that a historic positive crossmatch is not necessarily a contraindication to 
transplantation; rather, it should be considered a risk factor in renal transplantation 
(Leavey et al. 1997) . 
 
The role of different IgG subclasses of alloantibodies in allograft survival after kidney 
transplantation is still controversial. The presence of donor HLA-specific IgG 
Complement Fixing Antibodies (CFAs) (IgG1 and IgG3), for donor HLA class I or class 
II, in transplant serum, represents a risk factor for rejection in kidney transplantation 
(Regan et al. 1996; Monteiro et al. 1997; Griffiths et al. 2004). However, the role of non-
complement-fixing HLA-specific  antibodies is still not fully understood: prolonged graft 
survival has been demonstrated when NCFA IgG2 and IgG4 antibodies were present 
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(Heinemann et al. 2007) but this finding contradicts some reports that suggest IgG2 and 
IgG4 DSA may cause early graft failure (Karuppan et al. 1992; Nanni-Costa et al. 1996). 
These antibodies can be the result of immunoglobulin class switching, from previously 
provoked donor-specific complement-fixing IgG1 and IgG3, to the non-complement-
fixing IgG2 and IgG4 (Arnold et al. 2008). Arnold et al. reported that most of these 
NCFA against class I and II had HLA specificity correlating to the previously rejected 
graft (Arnold et al. 2004). 
 
This project 
In a pilot study Prof. Warrens and his team used flow cytometry to study the effect of IgG 
subclasses in sensitised renal transplant recipients with class I HLA-specific antibodies. 
They concluded that a subclass pattern of HLA-specific antibodies, that was skewed 
towards the IgG1 subclass, represented a risk factor for graft loss (Griffiths et al. 2004). 
The clinical significance of pre-transplant DSA identified using solid phase assays, 
despite negative CDC and FCXMs, is unclear. In this study, I was very interested in 
correlating the clinical outcomes of renal transplant recipients with pre-transplant DSA 
and negative pre-transplant CDC and FCXMs, with a control group of patients without 
pre-transplant DSA.  Furthermore, I also wanted to observe if there was a correlation 
between the subclass of DSA and the clinical outcome. 
2.2. Hypotheses 
 
• That low levels of donor HLA-specific IgG antibodies, below the level of detection 
by complement-dependent cytotoxicity and flow cytometry, still represent a risk 
factor for graft rejection. 
• That non-donor HLA-specific and donor HLA-specific antibodies both represent 
risk factors for graft survival. 
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2.3. Project Plan 
 
• To identify pre-transplant HLA-specific IgG antibodies using poly-antigenic and 
oligo-antigenic beads using X-MAP technology.  
• Developing novel assays (using X-MAP technology) to identify class I and class II 
HLA-specific IgG subclasses. 
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2.4. Materials and methods 
2.4.1. Detection of HLA-specific antibodies: 
 
To detect the presence of HLA-specific IgG antibodies I used X-MAP technology.   
2.4.1.1. Screening for HLA-specific IgG antibodies of any specificity  
 
 
Principle 
 
The Lifecode life screen kit (Quest Biomedical) is a poly-antigenic bead-based 
immunoassay used to qualitatively detect IgG antibodies to HLA class I and class II 
antigens. It consists of five components: Life screen poly-antigenic beads which are 
coated with purified mix class I or class II HLA glycoproteins (including four control 
bead preparations); goat anti-human IgG conjugated to phycoerythrin (PE); wash buffer; 
positive control serum (which will react with most or all of the HLA beads) and negative 
control serum (which will react with few, if any, of the HLA beads). 
 
Method 
Filter plate wells were pre-wet with 100-300 µl of distilled water. After 2-5 minutes, the 
water was removed by gentile aspiration using a vacuum manifold. After that, the HLA 
beads were centrifuged at 800 g for one minute. 40 µl of wash buffer was added to the 
test well of the filter plate and then 12.5 µl of patient serum or control serum was also 
added and mixed gently. 5µl of HLA beads was then added to each of the assigned test 
wells. The plate was covered with foil to protect from light and incubated at room 
temperature for 30 minutes on a rotating platform (200 rotations per minutes; to keep the 
beads in suspension). After incubation, 100 µl of wash buffer was added to each well and 
the plate was aspirated using the vacuum manifold. Another two washing steps were 
performed using 250µl of wash buffer added to each test well. Next, 50µl of diluted 
detection antibody [Phycoerythrin (PE) conjugated goat anti-human pan-IgG] (1µg/ml) 
was added to each test well.  The plate was covered with foil and incubated for 30 
minutes at room temperature on a rotating platform. Finally, the beads were resuspended 
by adding 130-150µl wash buffer to each test tube. For collecting data, a Luminex100 
instrument was used as recommended by the manufacturers. The signal intensity from 
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each bead was compared to the signal intensity of a negative control bead, included in the 
bead preparation, to determine if each bead suspension was positive or negative for 
bound alloantibody (See section below for more information about data analysis).                            
2.4.1.2. Class I & II HLA-specific antibody identification kit 
The same method was used for screening (poly-antigenic) and identification (oligo-
antigenic) of serum antibodies, except that in the latter case, class I & II antigen-coated 
beads, supplied with the kit, were used.  HLA class I oligo-antigenic beads are coated 
with few purified HLA class I glycoproteins (HLA-A, HLA-B and HLA-C) recombinant 
antigens whereas class II beads are coated with few purified HLA class II glycoproteins 
(HLA-DR and HLA-DQ). Both panel contains both high and low frequency antigens. 
2.4.2. IgG subclass identification 
2.4.2.1.1. Class I HLA-specific antibodies 
Materials 
Lifecodes class I and II identification (oligo-antigenic) kits (Quest Biomedical) were used 
in conjunction with the following antibodies: biotin-conjugated goat anti-human IgG1 
(clone 8c/6-39, Sigma), biotin-conjugated goat anti-human IgG2 (clone HP-6014, 
Sigma), biotin-conjugated goat anti-human IgG3 (clone HP-6050, Sigma), biotin-
conjugated goat anti-human IgG4 (clone HP-6050, Sigma), and streptavidin-PE 
(Calbiochem). 
 
Method 
The same protocol was used as outlined in section (4.1.1) except for two steps - the 
addition of the biotin-conjugated detection antibodies and streptavidin-PE: after 
incubation of the sera with the appropriate beads, 50µl of diluted biotin conjugated goat 
anti-human IgG1/IgG2/IgG3/IgG4 antibody 1µg/ml was added to each test well in place 
of the anti-human pan IgG-PE antibody. The plate was covered with foil and incubated 
for 90 minutes at room temperature on a rotating platform. Wells were washed three 
times and then, streptavidin-PE was diluted (1:20) and added to each test well and 
incubated for 30 minutes, at room temperature, in the dark, on a rotating platform. Two 
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more washing steps were then performed before analysis of the beads. Beads were 
resuspended in 130-150µl wash buffer and analysed using a Luminex100 instrument (used 
as recommended by the manufacturer; See section  2.4 for more information).  
 
The performance characteristics of the assay are influenced by a number of factors, 
including reagent dilutions and washing steps. These factors are calibrated and optimised 
using different titrations for the reagents and controls. 
2.4.2.1.2. Class II HLA-specific antibodies 
 
The same method, as described above for class I HLA-specific IgG1/2/3/4 identification, 
was used for detection of class II HLA-specific IgG subclasses except that class II 
glycoprotein coated beads were used. 
2.4.3. Analysis of Bead Assay Data 
For the purpose of screening and identifying the total IgG contribution to HLA-specific  
antibodies, Luminex LifeMatch software was used for analysis. To determine if the signal 
generated by the analysis of a specific bead is positive, the individual bead median 
fluorescence intensity (MedFI) is divided by the MedFI for each negative control bead 
(CON1, CON2, and CON3). From these quantities, the background adjustment factor 
(BAF), appropriate for each bead/CON combination, is subtracted. The BAF is a 
predetermined MedFI ratio for each bead/CON combination which is used to compensate 
for background noise due to bead variation. It is provided by the manufacturers for each 
batch of kit. Finally, a fourth negative control calculation, “CalcCON”, based on the 
performance of the non–reacting HLA antigen-bearing beads is determined. CalcCON = 
(lowest MedFI of an HLA antigen-bearing bead) + 20. Cut off= negative control sample 
mean x 1.5.  See Figure 14 for a summary of this statistical analysis. A positive value for 
two or more of the adjusted ratios indicates a positive bead reaction. A negative value for 
three or more of the adjusted ratios indicates a negative bead reaction. 
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Figure 14.  Calculations for statistical analysis of bead assay data. 
The four adjusted ratios were calculated for each bead.  A positive value for two or more of the 
adjusted ratios indicates a positive bead reaction. A negative value for three or more of the 
adjusted ratios indicates a negative bead reaction. MedFI: Median Fluorescence Intensity. 
 
2.5. Results 
I obtained access to the records and stored samples of the Hammersmith Hospital kidney 
transplant patients from the Renal Database at the Histocompatibility and 
Immunogenetics Laboratory, Division of Immunology, Hammersmith Hospital, and from 
those stored samples I selected individuals based on the following criteria: 
 
The inclusion criteria (both criteria needed to be satisfied for a patient to be included): 
• Patients with a high level of panel-reactive antibodies (PRA) level (more than 30%) 
in historical samples 
• Patients who had undergone renal transplantation following a negative flow 
cytometric direct cross match. 
The exclusion criterion: 
• Patients who had lost their kidney as a result of a surgical problem. 
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After screening all patients (transplanted between 1998 and 2007), 434 were identified 
who met these criteria.  The HLA types of both donors and recipients were recorded. The 
research protocol was approved by the Hammersmith and Queen Charlotte’s Research 
Ethics Committee (reference number 2002/6295) 
 
My first series of objectives were: 
1.  To determine if X-MAP technology-based assays were able to identify donor-
specific antibodies that were undetectable, using FCXM, on donor cells at the time of 
the transplant and, if so, what the clinical implications of this would be.  
2.  To determine the IgG subclass pattern of these HLA-specific antibodies and to 
attempt to correlate them with the clinical outcome of transplantation. 
3.  To compare the range of non-donor-specific antibody specificities, identified in 
patients’ pre-transplant sera using X-MAP technology, with those that had been 
defined by more conventional techniques. 
2.5.1.  Screening for the presence of HLA-specific antibodies 
I began by looking for HLA-specific antibodies in 434 sensitised patients who had been 
transplanted with a negative FCXM crossmatch (as well as a negative CDC crossmatch). 
Sera used were those from the same immediate pre-transplant sample that had been used 
for the negative direct crossmatch. Based on historical sample data, the majority of 
patients had panel reactive antibodies (PRA) values in the pre-transplant serum of less 
than 30%; 30% was the threshold value set for the selection criterion. I first screened 
“Current serum” samples (samples collected at the time of the transplant), using the 
screening (poly-antigenic) Luminex Lifecode kit, to identify patients with class I HLA-
specific antibodies or class II HLA-specific antibodies or both (Figure 15). On the basis 
of this assay, 107 (25%) patient samples were positive for the presence of HLA-specific 
antibodies. I determined that of these 107 patients, 31 (29%) had anti-class I and II 
antibodies, 41 (38%) had only anti-class I antibodies and 35 (33%) had only anti-class II 
antibodies. However, 327 (75%) patient samples were negative for both. These samples 
were used as negative controls in future experiments.       
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Figure 15.  Detection of pan IgG HLA-specific antibodies using X-MAP technology 
 
The above graph shows the variety different HLA-specific antibodies found, in patients’ 
immediate pre-transplant serum samples, using poly-antigenic beads.  The HLA class for which 
detected antibodies were specific is shown on the x-axis.  The number of patients is shown for 
each sera type in white boxes underneath the x-axis.  Cut off = negative control sample mean x 
1.5.  P<0.05 versus control. 
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2.5.2. Detection of class I and class II HLA-specific antibody specificities 
Further investigation was undertaken, using an identification (oligo-antigenic) Luminex 
Lifecode kit, to confirm the screening assay test and to identify the specificities of class I 
HLA-specific and class II HLA-specific antibodies in individuals with one or both types 
of antibodies. Of the 41 patients, in which the presence of class I HLA-specific antibodies 
was suggested by the screening test, I was able to define class I specificities in 30 patients 
(73%), using the identification test (Figure 16). Of the 35 patients with class II HLA-
specific antibodies, I was able to define specificities using the Luminex lifecode 
identification kit in 33 (94%) and of the 31 patients with antibodies against HLA class I 
and HLA class II, I was able to define HLA-specific antibody specificities in 24 sera 
samples (77%) (Figure 16 overleaf). 
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Figure 16.  Identification of the HLA specificity of HLA-specific antibodies in patient 
samples, using class I and class II oligo-antigenic kits. 
The above graph shows the number of patients in whose immediate pre-transplant sera it was or 
was not possible to define specificities using oligo-antigenic beads. The white segments represent 
those in whom HLA specificities could not be defined, and the grey segment represents those in 
whom HLA specificities could be defined.  The HLA class for which detected antibodies where 
specific is shown on the x-axis.  
Cut off = negative control sample mean x 1.5. P<0.05, versus control group.  
2.5.2.1. Summary of screening and identification of class I and II HLA specificities 
No patient with a positive result in the identification oligo-antigenic assay was negative 
in the screening poly-antigenic assay. However, 20 of the 107 (19%) who were positive 
in the screening assay were negative in the identification assay (Figure 16). This suggests 
that the screening assay is more sensitive for detecting HLA-specific antibodies, or the 
identification assay is incomplete; the beads used may not have the antigens for detecting 
certain HLA-specific antibodies.       
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2.5.3.  Detection of the presence of IgG subclass antibodies using Luminex 
technology 
2.5.3.1.  Identification of HLA-specific IgG subclasses  
As previously mentioned, complement activation is an important process in graft 
rejection. Complement activation requires the presence of specific IgG1 and IgG3 
antibodies. Therefore, being able to identify the antibody subclasses found in patient sera 
may provide further information as to the susceptibility of a patient to rejection.  There 
are no kits, currently available, that allow the identification of the IgG subclasses of 
HLA-specific antibodies. Consequently I had to develop an HLA-specific IgG subclass 
identification kit for this project.  I did this by replacing the pan-IgG detection reagent, 
supplied with the oligo-antigenic kit, with a series of IgG subclass-specific antibodies. 
These detection antibodies were biotin-conjugated and were used in conjunction with 
streptavidin-PE for detection.  
 
I performed preliminary titration experiments, using different concentrations of the 
detection antibodies and different concentrations of streptavidin-PE, to determine the 
appropriate concentrations for use to allow sensitive and reliable detection. In order to 
perform these experiments I chose positive controls for both class I and class II HLA-
specific antibodies.  These controls are described in the following sections before the 
results of titration experiments are shown. 
2.5.3.1.1.  Class I HLA-specific antibody control samples 
A positive control group (n=6) for the development of the IgG subclass-specific class I 
HLA-specific assay was chosen based on positive results in the pan IgG class I X-MAP 
enzyme-linked immunosorbent assays (ELISA) for antibodies specific for HLA-A2 (a 
commonly found HLA class I type). Fifty highly sensitised kidney patients were tested 
for the presence of HLA-specific A2 antibodies using ELISA and pan IgG X-MAP 
technology. Of these 50 serum samples, 6 samples were positive (Table 3); sera from 
these 6 patients were used as positive controls for future experiments. 
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Positive control group 
 
Antibody specificities   
using ELISA identification 
kit 
Antibody specificities using 
class-I oligo-antigenic beads 
(X-MAP) 
Patient 1 A2, B51 A2, B51, B63 
 
Patient 2 A2, B35 A2, B35, B14 
 
Patient 3                A2, B7 A2, B7, B18 
 
Patient 4 A2, B18 A2, B18, B63 
 
Patient 5 A2, B14 A2, B14, B39 
            Patient  6 A2, B52 A2, B52, B27 
 
Table 3.  Class I positive control group. 
Antibody specificities were determined using ELISAs and pan IgG class I oligo-antigenic beads.   
The positive control group was drawn from the group of highly sensitized renal patients.    
 
2.5.3.1.2.  Class II HLA-specific antibody control samples 
A positive control was supplied with the anti-class II oligo-antigenic kits so I first used 
this to develop an anti-class II IgG subclass kit. However, using this control I was able to 
detect HLA-specific IgG1 and IgG3 antibodies but not IgG2 nor IgG4 antibodies. In 
order to find positive controls for all four subclass assays, I tested 20 highly sensitised 
kidney patients for the presence of anti-DR7 antibodies. Of 20 serum samples, 4 samples 
were positive using pan IgG X-MAP technology and ELISA (Table 4). In these sera, I 
was able to identify anti-class II specificities of both IgG2 and IgG4 subclasses and I 
named them “IgG2/4”. These assays demonstrated that all four of the subclass-specific 
assays were working and the patient samples were suitable for use as positive controls in 
future experiments. 
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Positive control group 
 
Antibody specificities   
using ELISA identification 
kit 
Antibody specificities using 
class-II oligo-antigenic beads (X-
MAP) 
Patient 7            DR7, DQ2 DR7,  DQ2 
 
Patient 8            DR7, DQ2 DR7, DR17,  DQ2 
 
Patient 9            DR7, DQ6 DR7, DR15, DQ5 
 
Patient 10            DR7, DQ2 DR7, DR15, DQ2, DQ5 
 
Table 4.  Class II positive control group. 
Antibody specificities were determined using ELISA and pan IgG class-II oligo-antigenic beads. 
The positive control group was drawn from the group of highly sensitized renal patients.      
 
2.5.3.1.3.  Optimisation of detection antibodies and streptavidin-PE for HLA-specific 
antibody IgG subclass identification  
Having identified suitable positive control samples, the concentrations of detecting 
antibodies and streptavidin-PE to be used in these assays was optimised for detection of 
class I HLA-specific and class II HLA-specific antibody IgG subclasses.  
 
In assays designed to detect the specific IgG subclasses of class I HLA-specific 
antibodies, the highest mean fluorescence intensity (MFI) was detected using a detection 
antibody concentration of 0.1µg/ml (Figure 17). The reasons why I did not go with higher 
dilutions using detection antibody because first the Luminex kits were very expensive. 
Second, the positive controls used were limited to samples collected from highly 
sensitized renal patients. These samples were used for routine crossmatch testing.  
The highest MFI was detected using a streptavidin-phycoerythrin concentration of 
0.1μg/ml or 0.05µg/ml (Figure 18).  The same was true for assays designed to detect the 
specific IgG subclasses of class II HLA-specific antibodies (Figure 19 and Figure 20). 
These conditions were thus used in validation experiments and all other experiments 
afterwards. 
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Figure 17.  Titration of IgG subclass-specific antibody (biotinylated anti-IgG1/2/3/4) with 
class I oligo-antigenic beads. 
HLA-coated Luminex beads were incubated with positive or negative control group sera.  The 
positive control group consist of pooled 6 different highly sensitised renal patients’ sera as 
described in Table 3. The negative control group consisted of 5 different male AB negative 
serum. For the positive control group (dark grey, light grey, white and striped) the detection 
antibody IgG1, IgG2, IgG3 and IgG4 was used at various concentrations (0.1µg/ml, 0.05µg/ml, 
0.025µg/ml and 0.0125µg/ml) created by serial dilution of the antibody (1:10, 1:20, 1:40 and 
1:80). However, for negative control group the detection antibody was used at just the maximum 
concentration (0.1µg/ml) to minimise reagent usage.  Streptavidin conjugated to PE was used at 
0.05μg/ml.  The amount of HLA-specific antibody, as represented by mean fluorescence intensity 
(MFI) is shown on the y-axis. Individual bars represent mean of 5 specific oligo-antigenic beads. 
These beads were coated with HLA-A2 antigen. The highest MFI for all IgG subclass was 
detected at 0.1µg/ml. Cut off value = mean of negative control MFI x 1.5. Data represent 
mean+SD of triplicate experiments. Results shown are of one experiment representative of three. 
P<0.005 versus control. In this experiment a plateau value, for MFI, was not reached and was not 
sought because of the experimental costs (beads and reagents) and not wanting to consume 
patient samples for routine analysis.     
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Figure 18.  Titration of streptavidin-phycoerythrin using class I oligoantigenic beads. 
HLA coated Luminex beads were incubated with positive and negative control group.  Positive 
control group was 6 different highly renal patients’ sera as described in Table 3. Negative control 
group (dark grey column) was a pool of different 5 male negative AB sera. For positive and 
negative control groups, the biotinylated detection anti-IgG subclass antibody was used at a 
concentration of  0.1µg/ml. Streptavidin conjugated to PE was used at various concentrations 
0.1µg/ml, 0.05µg/ml and 0.025µg/ml, corresponding to serial dilutions of 1:10, 1:20 and 1:40. 
For the positive control group the MFI for all IgG subclass plateaued at 0.05µg/ml. However, for 
negative control group the lowest MFI was also at a concentration of 0.05µg/ml (The serial 
dilution of streptavidin-PE was also performed with negative control samples (data not shown). 
The amount of HLA-specific antibody, measured by mean fluorescence intensity (MFI) is shown 
on the y-axis. Individual bars represent mean of 5 specific oligo-antigenic beads. These beads 
were coated with HLA-A2 antigen. Cut off value = mean of negative control MFI x 1.5. Data 
represent mean+SD of triplicates experiments. Results shown are of one experiment 
representative of three. P<0.005 versus control.   
 
 
 
Chapter 2 
 115
 
Figure 19.  Titration of IgG subclass-specific antibody (biotinylated anti-IgG1/2/3/4) using 
class II oligoantigenic beads. 
HLA coated Luminex beads were incubated with positive and negative control group sera.  The 
positive control group was 4 different highly renal patients’ sera as described in Table 4. The 
negative control group was sera from 5 different male negative AB. For the positive control group 
the subclass-specific antibody (anti-IgG1, -IgG2, -IgG3 and -IgG4) was used at various 
concentrations of 0.1µg/ml, 0.05µg/ml, 0.025µg/ml and 0.0125 µg/ml, prepared by serially 
diluting the antibody 1:10, 1:20 and 1:40. For the negative control group the detection antibody 
was used at just the maximum concentration (0.1µg/ml=1:10). The amount of HLA-specific 
antibody detected, measured by mean fluorescence intensity (MFI) is shown on the y-axis. 
Individual bars represent the mean of 5 specific oligo-antigenic beads. The highest MFI for all 
IgG subclass was detected at 0.1µg/ml. Cut off value = mean of negative control MFI x 1.5. Data 
represent mean+SD of triplicate experiments. Results shown are of one experiment representative 
of three. P<0.005 versus control. In this experiment a plateau value, for MFI, was not reached and 
was not sought because of the experimental costs (beads and reagents) and not wanting to 
consume patient samples for routine analysis.  
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Figure 20.  Titration of streptavidin-phycoerythrin using class II oligoantigenic beads. 
HLA coated Luminex beads were incubated with positive and negative control group sera.  The 
positive control group was 4 different highly renal patients’ sera as described in Table 4. The 
negative control group was 5 different male AB negative sera and a negative control supplied 
with the kit. For positive and negative control groups the biotinlated IgG subclass-specific 
antibodies were used at a concentration of 0.1µg/ml. Streptavidin-PE was used at various 
concentrations (0.1µg/ml, 0.05µg/ml and 0.025µg/ml) prepared by serial dilution (1:10, 1:20 and 
1:40). For the positive control group the highest MFI for all IgG subclass was detected at 
0.05µg/ml. However, for negative control group only the data showing use of concentration of 
0.05µg/ml is shown. The amount of HLA-specific antibody, measured by mean fluorescence 
intensity (MFI), is shown on the y-axis. Individual bars represent mean of 5 specific oligo-
antigenic beads. Cut off value = mean of negative control MFI x 1.5.  Data represent mean+SD of 
triplicates experiments. Results shown are of one experiment representative of three. P<0.005 
versus control. 
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2.5.3.1.4.  Testing the sensitivity and specificity of class I and class II HLA-specific IgG 
antibody subclass assays 
It was essential that the assays gave specific results; not yielding false positive or false 
negative results. To test this for the anti-class I IgG subclass assays, I used class I and 
class II antigen-coated beads and pooled male blood group AB negative serum as a 
negative control.  I found all the HLA class II beads to be negative, but there was some 
non-specific binding (false positives) with a small number of class I beads. I compared 
these results with the negative control provided with the screening (poly-antigenic) and 
identification (oligo-antigenic) kits and these too showed non-specific binding to the 
same beads I had found using AB serum. Considering these findings, I was able to 
identify those beads that gave non-specific positive signals in the assays using subclass-
specific antibodies (Table 5) and I excluded binding with these beads, as false positive 
reactions, when they occurred with patients’ sera.           
Type of HLA antigens that coat  each oligo-antigenic bead Beads code numbers 
according to manufacturer  HLA-A- HLA-A- HLA-B- HLA-B- HLA-Cw- HLA-Cw- 
59LB 68 74 72 8 2 7 
1BW 1 26 55 57 3 6 
35CBC 2 30 18 61 2 5 
814 1 6601 41 65 17 8 
107 23 74 40 51 15 16 
109 11 31 39 61 3 7 
752 11 31 35 62 4 8 
72LB 23 74 35 41 4 8 
106 11 31 39 61 3 7 
48DFW 2 31 13 35 4 6 
18LB 23 36 58 7 4 7 
DB 2 25 27 8 1 7 
 
Table 5.  False positive class-I beads. 
This table shows the oligo-antigenic bead number for beads that gave false positive results 
when tested against AB male serum and negative controls supplied with both oligo and poly-
antigenic beads. For example, bead 59LB is coated with HLA-A68, HLA-A74, HLA-B72, 
HLA-B8, HLA-Cw2 and HLA-Cw7.  Each bead is coated with HLA-A, HLA-B and HLA-C 
antigens. 
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After I had developed the anti-class I IgG subclass-specific assays and identified beads 
that exhibited non-specific binding, I used them to determine the subclass distribution of 
anti-class I antibodies in control sera. Table 6 shows the pattern of specificities by IgG 
subclass using the control sera supplied with the identification (oligo-antigenic) kit. Of 
note, a small number of specificities identified in the pan IgG assay were not detectable 
in any of the subclass-specific assays. To check for reproducibility, I tested each serum 
from 6 randomly selected highly sensitised patients (with PRA ≥90%) on a second 
occasion and found a high reproducibility and specificity of the assay (data not shown). 
 
For the anti-class II IgG subclass assays I used the negative controls supplied with the kit 
and male AB negative sera, to test for the specificity of the assays. All class II beads gave 
negative results when incubated with negative control sera (Table 7).  This demonstrated 
that all four of the subclass-specific assays were detected with specificity.  
 
Legend for Table 6, page 119.   
Pan IgG and IgG-subclass specific specificities of negative and positive controlled 
supplied with the identification kit. Refer to section 2.5.3.1.4.  As explained in Figure 14 
on page 105, a positive value for two or more of the adjusted ratios indicates a positive 
bead reaction whereas a negative value for three or more of the adjusted ratios indicates a 
negative bead reaction. Cut off = negative control sample mean x 1.5. 
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  Class I HLA-specific antibodies 
IgG IgG IgG 
Controls HLA-A Pan 1 2 3 4 HLA-B Pan 1 2 3 4 HLA-C Pan 1 2 3 4 
Negative 
control - - - - - - - - - - - - - - - - - - 
1 + - - - - 7 + - - + - 1 + - + - - 
2 + + - + - 8 + + - + - 2 + + + + + 
3 + + - + - 13 + - - + - 3 + - - + - 
11 + - + - - 18 + + - + - 4 + - + + - 
23 + + - + + 27 + - + + + 5 + + - + + 
24 + + + + + 35 + - - + + 6 + + - + - 
25 + + - + - 37 + - - + + 7 + + - + - 
26 + - - - - 38 + - - - - 8 + - - + + 
29 + - + - + 39 + + - + - 12 + - + - - 
30 + - - + + 40 + + - + + 14 + - - + + 
31 + - + +  41 + - - + + 15 + + - + + 
32 + + - + + 42 + - + - - 16 + + - + + 
33 + + - + - 44 + - + - - 17 + - + - - 
34 + - - - - 45 + + - + + 18 + + - + + 
36 + + - + + 46 + - - - -       
68 + + - + + 47 + + - + +       
74 + + + + + 48 + + - + +       
80 + - - - - 49 + - - + +       
6601 + - - + - 50 + + - + -       
6602 + - - - - 51 + - - + +       
      52 + - - - -       
      53 + + - + -       
      54 + - - + -       
      55 + - - - -       
      56 + - - - -       
      57 + - - - -       
      58 + - + - -       
      60 + - - + -       
      61 + + - + +       
      62 + - + + +       
      63 + + - - -       
      64 + + - + +       
      65 + - - + -       
      67 + + - + -       
      71 + - - - -       
      72 + - - + +       
Positive 
controls 
supplied 
with class I 
ID kit 
      75 + - - - -       
Table 6.  Anti-class I X-MAP assays:  Pan IgG and IgG-subclass specificities of positive 
and negative control sera.   Please see previous page for the table legend. 
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Class II HLA-specific antibodies 
IgG IgG 
Controls HLA-DR Pan 1 2 3 4 HLA-DQ Pan 1 2 3 4 
Negative 
control supplied  
with class II ID 
kit and AB 
male sera 
- - - - - - - - - - - - 
1 + + - + - 2 + + - + - 
4 + + - - - 4 + - - - - 
7 + + - + - 5 + + - + - 
8 + - - - - 6 + + - + - 
9 + + - + - 7 + + - + - 
Positive control 
supplied with 
class II ID kit 
10 + + - + - 8 + + - - - 
  11 + - - - - 9 + + - - - 
  12 + - - - -       
  13 + + - - -       
  14 + + - - -       
  15 + + - + -       
  16 + + - - -       
  17 + - - - -       
  18 + - - - -       
  103 + + - + -       
              
IgG 2/4-pos-
control 1 + - - - + 2 + - + - + 
  4 + - - - - 4 + - + - - 
  7 + - + - + 5 + - + - + 
  8 + - + - - 6 + - + - + 
  9 + - + - + 7 + - + - - 
  10 + - + - + 8 + - - - - 
  11 + - + - - 9 + - + - + 
  12 + - + - -       
  13 + - + - -       
  14 + - + - -       
 
Table 7.  Anti-class II X-MAP Assays: Pan IgG and IgG-subclass specificities of 
negative and positive control sera.  
Pan IgG and IgG-subclass specific specificities of negative and positive controlled. Refer 
to section 2.5.3.1.4.  As explained in Figure 14 on page 105, a positive value for two or 
more of the adjusted ratios indicates a positive bead reaction whereas a negative value for 
three or more of the adjusted ratios indicates a negative bead reaction.  Cut off= negative 
control sample mean x 1.5. 
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Having optimised the X-MAP technology bead assays and confirmed the sensitivity and 
reproducibility, I went on to detect the IgG subclasses of class I HLA-specific and class II 
HLA-specific antibodies in patient sera.  I will discuss the class I and class II results in 
turn. 
2.5.4.  Detecting class I HLA-specific IgG antibody subclasses in pre-
transplant sera using X-MAP technology assays 
On the basis of the screening assay (Figure 15), I determined that 41 patient samples 
contained class I HLA-specific antibodies only. Reviewing the subclasses of the HLA-
specific antibodies using those 41 patients’ sera, I was able to detect the presence of IgG1 
class I HLA-specific in 14 (34%) sera, IgG2 class I HLA-specific in 5 (12%) sera, IgG3 
class I HLA-specific in 12 (29%) sera, and IgG4 class I HLA-specific in 10 (24%) sera 
(Table 8 for an example of how this data was collected for a single patient). Five 
specificities identified in the pan-IgG assay were not identified in any of the subclass-
specific assays. Table 8 illustrates that, occasionally, some specificities were detected in 
one of the subclass-specific assays, but not in the pan IgG assay. Surprisingly, as shown 
in Table 9, two patients had a large number of specificities detected in the IgG3 and IgG4 
subclass-specific assays but none detected in the pan-IgG assay. In one case, one of these 
was a donor-specific antibody. I repeated this assay three times running IgG3 and IgG4 
subclass-specific and pan IgG assays in parallel, but I always found the same results.  It is 
unclear why the pan IgG assay did not detect antibodies but this suggests that the subclass 
assays developed in this project may be more sensitive.   
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Class I HLA-specific antibodies 
IgG IgG IgG 
Serum ID HLA-A Pan 1 2 3 4 HLA-B  Pan 1 2 3 4 HLA-C Pan 1 2 3 4 
c-99-00561 1 + + - - + 7 + - - - - 1 + + - - - 
  11 + + - - + 8 + + - - + 3 + + - - - 
  23 + + - - + 13 - + - - - 4 + + - - - 
  24 + - - - - 18 - + - - + 5 - - - - +
  25 + + - - + 27 - - - - + 7 + + - - - 
  26 + + - - + 35 + + - - + 8 + + - - +
  29 + + - - - 38 - - - - + 12 + - - - +
  31 - + - - + 39 + + - - - 15 + + - - - 
  34 + + - - - 40 - - - - + 16 + - - - - 
  36 + + - - + 41 - + - - + 18 + - - - - 
  74 - - - - + 44 + + - - -       
  80 + - - - - 45 + - - - +       
  6601 + + - - + 46 + + - - -       
  6602 + - - - - 47 + + - - -       
        48 + + - - -       
        54 + + - - +       
        55 + + - - +       
        57 + + - - -       
        58 + + - - -       
        62 + + - - -       
        64 - - - - +       
        65 + + - - +       
        71 + + - - -       
        75 + + - - +       
        78 + - - - -       
        81 + - - - -       
 
Table 8.  An example of a single patient in whom comparison is made, using X-MAP technology, 
between antibodies detected in pan IgG and subclass-specific class I HLA-specific assays. 
In this example, only IgG1 and IgG4 antibodies were detected. Contemporaneous positive controls for the 
IgG2 and IgG3 assays were positive (data not shown).  As explained in Figure 14 on page 105, a positive 
value for two or more of the adjusted ratios indicates a positive bead reaction whereas a negative value for 
three or more of the adjusted ratios indicates a negative bead reaction.  Cut off= negative control sample 
mean x 1.5. 
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Class I HLA-specific antibodies 
IgG IgG IgG 
Serum ID HLA-A Pan 1 2 3 4 HLA-B  Pan 1 2 3 4 HLA-C Pan 1 2 3 4
c-99-00278 3 - - - - + 18 - - - - + 2 - - - - +
  23 - - - - + 27 - - - - + 3 - - - - +
  24 - - - - + 40 - - - - + 5 - - - - +
  25 - - - - + 41 - - - - + 14 - - - - +
  29 - - - - + 45 - - - - + 15 - - - - +
  30 - - - - + 49 - - - - + 16 - - - - +
  33 - - - - + 51 - - - - + 18 - - - - +
        57 - - - - +       
        61 - - - - +       
        62 - - - - +       
        65 - - - - +       
        71 - - - - +       
        78 - - - - +       
        81 - - - - +       
        82 - - - - +       
                    
c-04-03892 1 - - - + - 7 - - - + - 1 - - - + -
  2 - - - + - 8 - - - + - 2 - - - + -
  3 - - - + - 10 - - - + - 3 - - - + -
  11 - - - + - 13 - - - + - 4 - - - + -
  23 - - - + - 18 - - - + - 5 - - - + -
  24 - - - + - 27 - - - + - 6 - - - + -
  25 - - - + - 35 - - - + - 7 - - - + -
  26 - - - + - 37 - - - + - 8 - - - + -
  29 - - - + - 38 - - - + - 12 - - - + -
  30 - - - + - 39 - - - + - 14 - - - + -
  31 - - - + - 41 - - - + - 15 - - - + -
  32 - - - + - 42 - - - + - 16 - - - + -
  33 - - - + - 44 - - - + - 17 - - - + -
  34 - - - + - 45 - - - + - 18 - - - + -
  36 - - - + - 46 - - - + -       
  68 - - - + - 47 - - - + -       
  74 - - - + - 48 - - - + -       
  80 - - - + - 49 - - - + -       
  6601 - - - + - 50 - - - + -       
  6602 - - - + - 51 - - - + -       
Table 9.  Two examples of patients in which a comparison, using X-MAP 
technology, between pan IgG and subclass-specific class I HLA-specific assays is 
made.  Please see the next page for the table legend.  
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Legend for Table 9, page 123. 
In these examples, discordant results between anti-class I total IgG and IgG3 and IgG4 
are noted. Cells highlighted represent donor-HLA-specific antibodies. As explained in 
Figure 14 on page 105, a positive value for two or more of the adjusted ratios indicates a 
positive bead reaction whereas a negative value for three or more of the adjusted ratios 
indicates a negative bead reaction. Cut off= negative control sample mean x 1.5.  
 
2.5.5.  Detection of the presence of class II HLA-specific IgG subclass 
antibodies using X-MAP technology.  
On the basis of a screening assay (Figure 15), I found that 35 samples had antibodies 
against HLA class II only. Reviewing the subclasses of the HLA-specific antibodies 
using these 35 patients’ sera, I was able to detect the presence of class II HLA-specific 
IgG1 in 11 (31%) sera, class II HLA-specific IgG2 in 4 (11%) sera, class II HLA-specific 
IgG3 in 16 (46%) sera, and class II HLA-specific IgG4 in 8 (23%) sera samples. In three 
cases, I detected more than one subclass in the same serum. Table 10 shows three 
examples in which the specificity of antibodies detected in these sera were consistent 
with that shown for the total IgG. 
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                 Class II HLA-specific antibodies 
IgG IgG 
Serum ID  HLA-DR  Pan 1 2 3 4 HLA-DQ  Pan 1 2 3 4 
c-99-000561 7 + + + - - 2 + + + - - 
  8 + + + - - 7 + + + - - 
  9 + + + - - 9 + + + - - 
  11 + + + - -       
  13 + + + - -       
  14 + + + - -       
  17 + + + - -       
              
c-03-01038 7 - + - + - 2 + + - 2 - 
  8 + + - + - 6 + + - 6 - 
  9 + + - + - 7 + + - 7 - 
  10 + + - + - 9 + + - 9 - 
  11 + + - + -       
  13 + + - + -       
  17 + + - + -       
              
c-04-04407 1 + + - - + 2 + - - - + 
  4 + - - - - 5 + + - - + 
  7 + + - - + 7 + - - - - 
  9 + + - - + 8 + - - - - 
  10 + + - - + 9 + + - - + 
  12 + - - - -       
  14 + - - - +       
  15 + + - - -       
  16 + - - - -       
 
Table 10.  Three examples comparing the detection of pan IgG and IgG subclasses 
of HLA-specific antibodies using X-MAP technology assays.  
Table cells highlighted, with thick outlines, represent donor HLA-specific antibodies. A 
small number of specificities identified in the pan-IgG assay were not identified in any of 
the subclass-specific assays.   As explained in Figure 14 on page 105, a positive value for 
two or more of the adjusted ratios indicates a positive bead reaction whereas a negative 
value for three or more of the adjusted ratios indicates a negative bead reaction.  Cut off= 
negative control sample mean x 1.5. 
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2.5.6.  Detection of the presence of class I and class II HLA-specific IgG 
subclass antibodies using X-MAP technology 
 
In the previously described screening poly-antigenic assay (Figure 15), I identified the 
presence of both class I and II HLA-specific antibodies in 31 sera. Performing assays for 
the class I HLA-specific IgG subclasses, I was able to detect the presence of class I HLA-
specific IgG1 in 19 (61%) sera, class I HLA-specific IgG2 in 6 (19%) sera, class I HLA-
specific IgG3 in 8 (26%) sera, and class I HLA-specific IgG4 in 3 (9.6%) sera. Similarly 
for class II, I was able to identify the presence of class II HLA-specific IgG1 in 13 (3.2%) 
sera, class II HLA-specific IgG2 in 2 (6.4%) sera, class II HLA-specific IgG3 in 8 (26%) 
sera, and class II HLA-specific IgG4 in 3 (9.6%) sera (Data not shown in a figure). 
 
I therefore set about determining the presence of donor specific (DSA) or non-donor-
specific (NDSA) in the sera of patients, using the X-MAP technology assays described 
above, before correlating these data with graft and patient survival data.  
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2.5.7.  Differentiation between the presence of DSA and NDSA anti-class I 
and anti-class II IgG subclasses in patient sera 
 
To find out whether HLA-specific antibodies were donor-specific or not, I compared the 
HLA-specific antibodies identified using the modified subclass identification kits and the 
known donor HLA types. In total, 58 out of 78 (74%) patients had DSA as well as NDSA 
while 29 (37%) had only NDSA. I also detected the presence of complement-fixing-
antibodies (CFA) and non-complement-fixing antibodies (NCFA) in both groups. Figure 
21 illustrates that CFA (IgG1 and IgG3) are dominant among both DSA and NDSA 
groups.  
 
 
Figure 21.  Patterns of HLA-specific antibody disparities in 78 current serum samples using 
IgG subclass assays. 
Complement-fixing class I and class II HLA-specific antibodies (CFA) are dominant among both 
DSA and NDSA groups. P<0.05.   
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2.5.8.  Correlation between the clinical outcome and the presence of DSA 
or NDSA 
 
I studied the correlation between renal function or allograft survival and; the presence of 
low level DSA (detected by oligo-antigenic kits and IgG subclass modified kits), or; the 
presence of NDSA.  For each experiment a Negative control group was included – this 
was a group of patients who did not have HLA-specific antibodies.  The groups with 
HLA-specific antibodies (DSA or NDSA as and when appropriate) were then compared 
with this Negative control group in each experiment.  The results of these studies are 
shown in Figures 23 – 26 and are described below.  
 
Over a 5-year follow-up, there was no difference in patient survival (Figure 22) or graft 
survival (Figure 23) between the Negative control group (patients with no antibodies 
against HLA) and the DSA-positive group (p= 0.7679, p=0.387) respectively.   
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Figure 22.  Patient survival after renal transplant according to HLA-specific 
antibody status in current sera over five years follow up. 
Pre-transplant sera contained DSA (DSA Positive; n=58) or had no detectable HLA-
specific antibodies (Negative control; n=327).  No statistical difference in patient survival 
between the two group.  P = 0.7679.  The log rank test was used for statistical analysis of 
the results. 
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Figure 23.  Graft survival after renal transplant according to HLA-specific antibody 
status in current sera over five years follow up.  
Pre-transplant sera contained DSA (DSA Positive; n=58) or had no detectable HLA-
specific antibodies (Negative control; n=327). No statistical difference was detected 
between the two groups P= 0.387.  The log rank test was used for statistical analysis of 
the results. 
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I next looked at the impact of the presence of DSA, on renal function (as determined by 
creatinine levels assays performed by Hammersmith Hospital Clinical Biochemistry 
Laboratory) (Figure 24). At three years post-transplantation there was no difference 
between the DSA-positive group and the Negative control (no HLA-specific antibodies) 
group (Figure 24).  
 
 
 
 
 
Figure 24.  Serum creatinine levels at three years post transplant. 
Serum creatinine was measured (μmol/l) in patients at various time points up to three years post 
transplant. There was no statistical difference between the creatinine levels of the DSA group 
(DSA Positive; n=58) and the negative control (no HLA-specific antibodies) group (Negative 
control; n= 327). The Student’s t-test was used for statistical analysis of the results.  Data 
represent mean+SD, P= Not Significant (NS).  
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The Modification of Diet in Renal Disease study equation-estimated Glomerular 
Filtration Rate (MDRD-eGFR), using standardized serum creatinine values, is used to 
estimate the renal function (Levey et al. 2006). The MDRD takes into consideration age, 
sex and serum creatinine level in determining eGFR. Applying MDRD to the patients in 
this study showed no statistical difference between the DSA-positive group and the 
Negative control (no HLA-specific antibodies) group up to three years post transplant 
(Figure 25). 
 
 
 
Figure 25.  Estimates of patient eGFR, using the MDRD formula, three years post-
transplant. 
The eGFR was determined using the MDRD formula, for patients for three years post-
transplant. There was no statistical difference in MDRD-eGFR level between the DSA 
positive group (DSA Positive; n=58) and the negative control (no HLA-specific 
antibodies) group (Negative Control; n=327) for up to three years post-transplantation. 
The Student’s t-test was used for statistical analysis of the results.  Data represent mean+ 
SD, p=NS.  
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As there were no significant differences between patient survival, graft survival and renal 
function, at three years post transplant, between patients with DSA and patients with no 
HLA-specific antibodies, at the time of transplant, I went on to look at rejection episodes 
versus the presence of DSA.  The DSA-positive group had significantly more rejection 
episodes compared with the negative control group (p=0.0189) (Figure 26). In the 
negative control group, the 90% of patients were rejection-free, whereas in the DSA-
positive group just over 60% of patients remained rejection-free. Interestingly, in the 
DSA-positive group, rejection episodes continued to occur beyond the first year (Figure 
26). 
 
Figure 26.  Kaplan–Meier graph of rejection-free survival for patients with DSA or no 
HLA-specific antibodies. 
Actuarial rejection episodes compared to the antibody status of current sera. Patients with DSA 
(DSA Positive; n = 58) in their sera at the time of transplant had more rejection episodes 
compared to patients without HLA-specific antibodies (Negative control; n = 327) at the time of 
transplant (p= 0.0189).  The log rank test was used for statistical analysis of the results. 
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When I compared the graft survival of patients whose DSAs were exclusively of 
complement fixing subclasses, with the graft survival of patients whose DSAs were 
exclusively of non-complement fixing subclasses, there was a markedly inferior graft 
survival in those with complement fixing subclasses (Figure 27).  Most patients fell 
into the categories of having only complement-fixing subclasses or only non-
complement fixing subclasses.  However, the numbers were still quite small, so despite 
the difference in survival graphs seen in Figure 27, they did not reach statistical 
significance in the Log rank test. 
 
Figure 27.  Kaplan–Meier allograft survival graph for patients with non-
complement-fixing DSA only, complement fixing DSA only or no HLA-specific 
antibodies. 
Data from patients with non-complement-fixing DSA (n=22), complement-fixing DSA 
(n=49) and no HLA-specific antibodies (Negative control; n = 327) in current sera are 
plotted. No statistical differences in graft survival were seen between the groups. p =NS.  
The log rank test was used for statistical analysis of the results. 
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A similar pattern was seen when graft survival of patients who had DSA was compared 
with that of patients who had only NDSA (Figure 28). However, although there was a 
trend suggesting that the presence of DSA was associated with lesser graft survival, the 
difference did not reach statistical significance. 
 
Figure 28.  Kaplan–Meier allograft survival graph for patients with NDSA, DSA 
and no HLA-specific antibodies. 
Data from patients with NDSA (n=29), DSA (n=58) and no HLA-specific antibodies 
(Negative control; n = 327) in current sera are plotted.  No statistical differences were 
detected between the three groups,  p=NS. The log rank test was used for statistical 
analysis of the results. 
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2.6. Discussion  
It is well established that there is a strong association between the presence of HLA-
specific antibodies after transplantation and graft failure. This indicates the importance of 
monitoring HLA-specific antibodies pre-transplantation (Patel and Terasaki 1969). As 
technology has advanced, we have developed newer, more sensitive techniques for 
identifying antibodies. The initial CDC assay was supplemented by the FCXM and this 
has been further supplemented by ever more sensitive solid phase assays, of which X-
MAP technology is the most recent (Fuggle and Martin 2008). El-Awar et al. reported 
studies of 58 sera tested by 63 laboratories, using conventional methods or X-MAP 
technology (single antigen beads). They found that 81% of specificities that were 
detected in single-antigen (SA) X-MAP technology assays were not detected by CDC 
(El-Awar et al. 2005). I have undertaken this project in the context of trying to identify 
where this technology sits in the clinical hierarchy. Some feel that these new tests have 
been adopted too enthusiastically. For example, Christiaans et al. reported that, in highly 
sensitised patients, there is no significant difference in 1-year graft survival between 
FCXM positive patients (87%) and FCXM negative patients (87%) and he concluded 
that, transplantation with a mandatory negative FCXM would have unnecessarily 
excluded 28% of the recipients from transplantation; these patients are in fact doing well 
and benefitting from the transplant (Christiaans et al. 1996). 
 
Other laboratories rely on the X-MAP technology assays to determine the HLA 
specificity of HLA-specific antibodies, and use the information obtained for allocation of 
donor organs (Billen et al. 2008). Although the clinical relevance of antibodies detected 
by these bead-based techniques is still a matter of debate, prospective crossmatching 
using X-MAP technology assays is recommended by some (Christiaans et al. 1996; 
Mizutani et al. 2007).  The reason that there is some controversy over the clinical 
relevance of bead-based techniques lies in the way that the assays work; in the oligo-
antigenic bead assays, a mixture of beads coated with various antigens is used to test for 
the presence of HLA-specific antibodies.  The limitation is that each bead is coated with 
different antigens and not all antigens are represented equally in the bead mixture. Some 
antigens, present in the human population, may not be represented at all.  Consequently, 
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in an aliquot of beads, used to test one patient’s serum sample, there may not be any 
beads coated with an antigen to which the patient has antibodies.  This would result in a 
false negative.  The consequence of this could be that some patients with DSA would be 
scored as negative and thus may undergo transplant in the presence of DSA and later 
experience humoral rejection.  These problems have limited the widespread acceptance 
and use of oligo-antigenic bead assays instead of CDC and flow crossmatch, in the clinic. 
 
In this study, during the optimisation of assays to detect the IgG subclasses of HLA-
specific antibodies, we avoided these problems by choosing a class I antigen (HLA-A2) 
and a class II antigen (HLA-DR7) that was highly represented on the beads we were 
using and: furthermore, highly represented in the population we were testing.  This 
avoided getting false negatives that may have occurred if we had looked for antigens 
present at low levels in the bead mixtures and population.   
 
When testing the sensitivity and specificity of class I and class II HLA-specific IgG 
assays with pooled male blood group AB negative serum, there was some non-specific 
binding (false positives) to class I but not to class II antigen-coated beads.  I was able to 
identify the beads that gave non-specific positive signals in the anti-class II assays using 
subclass-specific antibodies (Table 5) and I excluded binding with these beads, as false 
positive reactions.  It may be that these false positives were in fact binding of natural 
antibodies (which are more frequently anti-class I antibodies than anti-class II antibodies) 
to the beads, as found by Morales-Buenrostro et al. (2008) who showed that antibodies to 
class I were found in 42% of nonalloimmunised males (Morales-Buenrostro et al. 2008).  
The conclusion of their study was that these HLA-specific antibodies are the result of 
immune responses to microorganisms, ingested proteins and allergens which have cross-
reactive epitopes (Morales-Buenrostro et al. 2008).       
 
Mizutani et al showed that there is a strong correlation between the strength (titer) of de 
novo HLA-specific antibodies in serum samples and graft rejection. Serial dilution of 
strong HLA-specific allo-antibodies (up to 1:25) and testing with HLA-antigen-coated 
beads showed that the titer of the reaction to different HLA antigens is directly correlated 
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to maximum fluorescence values and the molecules of equivalent soluble fluorochrome 
(MESF) values obtained by Luminex machines. Thus, the strength of antibodies can be 
measured utilizing maximum fluorescence and MESF. In this group’s study, the strength 
of antibodies in the sera from 39 patients, who subsequently had graft failure, were 
markedly higher than those in the sera of 26 patients who continued to have good graft 
function (p = 0.0084) (Mizutani et al. 2007). The level of antibody binding and 
consequent fluorescence intensity is dependent on the binding affinity and the antigen 
density. Binding and dissociation constants of an antibody with its target are known to 
vary between antibodies and there is evidence that antigen levels vary between sets of 
micro-particles. Therefore, fluorescence intensity can only be directly compared for one 
individual’s antibodies, in different serum samples, binding to micro-particles from the 
same bead lot or alternatively, by normalising the data for the quantity of antigen per 
beads. Taking this into consideration it has been demonstrated that the strength of 
fluorescence on the micro-particles can be directly related to antibody titer (Mizutani et 
al. 2007). However, no such analysis has been undertaken for the clinical impact of low 
level pre-formed antibodies, which is the subject of my study.     
Another important factor in analysing antibodies is to differentiate between donor-
specific antibodies (DSA) and non-donor-specific antibodies (NDSA). The identification 
of both DSA and NDSA could not be done in the past with anything like the accuracy 
currently possible because the standard methods did not have the specificity needed to 
properly identify all antibodies present in a given serum (Mao et al. 2007b).  
In this study, I used oligo-antigenic beads and X-MAP technology to review 434 patients 
who were transplanted between 1998 and 2007. Of these patients, 107 had pre-transplant 
HLA-specific antibodies of which 58 (54%) were DSA and 29 (27%) were NDSA. There 
were 20 cases in which I identified HLA-specific antibodies using poly-antigenic beads 
but I was unable to identify specificities using oligo-antigenic beads. One explanation for 
this might be that poly-antigenic beads are more sensitive than oligo-antigenic beads and 
can detect lower levels of HLA-specific antibodies.  
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The major finding of this study was that the presence of DSA in pre-transplant serum, at 
levels too low to give a positive CDC or FXCM, is still associated with increased acute 
rejection. Low titer antibodies present at the time of transplantation are not likely to result 
in hyperacute rejection but their presence indicates that the recipient is at high risk of 
early antibody-mediated rejection (Fuggle and Martin 2008). The current results were 
compared with those observed by Gibney et al., who reported that in patients with graft 
dysfunction, who had undergone kidney transplantations with a negative AHG-CDC, 20 
of 55 patients were found to have DSA upon retesting with X-MAP technology.  He 
concluded that patients with low-level DSA, detected by X-MAP technology, had higher 
rates of primary graft non-function and lower rates of graft survival at 6 months (Gibney 
et al. 2006). Similarly, Zhang et al. prospectively studied 49 immunologically high-risk 
kidney transplant recipients for HLA-specific antibodies using ELISA and X-MAP 
technology (Zhang et al. 2005). All recipients were pre-transplantation CDC and flow 
crossmatch negative. A total of 22.4% of recipients developed de novo DSA and 38.8% 
developed NDSA HLA-specific antibodies after transplantation. Patients who developed 
acute humoral rejection had DSA (Zhang et al. 2005).  My results are consistent with 
those of these described studies; the presence of DSA in pre-transplant sera is strongly 
linked to subsequent acute rejection. 
In the current study, the impact of renal function, as determined by creatinine level at 
three years post transplantation and on graft and patient survival, shows no differences 
between DSA-positive and negative control groups. This finding is comparable to Gupta 
et al. who clearly show that the presence of DSA, detected only by X-MAP technology, 
in the context of negative CDC and FCXM, is not associated with hyperacute rejection or 
graft function at 1-year (Gupta et al. 2008).      
Another important finding in the current study is that, most patients fell into the 
categories of having only donor-specific complement-fixing antibody (CFA) subclasses 
or only donor-specific non-complement-fixing antibody (NCFA) subclasses. However, 
the numbers in the study were quite small so despite the differences seen in survival, 
results did not reach statistical significance.  NCFA may not lead to immediate graft loss, 
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but could be used as a marker of increased risk of rejection or graft loss over time. 
Although the roles of different IgG subclasses of alloantibodies, in determining kidney 
allograft survival, is still controversial, it has been suggested that non-complement-
binding IgG2 and IgG4, alloantibodies contribute to the development of rejection (Cecka 
and Terasaki 1994; Fuller et al. 1999). However, Heinemann et al. detected the presence 
of NCFA HLA-specific antibodies, using ELISA and X-MAP technology assays, in 
isolated accumulated antibodies and he reported that the presence of these antibodies 
does not contribute to allograft rejection (Heinemann et al. 2007).  Thus the role of 
NCFA is still unclear.  
Another finding in the current study was the predominant detection of IgG1 and IgG3 
subclasses of class I and class II HLA-specific antibodies, respectively. A limited number 
of studies have highlighted the clinical effects of the four IgG subclasses individually. 
Bartel et al reported that many sera were shown to contain a mixture of CFA and NCFA 
IgG subclasses. Using a modified Flow PRA screening kit, for both class I and II, he 
studied the relationship between the presence of preformed CFA and the risk for kidney 
allograft rejection. He reported that IgGl type panel reactivity was predominant (HLA 
class I and II reactivity was detectable in 93% and 91% of IgG-positive sera), followed 
by IgG3, IgG2 and IgG4. In addition, he concluded that previous transplantation 
represents a major risk factor for the development of CFA (Bartel et al. 2007). This 
finding was in line with the previous studies, for instance,  Griffiths et al. have suggested 
that skewing of IgG presensitization toward IgG1 (detected using flow cytometric assays) 
is associated with worse prognosis (Griffiths et al. 2004). In addition, Kerman et al. and 
Monteiro et al. also demonstrated a correlation between ELISA-based detection of 
alloreactive IgG1 and adverse renal allograft outcomes (Kerman et al. 1996; Monteiro et 
al. 1997). A recent study by Smith et al, using a method to detect C4d fixing HLA-
specific antibodies with Luminex beads, correlated the presence of pre-transplant DSA 
with a negative effect on graft survival in cardiac transplant patients (Smith et al. 2007). 
The effect of DSA on allograft survival was analysed according to titer, IgG subclass, and 
ability to fix C4d on to Luminex beads. The ability to fix C4d, but not antibody titer or 
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IgG subclass, was strongly associated with poor allograft survival in cardiac transplant 
patients (Rose and Smith 2009).       
There are many parameters influencing the activation of the complement system. For 
example, HLA-specific antibody levels, IgG subclasses, the nature of antigen-antibody 
reaction and the poly-specificity of the HLA-specific antibody response. Chronic 
exposure to low levels of HLA-specific antibodies may produce injuries to the allograft 
even if levels of complement are insufficient to result in C4d deposition (Lachmann et al. 
2009). Kushihata et al evaluated the role of all these parameters using flowcytometry and 
compared the results to those obtained with the standard CDC. He concluded that 
measuring C3b, in addition to the measurement of HLA-specific antibodies, may improve 
the way of evaluating sensitized organ transplant candidates (Kushihata et al. 2004). 
 There are some limitations in the current study: the modest number of patients included 
and the inability to compare our data with the information from kidney biopsies stained 
for C4d. This was something I attempted to do but was unsuccessful due time constraints. 
2.7. Conclusion 
This study showed that patients with a negative CDC and flow crossmatch can be further 
stratified into risk subgroups by testing for the presence of low level DSA using X-MAP 
technology. Adverse immunological and clinical outcomes appear more common in 
patients with low levels of DSA. Therefore, a conventional CDC and FCXM should no 
longer be considered sufficient to identify the status of sensitized patients. Low titer 
antibodies will only be detected by the more sensitive solid phase assays so an 
understanding of the various techniques, including X-MAP technology, that can be used, 
enables improved assessments of the risk associated with the presence of low level DSA. 
The routine use of X-MAP technology to detect low level DSA prior to transplantation 
could be introduced to allow accurate definition of high risk donor antigens and hence 
improve selection of appropriate donors and therapeutic protocols before and after 
transplantation by allowing a more accurate assesment of immunological risk.     
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3.1.  Introduction 
In the introduction of this thesis, I talked about how B cells can recognise antigen in its 
native form and how they act as APCs in direct and indirect allorecognition. I also, 
described, in detail, naïve B cell activation, clonal expansion, and differentiation into 
plasma cells and memory cells (Section 1.4). In addition, I outlined various methods that 
have been used in previous studies to detect the frequency of antigen-specific B 
lymphocytes and I pointed out the advantages and disadvantages of each method and why 
I chose ELISpot assays for this project. In the previous chapter I showed that the presence 
of pre-transplant DSA is a risk factor for graft rejection.  In this chapter I describe 
experiments undertaken to develop assays that can be used, pre-transplant, to assess the 
potential of memory B cells to mount an anti-graft response. In the following paragraphs, 
I introduce the premise for enumerating antigen-specific circulating B cells (cells with the 
potential for immediate expansion following antigen encounter) pre-transplant.  
 
There are a number of studies describing a correlation between specific serum antibody 
titre and the frequency of naïve B cells (CD19+CD20+Ig+CD38+) and specific memory B 
lymphocytes (CD19+CD20+IgM/IgG/IgA+CD27+CD38-) following exposure to an 
antigen. These correlations have been reported for some auto-antigens and nominal-
antigens (Mulder et al. 2001; Shokrgozar and Shokri 2001): Ueki et al. observed the 
changes in human B cells at a clonal level before and after immunization with rabies 
virus: Before immunization, the B cells produced low affinity IgM antibodies to the 
viruses, whereas after immunization, different anti-virus IgG and IgA antibody-producing 
cells appeared in the circulation and increased from less than 0.005% to greater than 10% 
of the total B cells committed to the production of IgG and IgA (Ueki et al. 1990). Using 
ELISpot and Limiting Dilution Assays (LDA), Shokrgozar et al. observed a positive 
correlation between the mean serum titre of anti-Hepatitis B (anti-HB) antibody and the 
frequency of circulating anti-HBs antibody producing B cells at 2 weeks and 4 weeks 
(Shokrgozar et al. 2006). Another study, using the LDA assay, showed a significant 
correlation between the level of anti-Rh antibodies and the frequency of circulating Rh-
specific B lymphocytes. This result was observed in three Rh-negative women bled at 
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different time-points following exposure to the Rh antigens through multiple pregnancies 
(Pasha et al. 2004). 
 
Sera from prospective transplant patients are usually screened for HLA-specific 
antibodies prior to transplantation, but presently available tests such as CDC and ELISA 
do not permit quantification of the whole B cell alloantigen-directed response. Using a B 
cell precursor frequencies (BCPF) assay, Mulder et al. found that lymphocytes of 15 
HLA-seropositive multiparous women were found to contain HLA-specific alloantibody 
secreting B-lymphocytes. This BCPF assay is an EL4.B5-based system which involves 
the culture of B-lymphocytes in the presence of the mouse thymoma cell line EL4.B5 
which expresses CD40L and can therefore provide costimulation. In Mulder’s study, B 
cells of HLA-specific antibody seropositive, multiparous females were cultured in LDAs. 
The HLA-specific antibody specificities detected in the B cell culture supernatants were 
in agreement with HLA serum specificities detected in the CDC assay (Mulder et al. 
2001). 
 
Conflicting results between serum HLA-specific antibody level and circulating antigen-
specific B cells may be expected for the following reasons:  In vivo, plasma cells are 
responsible for the continuous maintenance of serum antibody levels (Manz et al. 2002); 
however, memory B cells are responsible for driving the rapid immune antibody response 
to a recall antigen. In vitro assessment of the humoral immune response to an antigen 
does not necessarily reflect the in vivo process in that more plasma cells reside in bone 
marrow than in the circulation and memory B cells do not secrete antibody until 
stimulated (Slifka and Ahmed 1996). It was thought, therefore, that it would be useful to 
develop an ELISpot assay for detecting long-lived PC in the bone marrow (cells can 
maintain IgG serum titres for more than 1 year (Manz et al. 1999)) and, in parallel, use 
CD138 to identify the phenotype of long-lived PCs. CD138 is a heparan sulphate 
proteoglycan, which mediates cellular adhesion to collagen and might play a role in 
adhesion to bone marrow stromal cells (Horst et al. 2002). In this study CD138 was 
detected on plasma cell (PC) in bone marrow and peripheral blood but not on pre-
germinal centre B cells (Wijdenes et al. 1996).  
 
Chapter 3 
 145
 
3.2.  Aims and objectives 
 
The aim of this project was to develop assays that detect the responses of the various cells 
of the B cell compartment, reflecting innate allo-reactivity, as well as reactivity induced 
by historical sensitisation events.  The premise of this aim was to develop a system that 
could be used to make an assessment of an individual’s B cell immune system status in 
order to predict the likelihood and vigour of rejection episodes and furthermore, to 
monitor therapeutic responses. 
 
In order to pursue this aim, I set out the following objectives for the project: 
 
1. To develop a B cell culture system using non-specific stimulation using CD40L, IL-
10, IL-4 to optimize the culture conditions 
2. To develop IgM- and IgG-detecting ELISpot assays to determine the number of 
antibody-secreting cells 
3. To use this B cell culture system to optimise and standardise the ELISpot assay 
4. To apply these methods to determine the humoral reactivity against alloantigen in 
sensitised patients    
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
 146
 
3.3.  Material and Methods 
3.3.1. Collection of whole blood  
Blood samples were collected by venepuncture into evacuated collection tubes containing 
sodium heparin as the anticoagulant. Control samples were collected from five healthy 
male volunteers age range (35-55 years; people working in the Tissue Typing Laboratory 
at the Hammersmith Hospital and Immunology department at the Imperial College 
London). Patients’ samples were collected from the Renal Transplant Unit at the 
Hammersmith Hospital.  Ethical approval was granted by the Hammersmith Hospital and 
Queen Charlotte’s Research Ethics Committee (Number 07/H0707/104).   
3.3.2.  Peripheral blood mononuclear cells (PBMC) separation 
Whole blood was diluted 1:2 with phosphate buffered saline (PBS) in 50 ml Falcon tubes 
and layered over ficoll-hypaque gradients (Lymphoprep, Sigma). The sample was 
centrifuged for 20 min at 800 g (brake off). After that, lymphocyte cells were collected 
from the interface and washed twice with PBS.  Next the tubes were centrifuged for 10 
minutes at 400 g. RBCs were then lysed using pre-chilled (4oC) ammonium chloride 
(0.15 M NH4Cl) for five minutes.  During the five minute incubation cells were kept at 
room temperature.  Then platelets were removed by a second centrifugation over ficoll-
hypaque diluted 1:2 with PBS. Following the final wash the cells were resuspended in 
RPMI supplemented according to the assay to be performed. Finally, cells were counted 
and viability evaluated by Trypan blue exclusion using a haemocytometer.  
3.3.3.  B cell isolation  
The Dynal® B cell negative isolation kit (Invitrogen) was used. B cells were isolated 
using the antibody mix, which contains mouse IgG antibodies to deplete all peripheral 
blood cells except the target cells: CD2 (T cells, NK cells), CD14 (macrophages, 
granulocytes), CD16 (specific for both CD16a and CD16b) (monocytes),CD36 (platelets,  
erythrocytes), CD43 (activated B cells, such as plasma cells) and CD235a (glycophorin A 
found on erythrocytes). 
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The buffer used in this isolation was calcium- and magnesium-free PBS, supplemented 
with 0.1% BSA and 2mM EDTA. 100 μl containing 1 x 107 peripheral blood 
mononuclear cells (PBMCs) in PBS was transferred into a plastic tube. Then, 20 μl of 
antibody mix was added. The mixture was incubated for 20 minutes at 2-8°C on a 
rotating plate. The cells were then washed and resuspended in 800 μl of buffer. Then, 200 
μl of pre-washed Depletion Dynal beads was added. The mixture was incubated for 15 
min at 18-25°C with gentle tilting and rotation. Then, the bead-bound cells were 
resuspended in 1 ml of buffer.  The tube was placed in the magnet for 2 min. After that, 
the supernatant containing the negatively isolated B cells were transferred into a new 
tube. Finally, the washing steps were repeated for 2 to 3 times. 
3.3.4.  Cell cultures 
3.3.4.1.  PBMC or B cells stimulated non-specifically with CD40L, IL-10 and IL-4  
PBMCs or B cells isolated from whole blood were washed twice in RPMI supplemented 
with 5% L-glutamine, 5% penicillin, 5% streptomycin and 50% heat-inactivated AB male 
serum and then resuspended in culture medium at a concentration of 106/ml. In every 
experiment, PBMCs or B cells (2x105 in 200 µl/well) were stimulated, in triplicate, in 96-
well plate cultures with 100 ng/ml CD40L (Sigma), 100 ng/ml IL-10 (Sigma) and 20 
ng/ml IL-4 (Sigma). PBMCs or purified B cells were cultured (37oC in 5% CO2) in 96 
well plates for 1, 3, 4, 5, 6, 7 or 8 days prior to transfer into ELISpot plates for a further 
48 hours culture before development of the ELISpot.   
3.3.4.2.  Mitomycin-C (MMC) treatment cells 
150 µl MMC (1 μg/ml) was added to a suspension of 5 x 106 in 2ml PBMC or B cells and 
incubated for 30 minutes at 37°C. After treatment, the cell suspension was washed 3 
times with RPMI. Cell viability was assessed by trypan blue exclusion.   
3.3.4.3.  Stimulation assay  
Recipient PBMCs or B cells (1 x 106 /ml) were resuspended in RPMI containing 50% AB 
serum, 5% penicillin and 5% streptomycin. Then, the stimulator cells were diluted (1:1, 
1:2, and 1:4) and distributed into a 96-well culture tray. After that, to each well 
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allogeneic, mitomycin-C treated PBMCs (1 x 105/100 µl) were added. The plate was then 
incubated at 37oC in 5% CO2 for 4 or 8 days before the cells were transferred to an 
ELISpot plate for a further 48 hours.  
3.3.5.  Plasma cell ELISpot assay development 
ELISpot 96 well filter plates (Millipore) were coated with 200 μl goat anti-human IgG or 
IgM (Sigma) and incubated overnight at 4oC. The plate was washed 6 times with 200µl 
PBS and then blocked with 200µ1 4% (w/v) bovine serum albumin (Sigma) in PBS, for 
one hour at room temperature prior to use. 200µ1 of stimulated cultured PBMCs or B 
cells were plated into the precoated wells and incubated at 37 oC in 5% CO2 for 48 hours. 
After that, the plate was again washed 6 times and incubated for 2-3 hours at room 
temperature on the bench. Next, 100 µl (1µg/ml) of mouse anti-human pan IgG (Sigma) 
or IgM (Sigma) antibody was added. The plate was then washed 6 times again and 
incubated with 100µl (1 µg/ml) of (strepavidine-alkaline-phosphatase) (SAP) (Sigma-S-
2890) for one hour at room temperature in the dark. Then, the plate was washed 6 times 
and the colour of the reaction developed using 100µ1 of chromogen (AP Conjugate 
Substrate Kit, Bio Rad). The plate was then incubated on the bench for 10-15 at room 
temperature (19 - 22oC) in the dark. Finally, to stop the reaction, the plate was washed 
and air-dried. The plate was then read and analysed using the Autoimmune Diagnostika 
(AID) ELISpot plate reader. 
3.3.6.  Flow cytometry 
Flow cytometry was used to determine the efficiency depletion and to assess the quality 
of cell populations used in vitro functional assays. Responder and stimulator cell 
populations were stained with directly conjugated anti-CD20-APC (Caltag-MHCD2005).  
To identify the phenotype of cells of the B cell lineage, cells were stained with different 
combinations of the following directly conjugated mouse anti-human monoclonal 
antibodies: CD20-APC (Caltag-MHCD2005), CD38-PE (Sigma-HI157) and CD27-PE 
(Caltag-MHCD2704). Isotype controls used were mouse IgG2a-PE (Caltag-MHCD2704) 
and mouse IgG3-APC (Caltag-MHCD2005).  In brief, 100 µl of cultured cells (1 x 105 
/µl) were added to wells of a U-bottomed tissue culture plate and washed. Next, 1 μg/ml 
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anti-CD20 was added and incubated for 30 minutes on ice in the dark. Then, the plate 
was washed 3 times with cold PBS containing 2% BSA. Next, 1 μg/ml CD27-PE or 1 
μg/ml CD38 PE mixed with the cell pellet and incubated again for 30 minutes on ice in 
the dark. The tray was washed another 2 times with cold BSA. Finally, cells were fixed 
with fix buffer (PBS, 1% FCS, 0.1% sodium azide, 1% formaldehyde) (pH 7.4) before 
analysis by flow cytometry. 
3.3.7.  Antibody screening and identification using X-MAP technology   
Supernatants from the different cultures were collected and tested for the presence of 
HLA-specific antibodies using X-MAP technology; Methods were described in detail in 
Section 2.4. 
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3.4.  Results 
The purpose of this study was to develop functional assays to determine the frequencies 
of alloantigen-specific cells, of the humoral adaptive immune response, in renal 
transplant recipients. 
3.4.1.  Assay development plan 
In order to establish the above mentioned assays, I developed an ELISpot assay to detect 
the frequency of antibody-secreting human B cells.  To do this I optimised the 
preparation of stimulators (using mitomycin-C treated allogeneic PBMCs and mitomycin-
C treated allogeneic B cells) and the culture conditions used to simulate each of the 
groups of responders; plasma cells, naïve and memory B cells.  I titrated cell numbers, 
ratio of responder to stimulators (R: S), medium to be used and the incubation period.  I 
demonstrated the viability of these assays by using polyclonal stimulation of B cells with 
CD40L, IL-10 and IL-4.  To evaluate these assays and the phenotypes of the cells 
generated I used flow cytometry to identify CD20+ CD27+ (memory) or CD20+ CD38+ 
(plasma cells). 
 
In doing the above optimisation and evaluation steps I was able to determine if the 
ELISpot assay was sufficiently sensitive to detect plasma cells that secrete HLA-specific 
antibodies in the culture.  Furthermore I was able to identify the IgG subclass pattern of 
these specificities in both sera and supernatants, using X-MAP Technology, and attempt 
to correlate them with the clinical outcome of transplantation.  Finally, I was able to 
compare the range of HLA-specific antibodies detected in culture supernatant with those 
defined in pre-transplant and historical sera, using CDC and X-MAP Technology.  More 
details of the development, optimisation and evaluation steps are discussed, along with 
the results, in the following sections.  
 
3.4.2.  Developing an ELISpot to detect antibody-secreting B cells 
Before investigating the responses of cells in allogeneic cultures or using clinical 
samples, I optimised the ELISpot conditions to detect antibody production by B cells.  
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Firstly, I wanted to establish standard conditions that ensured IgG and IgM antibody 
production by B cells in culture; with these conditions standardised I could then go on to 
optimise the concentrations of reagents used in the ELISpot. I wanted to do these 
optimisation steps to produce the most economic and reliable assays feasible with the 
reagents and materials available.  
3.4.2.1.  Standardization of conditions for antibody production by PBMCs and B 
cells in ELISpot assays  
Using an ELISpot protocol already being used in this laboratory (See section 3.3.5), I 
tested the sensitivity of ELISpot assays to detect IgG- and IgM- producing cells, using  
different numbers/concentrations of human PBMCs and purified B cells, and measured 
the number of cells producing IgG and IgM antibodies at various time points after 
stimulation. Different concentrations of human PBMCs or purified B cells (2x105, 5x105 
or 1x106 cells/well; equivalent to 1x106 cells/ml, 2.5x106 cells/ml and 5x106 cells/ml, 
respectively) were stimulated with CD40L (100 ng/ml), IL-10 (100 ng/ml) and IL-4 (20 
ng/ml) chosen on basis of published literature (Fecteau and Neron 2003)and incubated, in 
96 well plates, for various periods of time before being transferred into ELISpot plates for 
48 hours prior to detection of antibody. The total culture length from the start of 
stimulation to antibody detection was 0, 3, 5, 6, 7, 8, 9, or 10 days, as shown on the x-axis 
of graphs.  
For ELISpot assays with PBMCs or B cells, spots, representing individual cells 
producing IgG or IgM antibodies, were detected when cells had been cultured for a total 
of 3 to 10 days before antibody detection.  The number of spots was maximal with cells 
cultured for a total of 6 days (IgG) and 10 days (IgM). The optimal cell number was 2 x 
105 cells/well (1x106 cells/ml) (Figure 29 and Figure 32). Greater numbers of antibody-
producing cells were found (a greater number of spots were detected) in assays using 
stimulated PBMCs than with purified B cells. This was true both for IgG and IgM 
antibody-production (See Figure 29 and Figure 30 compared to Figure 31 and Figure 32).   
 
Based on these data (Figure 29 - Figure 32), it was decided that PBMCs (2x105 cells/well 
= 1x106 cells/ml) should be used for further optimisation of the ELISpot protocol.  These 
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optimisation experiments are described in sections 3.4.2.2 - 3.4.2.4.   PBMCs were 
chosen because PBMCs stimulated more antibody production from the recipient B cells 
than purified B cells did and  PBMC-based assays are more economical because they do 
not require expensive B cell purification procedures. PBMCs may induce greater 
antibody production because they are able to provide the T cell help, in the form of 
cytokine and costimulatory molecules (CD40L), essential for efficient B cell stimulation 
and antibody production.  Purified B cells would not be able to provide this help and thus 
induce a much lower level of activation and antibody production.   
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Symbol Number of PBMC 
2 X 105 
5 X 105 
1 X 106 
 
 
Figure 29.  Standardizing the ELISpot assay for detecting IgG antibodies using PBMCs. 
PBMCs were plated in a 96 well culture plate, 200 μl/well, at a cell density of 2x105, 5x105 and 
1x106 cells/well, and stimulated with CD40L (100 ng/ml), IL-10 (100 ng/ml), IL-4 (20 ng/ml) for 
various periods of time.  Stimulated PBMCs were then transferred into and cultured in ELISpot 
plates for 48 hours before development of the assay.  The total culture times, from stimulation to 
ELISpot development, were 0, 3, 5, 6, 7, 8, 9 or 10 days (cells died when cultured for more than 
ten days). The ELISpot assay was used to detect IgG production.  The highest number of spots 
was detected on day 6 at cell density 2x105 cells/well.  For each experiment each condition was 
performed in triplicate, the mean +SD are shown in the figure.  The data shown are representative 
of three independent experiments. 
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Symbol Number of PBMC 
2 x 105 
5 x 105 
1 x 106 
 
Figure 30.  Standardizing the ELISpot assay for detecting IgM antibodies using PBMCs. 
PBMCs were plated in a 96 well culture plate, 200 μl/well, at a cell density of 2x105, 5x105 and 
1x106 cells/well, and stimulated with CD40L (100 ng/ml), IL-10 (100 ng/ml), IL-4 (20 ng/ml) for 
various periods of time.  Stimulated PBMCs were then transferred into and cultured in ELISpot 
plates for 48 hours before development of the assay.  The total culture times, from stimulation to 
ELISpot development, were 0, 3, 5, 6, 7, 8, 9 or 10 days. The ELISpot assay was used to detect 
IgG production. The highest number of spots was detected on day 10 at cell density 
2x105cells/well. For each experiment each condition was performed in triplicate, the mean +SD 
are shown in the figure.  The data shown are representative of three independent experiments.     
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Symbol Number of PBMC 
2 x 105 
5 x 105 
1 x 106 
Figure 31.  Standardizing ELISpot assay for detecting IgG antibodies using purified B cells. 
Purified B cells were plated in a 96 well culture plate, 200 μl/well, at a cell density of 2x105, 
5x105 and 1x106 cells/well, and stimulated with CD40L (100 ng/ml), IL-10 (100 ng/ml), IL-4 (20 
ng/ml) for various periods of time.  Stimulated PBMCs were then transferred into and cultured in 
ELISpot plates for 48 hours before development of the assay.  The total culture times, from 
stimulation to ELISpot development, were 0, 3, 5, 6, 7, 8, 9 or 10 days. The ELISpot assay was 
used to detect IgG production.  The highest number of spots was detected on day 6 at cell density 
2x105cells/well. For each experiment each condition was performed in triplicate, the mean +SD 
are shown in the figure.  The data shown are representative of three independent experiments.  
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Symbol Number of PBMC 
2 x 105 
5 x 105 
1 x 106 
 
Figure 32.  Standardizing ELISpot assay for detecting IgM antibodies using purified B cells. 
Purified B cells were plated in a 96 well culture plate, 200 μl/well, at a cell density of 2x105, 
5x105 and 1x106 cells/well, and stimulated with CD40L (100 ng/ml), IL-10 (100 ng/ml), IL-4 (20 
ng/ml) for various periods of time.  Stimulated PBMCs were then transferred into and cultured in 
ELISpot plates for 48 hours before development of the assay. The total culture times, from 
stimulation to ELISpot development, were 0, 3, 5, 6, 7, 8, 9 or 10 days. The ELISpot assay was 
used to detect IgM production.  The highest number of spots was detected on day 10 at cell 
density 2x105cells/well.  For each experiment each condition was performed in triplicate, the 
mean +SD are shown in the figure.  The data shown are representative of three independent 
experiments.  
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The ELISpot assay protocol used in this project, permitted indirect detection of IgG- and 
IgM-producing cells: a coating antibody was used to capture human IgG (or IgM) onto 
the ELISpot plate. The captured antibodies were then detected indirectly: a biotinylated 
detection antibody bound to the captured IgG (or IgM). The binding of that biotinylated 
antibody was detected using alkaline phosphatise-conjugated streptavidin (SAP) and an 
alkaline phosphatase chromogenic substrate. From this description it can be seen that 
there are a number of steps in ELISpot assay.  Consequently, several parameters had to be 
optimised to ensure a sensitive, reliable and economical assay. These parameters were the 
concentration of coating antibody, the concentration of biotinylated detection antibody 
and the concentration of SAP. These optimisation experiments are described below.    
3.4.2.2.  Optimising the Concentration of Coating Antibody for ELISpot  
The ELISpot procedure involves the addition of a coating (also known as a capture 
antibody) antibody to a 96-well ELISpot plate in a total volume of 200 μl per well. One 
of the most important parameters to standardize is the concentration of this antibody. A 
range of concentrations of coating antibody, between 0.125 μg/ml and 2 μg/ml were 
tested whilst the concentration of detecting antibody (1 μg/ml) and SAP (1 μg/ml) were 
kept the same throughout.  For the anti-human IgG assay I found that using 0.5 µg/ml, or 
more, of antibody was sufficient for detecting the maximum number of spots (antibody 
secreting cells) (Figure 33); there was not an obvious difference between using 0.5 μg/ml, 
1 μg/ml and 2 μg/ml. but, as the concentration was reduced below 0.5 μg/ml, the fainter 
the spots became and the fewer spots were detectable.  In the case of the anti-human IgM 
assay (Figure 34), I found that using 0.5 µg/ml coating antibody was saturating at early 
time points but the number of spots detected was reduced at later time points whereas 1 
µg/ml coating antibody was saturating at all time points.  On the basis of these 
experiments, a coating antibody concentration of 1 µg/ml, for both IgG and IgM 
ELISpots, was chosen as the optimal concentration to ensure reliable and sensitive 
detection in all subsequent experiments, at all time points.  0.5 μg/ml could have been 
used for the anti-human IgG assay but it was decided to use 1 μg/ml for logistical reasons 
and to avoid any underestimation of the number of positive cells.   
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Figure 33.  Optimisation of coating antibody concentration for human IgG antibody 
ELISpot assays. 
Mouse anti-human IgG antibody was diluted to various concentrations (2, 1, 0.5, 0.25 or 0.125 
µg/ml) in PBS and used to coat ELISpot plates at 40C overnight.  PMBCs (2x105 cells/well. 200 
μl/well) were stimulated with CD40L (100 ng/ml), IL-10 (100 ng/ml) and IL-4 (20 ng/ml), in 96 
well plates for various periods of time.  Stimulated PBMCs were then transferred into and 
cultured in ELISpot plates for 48 hours before development of the assay.  The total culture times, 
from stimulation to ELISpot development, were 0, 3, 5, 6, 7, 8, 9 or 10 days. Detection antibody 
was used at 1 μg/ml, SAP was used at 1 μg/ml and the chromogenic substrate was added as 
described in section 3.3.5.  Spots, representing antibody producing cells, were observed and 
counted on day 0, 3, 5, 6, 7, 8, 9 and 10. On the basis of the above data, a coating antibody 
concentration of 1 µg/ml was chosen as the optimal and standard coating antibody concentration 
to ensure reliable and sensitive detection.  Results shown are the mean +SD of three individual 
experiments each of triplicate values. 
Symbol Concentratrion of mouse anti-human IgG 
Coating Antibody 
 2 µg/ml 
 1 µg/ml 
 
0.5 µg/ml 
 0.25 µg/ml 
 0.125 µg/ml 
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Figure 34.  Optimisation of coating antibody concentration for human IgM antibody 
ELISpot assays. 
Mouse anti-human IgM antibody was diluted to various concentrations (2, 1, 0.5, 0.25 or 0.125 
µg/ml) in PBS and used to coat ELISpot plates at 40C overnight. PMBCs (2x105 cells/well. 200 
μl/well) were stimulated with CD40L (100 ng/ml), IL-10 (100 ng/ml) and IL-4 (20 ng/ml), in 96 
well plates for various periods of time.  Stimulated PBMCs were then transferred into and 
cultured in ELISpot plates for 48 hours before development of the assay.  The total culture times, 
from stimulation to ELISpot development, were 0, 3, 5, 6, 7, 8, 9 or 10 days.. Detection antibody 
was used at 1 μg/ml, SAP was used at 1 μg/ml and the chromogenic substrate was added as 
described in section 3.3.5.  Spots, representing antibody producing cells, were observed and 
counted on day 0, 3, 5, 6, 7, 8, 9 and 10. On the basis of the above data, a coating antibody 
concentration of 1 µg/ml was chosen as the optimal and standard coating antibody concentration 
to ensure reliable and sensitive detection.  Results shown are the mean +SD of three individual 
experiments each of triplicate values. 
Symbol Concentratrion of mouse anti-human IgM  
Coating Antibody  
 2 µg/ml 
 1 µg/ml 
 
0.5 µg/ml 
 0.25 µg/ml 
 0.125 µg/ml 
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3.4.2.3.  Optimising the Concentration of biotinylated detection antibody for 
ELISpot  
Similarly to the coating antibodies, the concentrations of the biotinylated detection 
antibodies, for both IgG- and IgM-ELISpot assays, had to be optimised to ensure reliable 
and sensitive detection of spots (antibody-producing cells). A range of concentrations of 
the detection antibodies, between 0.125 μg/ml and 2 μg/ml, was tested (See Figure 35 
and Figure 36) whilst the coating antibody (1 μg/ml) and SAP (1 μg/ml) concentrations 
were kept the same throughout.  
 
I found that a detection antibody concentration of 0.5 µg/ml was sufficient for sensitive 
and reliable detection of IgG- and IgM-producing cells (i.e. sufficient for spot detection) 
See Figure 35 and Figure 36.  This concentration of detection antibody was used 
hereafter. 
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Figure 35.  Optimisation of detection antibody concentration for human IgG ELISpot.   
ELISpot plates were coated with 1 µg/ml of mouse anti-human IgG. PMBCs (2x105 cells/well. 
200 μl/well) were stimulated with CD40L (100 ng/ml), IL-10 (100 ng/ml) and IL-4 (20 ng/ml), in 
96 well plates for various periods of time.  Stimulated PBMCs were then transferred into and 
cultured in ELISpot plates for 48 hours before development of the assay.  The total culture times, 
from stimulation to ELISpot development, were 0, 3, 5, 6, 7, 8, 9 or 10 days. The biotinylated 
mouse anti-human IgG detection antibody was used at various concentrations (2, 1, 0.5, 0.25 or 
0.125 µg/ml). SAP was used at 1 μg/ml and the chromogenic substrate was added as described in 
section 3.3.5.  On the basis of the above data, a detection antibody concentration of 0.5µg/ml was 
chosen as the optimal and standard detection antibody concentration to ensure reliable and 
sensitive detection. For each experiment each condition was performed in triplicate, the mean 
+SD are shown in the figure.  The data shown are representative of three independent 
experiments.    
Symbol Concentration of biotinylated mouse anti-human IgG  
Detection Antibody 
+ 2 µg/ml 
 1 µg/ml 
 
0.5 µg/ml 
 0.25 µg/ml 
 0.125 µg/ml 
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Figure 36.  Optimisation of detection antibody concentration for human IgM ELISpot. 
ELISpot plates were coated with 1 µg/ml of mouse anti-human IgM. PMBCs (2x105 cells/well. 
200 μl/well) were stimulated with CD40L (100 ng/ml), IL-10 (100 ng/ml) and IL-4 (20 ng/ml) in 
96 well plates for various periods of time.  Stimulated PBMCs were then transferred into and 
cultured in ELISpot plates for 48 hours before development of the assay.  The total culture times, 
from stimulation to ELISpot development, were 0, 3, 5, 6, 7, 8, 9 or 10 days. The biotinylated 
mouse anti-human IgG detection antibody was used at various concentrations (2, 1, 0.5, 0.25 or 
0.125 µg/ml). SAP was used at 1 μg/ml and the chromogenic substrate was added as described in 
section 3.3.5.  On the basis of the above data, a detection antibody concentration of 0.5 µg/ml was 
chosen as the optimal and standard detection antibody concentration to ensure reliable and 
sensitive detection. For each experiment each condition was performed in triplicate, the mean 
+SD are shown in the figure.  The data shown are representative of three independent 
experiments.   
Symbol  Mouse anti-human IgM biotin conjugate  
 2 µg/ml 
 1 µg/ml 
 
0.5 µg/ml 
 0.25 µg/ml 
 0.125 µg/ml 
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3.4.2.4.  Optimisation of SAP concentration 
Similar attention was given to optimising the concentration of the SAP. A series of 
experiments was done using fresh SAP at different concentrations; between 2 μg/ml and 
0.125 µg/ml (Figure 37  and Figure 38).   A concentration of 1 μg/ml SAP was chosen as 
sufficient for high sensitivity and reliability.  
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Figure 37.  Optimisation of Streptavidin Alkaline Phosphatase (SAP) concentration 
for human IgG ELISpot.   
ELISpot plates were coated with 1 µg/ml of mouse anti-human IgG. PMBCs (2x105 cells/well 
200 μl/well) were stimulated with CD40L (100 ng/ml), IL-10 (100 ng/ml) and IL-4 (20 ng/ml) in 
96 well plates for various periods of time. Stimulated PBMCs were then transferred into and 
cultured in ELISpot plates for 48 hours before development of the assay.  The total culture times, 
from stimulation to ELISpot development, were 0, 3, 5, 6, 7, 8, 9 or 10 days. The detection 
antibody (biotinylated mouse anti-human IgG) was used at 1 µg/ml. SAP was used at various 
concentrations (2, 1, 0.5, 0.25 or 0.125 µg/ml) and the chromogenic substrate was added as 
described in section 3.3.5.  On the basis of the above data, 1 µg/ml SAP was used as the optimum 
SAP concentration. For each experiment each condition was performed in triplicate, the mean 
+SD are shown in the figure.  The data shown are representative of three independent 
experiments. 
Symbol Concentration of 
Streptavidin Alkaline Phosphatase  
 2 µg/ml 
 1 µg/ml 
 
0.5 µg/ml 
 0.25 µg/ml 
 0.125 µg/ml 
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Figure 38.  Optimisation of Streptavidin Alkaline Phosphatase (SAP) concentration for 
human IgM ELISpot.   
ELISpot plates were coated with 1 µg/ml of mouse anti-human IgM. PMBCs (2x105 cells/well 
200 μl/well) were stimulated with CD40L (100 ng/ml), IL-10 (100 ng/ml) and IL-4 (20 ng/ml) in 
96 well plates for various periods of time.  Stimulated PBMCs were then transferred into and 
cultured in ELISpot plates for 48 hours before development of the assay.  The total culture times, 
from stimulation to ELISpot development, were 0, 3, 5, 6, 7, 8, 9 or 10 days. The detection 
antibody (biotinylated mouse anti-human IgM) was used at 0.5 µg/ml. SAP was used at various 
concentrations (2, 1, 0.5, 0.25 or 0.125 µg/ml) and the chromogenic substrate was added as 
described in section 3.3.5. Taking these data, together with the data shown in Figure 37, 1 µg/ml 
SAP was used as the optimum SAP concentration. For each experiment each condition was 
performed in triplicate, the mean +SD are shown in the figure.  The data shown are representative 
of three independent experiments. 
Symbol Concentration of Streptavidin Alkaline Phosphatase  
 2 µg/ml 
 1 µg/ml 
 
0.5 µg/ml 
 0.25 µg/ml 
 0.125 µg/ml 
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3.4.2.5.  Validation of standardised ELISpot assay using PBMCs and purified B cells  
The optimisation experiments, described in the previous sections, established standard 
conditions for doing ELISpot assays to detect IgG and IgM producing cells in stimulated 
PBMCs or purified B cell cultures.  To summarise (more details are given in section 
3.3.5), the protocol established was as follows: PBMCs or purified B cells were isolated 
from normal human volunteers. PBMCs and purified B cells (2x105/well) were 
stimulated, using CD40L (100 ng/ml), IL-10 (100 ng/ml) and IL-4 (20 ng/ml), for various 
periods of time. Cells were transferred to 96-well ELISpot plates, coated with either 
mouse anti-human IgG or mouse anti-human IgM coating antibody (1 μg/ml), 48 hours 
before development of the ELISpot assay. After the total culture time, plates were washed 
and the presence of IgG or IgM was detected. The detection antibodies (mouse anti-
human IgG or mouse anti-human IgM) were used at 0.5 µg/ml. The SAP was used at 1 
µg/ml.  
 
To validate this protocol using PBMCs and purified B cells, I performed ELISpot assays 
using the final protocol described above, with these cells with total culture times of 0, 3, 6 
and 10 days, using appropriate negative controls.  The negative controls were 
unstimulated PBMC or unstimulated purified B cells. Analysis of the ELISpot data 
indicated that the maximum number of IgG and IgM-secreting cells were detected in 
stimulated PBMC cultures (Figure 39 and Figure 40) and IgG production peaks at day 6 
whereas IgM production peaks at day 10; these data were consistent with data acquired 
using the non-optimised ELISpot (Section 3.4.2). Based on these validation results, I 
concluded that the ELISpot assay protocol I had developed was reliable and could be 
used to quantify antibody secreting cells responding to non-specific stimulation.  I 
therefore went on to investigate using this assay to quantify antibody secretion by 
PBMCs and purified B cells in response to specific stimulation. 
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Figure 39.  Detecting the frequency of antibody producing cells in stimulated PBMC cell 
cultures using optimised ELISpot assay. 
For IgG and IgM secreting cells the highest number of spots was detected on day 6 and 10 
respectively.  For each experiment each condition was performed in triplicate, the mean +SD are 
shown in the figure.  The data shown are representative of three independent experiments. 
 
 
 
 
Symbol Type of cells 
Antibody 
production 
 Stimulated PBMC with CD40L+IL-10, IL-4 IgG 
 Stimulated PBMC with CD40L+IL-10, IL-4 IgM 
 Unstimulated PBMC  IgG 
 Unstimulated PBMC  IgM 
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Figure 40.  Detecting the frequency of antibody secreting cells in stimulated, purified B cell 
cultures, using ELISpot assay. 
For IgG and IgM secreting cells: the highest number of spots was detected on day 6 and 10 
respectively.  For each experiment each condition was performed in triplicate, the mean +SD are 
shown in the figure.  The data shown are representative of three independent experiments. 
   
 
 
Symbol Type of cells 
ELISpot Ab 
specificity  
 B cells +CD40L+IL-10, IL-4 IgG 
 B cells +CD40L+IL-10, IL-4 IgM 
 B cells only IgG 
 B cells only IgM 
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Validation of the ELISpot assay protocol completed the optimisation required before 
testing the system for quantifying antibody producing cells stimulated by allogeneic cells.   
3.4.3.  Specific stimulation of B cells using allogeneic PBMC 
To test the frequency of peripheral blood allospecific B cells in vitro and explore their 
differentiation into ASC, I used PBMCs as responders and allogeneic mitomycin-C-
treated PBMC as stimulators (106/ml). In this system four controls were used:  
1.  Stimulator PBMCs only 
2.  Responder PBMCs only 
3.  Stimulator PBMC not treated with mitomycin-C, but stimulated non-specifically with 
CD40L, IL-10 and IL-4  
4.  Stimulator PBMC treated with mitomycin-C and stimulated non-specifically with 
CD40L, IL-10 and IL-4.  
 
The idea of using these controls was to evaluate the effectiveness of mitomycin-C and to 
confirm that the proliferation and differentiation of the responder B cells was due to 
specific stimulation by allogeneic-treated PBMC. In parallel, the surface phenotype of 
cells generated in these assays was determined using flow cytometry. 
3.4.3.1.  Optimisation of responder to stimulator cell ratio 
I investigated the optimum responder-to-stimulator (R:S) cell ratio to use, for maximal 
stimulation of antibody secreting cells, by varying the R:S ratio in ELISpot assays.  I 
evaluated the frequency of IgG- and IgM-secreting cells on day 6 and 10 as described 
previously in section 3.4.2.   I identified that the maximum level of both IgG- (Figure 41) 
and IgM- (Figure 42) secreting cells was generated, in this allogeneic system, at the 
responder- to- stimulator (R:S) ratio of 1:1. As described before when non-specific 
stimulation was used, the maximums occurred at days 6 and 10, for IgG- and IgM-
secreting cells respectively. The dose of mitomycin-C used appeared adequate. 
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Figure 41.  Optimising the responder to stimulator cell ratio for stimulating IgG secretion  
by responder PBMCs using stimulator allogeneic PBMCs, in ELISpot assays. 
PBMCs to be used as stimulators were stimulated with Mitomycin-C (1μg/ml, 30 min, 37°C), 
washed and added into culture with responder B cells (1x106 cells/ml) at the ratios indicated, in 
96 well plates.  After 4 or 8 days cells were transferred to ELISpot plates and cultured for a 
further 48 hours before development of the ELISpot.  The number of plasma cells secreting IgG 
was greater at day 6 than at day 10.  For each experiment each condition was performed in 
triplicate, the mean +SD are shown in the figure.  The data shown are representative of three 
independent experiments. 
 
Symbol Stimulators Responders 
∆ Mitomycin C -ve PBMC +CD40L+IL-10, IL-4 - 
▲ Mitomycin C +ve PBMC +CD40L+IL-10, IL-4 - 
● - PBMC only 
○ PBMC only - 
□ Mitomycin C +ve PBMC PBMC day-6 
■ Mitomycin C +ve PBMC PBMC day-10 
Chapter 3 
 171
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42.  Optimising the responder to stimulator cell ratio for stimulating IgM secretion 
by responder PBMCs using stimulator allogeneic PBMCs, in ELISpot assays. 
PBMCs to be used as stimulators were stimulated with Mitomycin-C (1μg/ml, 30 min, 37°C), 
washed and added into culture with responder B cells (1x106 cells/ml) at the ratios indicated, in 
96 well plates.  After 4 or 8 days cells were transferred to ELISpot plates and cultured for a 
further 48 hours before development of the ELISpot.  The number of plasma cells secreting IgG 
was greater at day 10 than at day 6.  For each experiment each condition was performed in 
triplicate, the mean +SD are shown in the figure.  The data shown are representative of three 
independent experiments. 
 
 
 
 
      
Symbol Stimulators Responders 
∆ Mitomycin C -ve PBMC +CD40L+IL-10, IL-4 - 
▲ Mitomycin C +ve PBMC +CD40L+IL-10, IL-4 - 
● - PBMC only 
○ PBMC only - 
□ Mitomycin C +ve PBMC PBMC day-6 
■ Mitomycin C +ve PBMC PBMC day-10 
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3.4.3.2.  Phenotyping 
To explore the identity of the B cells that responded in ELISpot assays, I used flow 
cytometry to characterise the responder B cell phenotypes:  I stained cells for the 
presence of CD20, CD27, and CD38 at 0, 6 or 10 days after initiation of the co-cultures 
(PBMCs with stimulated allogeneic PBMCs). I was able to detect the maximum level of 
CD38+ plasma cells (21%) on day 6, the maximum number of CD27+ memory cells were 
detected on day 10 (24%) (Figure 43).  This result was reproduced in three separate 
experiments.  These data show that, in this system, plasma cells respond more quickly to 
stimulation that memory cells do.  In addition, the plasma cell response starts to diminish 
after 6 days whereas the memory cell response is still highest (and possibly still 
increasing) at day 10.  
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Figure 43.  Identification of responder B cell phenotype. 
PBMCs harvested from cocultures (PBMCs incubated with mitomycin-C stimulated allogeneic 
PBMCs) were stained with antibodies against CD27 and CD20 or CD38 and CD20.  CD20 
staining was used to identify B cells.  The frequency of cells positively stained for these 
molecules is shown on the graph.  The expression of CD27+ on B cells reached peak levels on day 
10, whereas, for CD38+ B cells the peak was reached on day 6.  For each experiment each 
condition was performed in triplicate, the mean +SD are shown in the figure.  The data shown are 
representative of three independent experiments. 
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3.4.4. Specific stimulation of B cells using allogeneic B cells 
In the previous section I described stimulating responding B cells with allogeneic, 
mitomycin-C stimulated PBMCs. In this section I describe how I stimulated responding B 
cells with allogeneic mitomycin-C treated purified B cells to determine which the better 
stimulator cell population was; PBMCs or purified B cells.  
3.4.4.1.  Optimisation of responder to stimulator cell ratio 
I performed the same experiments using purified B cells that I had done with PBMCs; 
altering the R:S ratio and observing the frequency of antibody secreting cells on day 6 
and day 10.  Using ELISpot assays, I observed the highest frequency of antibody-
secreting cells, for IgG and IgM, on day 6 and 8 respectively (Figure 44 and Figure 45). 
The most effective (R: S) cells ratio was (1:1) (Figure 44 and Figure 45). These results 
are similar to those of the experiments where stimulated allogeneic PBMCs were used 
however, in this experiment, the frequency of the ASC was significantly lower than when 
stimulator PBMCs were used. This is consistent with the results obtained using non-
specifically stimulated B cells and PBMCs. 
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Figure 44.  Optimising the responder to stimulator cell ratio for stimulating IgG secretion  
by responder PBMCs using stimulated, allogeneic purified B cells, in ELISpot assays. 
B cells to be used as stimulators were stimulated with Mitomycin-C (1 μg/ml, 30 min, 37°C), 
washed and added into culture with responder B cells (1x106 cells/ml) at the ratios indicated, in 
96 well plates.  After 4 or 8 days cells were transferred to ELISpot plates and cultured for a 
further 48 hours before development of the ELISpot.  The number of plasma cells secreting IgG 
was greater at day 6 than at day 10.  For each experiment each condition was performed in 
triplicate, the mean +SD are shown in the figure.  The data shown are representative of three 
independent experiments. 
 
Symbol Stimulators Responders 
∆ Mitomycin-C -ve B cells +CD40L+IL-10, IL-4 - 
▲ Mitomycin-C +ve B cells +CD40L+IL-10, IL-4 - 
● - PBMC only 
○ B cells only - 
□ Mitomycin-C +ve B cells PBMC day-6 
■ Mitomycin-C +ve B cells PBMC day-10 
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Figure 45.  Optimising the responder to stimulator cell ratio for stimulating IgM secretion  
by responder PBMCs using stimulated, allogeneic purified B cells, in ELISpot assays.   
B cells to be used as stimulators were stimulated with Mitomycin-C (1 μg/ml, 30 min, 37°C), 
washed and added into culture with responder B cells (1x106 cells/ml) at the ratios indicated, in 
96 well plates.  After 4 or 8 days cells were transferred to ELISpot plates and cultured for a 
further 48 hours before development of the ELISpot.  The number of plasma cells secreting IgG 
was greater at day 10 than at day 6. For each experiment each condition was performed in 
triplicate, the mean +SD are shown in the figure.  The data shown are representative of three 
independent experiments.  
Symbol Stimulators Responders 
∆ Mitomycin- C -ve B cells +CD40L+IL-10, IL-4 - 
▲ Mitomycin-C +ve B cells +CD40L+IL-10, IL-4 - 
● - PBMC only 
○  B cells only - 
□ Mitomycin-C +ve B cells PBMC day-6 
■ Mitomycin-C +ve B cells PBMC day-10 
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3.4.4.2.  Phenotyping 
I used flow cytometry to characterise the responder B cell phenotypes in these cultures:  I 
stained cells for the presence of CD20, CD27, and CD38 at 0, 6 or 10 days after initiation 
of the co-cultures (PBMCs with stimulated purified B cells). Again on day 6, I was able 
detect the highest level of CD20+ CD38+ plasma cells (11%), whereas, CD20+ CD27+ 
memory cells were most frequent on day 10 (12%) (Figure 46). 
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Figure 46.  Identification of responder B cell phenotype. 
PBMCs harvested from co-cultures (PBMCs incubated with mitomycin-C stimulated allogeneic 
purified B cells) were stained with antibodies against CD27 and CD20 or CD38 and CD20.  
CD20 staining was used to identify B cells.  The number of cells positively stained for these 
molecules is shown on the graph.  The expression of CD27+ on B cells reached peak levels on 
day 10, whereas, for CD38+ B cells the peak was reached on day 6.  For each experiment each 
condition was performed in triplicate, the mean +SD are shown in the figure.  The data shown are 
representative of three independent experiments. 
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3.4.5.  Application of ELISpot to clinical samples 
Having optimised the culture conditions to activate B cells to proliferate and differentiate 
into ASC, having standardised the ELISpot assays to detect the frequency of plasma cells 
that secret IgG and IgM and finally, having shown the phenotype of responding B cells, 
using flow cytometry, I then used these assays to test the number of responding B cells in 
renal transplant patients.   
 
After obtaining access to the Renal Database at the HLA Typing Laboratory and 
Transplant Clinic, Hammersmith Hospital, patients were chosen for this study from 
kidney transplant patients, at the Hammersmith Hospital.  These particular patients were 
chosen because either CDC or X-MAP technology assays on historical samples were 
positive (in some cases both assays were positive) but CDC cross-match testing on 
current samples was negative. 30 ml of heparinized blood was collected from each 
recipient and donor within a week of the kidney transplant. Each patient sample was 
divided between myself and the HLA tissue-typing laboratory who performed 
crossmatching. Consent was obtained from both the recipient and donor to use their 
samples in my research work.    
 
I studied the following patients (Table 11): 
1. Two highly sensitised males (patients # 1 and 3) who had recently received kidneys 
from their wives. In each case, historical samples show that HLA-specific DSA had 
developed as a result of a previous kidney transplant. These HLA-specific DSA were 
detected using X-MAP technology. 
2. One female (patient # 4) who had had a previous deceased kidney transplant, blood 
transfusion and pregnancy but, surprisingly, had no HLA-specific antibodies 
detectable in her historical serum by CDC and subsequently received a kidney from 
her son.   
3. Another female (patient #2) who had developed DSA antibodies detectable in a 
historical sample as a result of pregnancy and had recently received a kidney from 
her husband.     
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4. Control group:  
a. Positive control: a healthy married female with two children who had detectable 
DSA using Luminex technology. 
b. Negative control: a healthy married female without children who had no HLA-
specific antibodies detectable using Luminex technology. 
 
 
Table 11.  Patients’ history. Bold indicates the presence of DSA 
3.4.5.1. In-vitro stimulation of patients’ PBMC with donor PBMCs 
To determine the frequency of respondents’ plasma cells in vitro, I co-cultured 1x105 
patients’ PBMCs (responders) with serial dilutions of mitomycin C-treated donor PBMC 
(stimulators) at R: S ratios of 1:1, 1:2, and 1:4. Cultures were incubated for 4 or 8 days 
prior to transfer into ELISpot 96-well trays. 
 
For patients #1, #2 and #3, I was able to identify the highest frequency of IgG antibody 
secreting cells after 6 days in culture (Figure 47). This implied the presence of memory B 
cells against donor antigens because the secondary response to donor antigens leads to 
fast proliferation and differentiation of the recipient memory B cells into plasma secreting 
IgG antibodies. This result was comparable to the positive control. The IgM antibody-
secreting cells were at their highest frequency on day 10 (Figure 48). For patient #4, due 
Method used to detect HLA-specific 
antibodies  
in Historical sample  Cross-match
Patient # Donor 
HLA 
sensitisation CDC X-MAP Technology CDC Flow 
1 Wife Kidney transplant neg 
pos  for class I                
A24,A25,A32, B49,B51,B63, B77 +extras Neg neg 
2 Husband Pregnancy neg B7,B60,CW10 Neg neg 
3 Wife 
Pregnancy, 
deceased kidney 
30% 
PRA  
pos for both class I&II 
A3,A11,A30,A31,A25,A26,A34,A66,B62+ 
extras Neg pos 
4 Son Transplant 
weak 
pos Not done Neg neg 
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to the presumed absence of donor specific memory B cells, very few spots were not 
detected. This result was comparable to the negative control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 47.  Detection of IgG-secreting cells in PBMCs from transplant recipients or 
controls.   
PBMCs from patients (responders) were co-cultured with serial dilutions of mitomycin-C-treated 
donor PBMC (stimulators) at R:S ratios of 1:1, 1:2, and 1:4. Cultures were incubated for 4 days 
prior to transfer into ELISpot 96-well trays. IgG was detected 48 hours later. DSA: donor-specific 
antibodies, Control 1: sensitised female who had detectable DSA, Control 2: unsensitised female.  
For each experiment each condition was performed in triplicate, the mean +SD are shown in the 
figure.  The data shown are representative of three independent experiments. 
 
 
Symbol Responder vs Stimulators 
 Patient1 vs Donor PBMCs 
 Patient 2 vs  Donor PBMCs 
 Patient 3 vs  Donor PBMCs 
 Patient 4 vs  Non-Donor PBMCs 
 Control 1 (Positive) 
 Control 2 (Negative) 
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Figure 48.  Detection of IgM-secreting cells in PBMCs from transplant patients or controls. 
PBMCs from patients (responders) were co-cultured with serial dilutions of mitomycin -C-treated 
donor PBMC (stimulators) at R:S ratios of 1:1, 1:2, and 1:4. Cultures were incubated for 8 days 
prior to transfer into ELISpot 96-well trays. IgM was detected 48 hours later. DSA: donor-
specific antibodies, Control 1: sensitised female who had detectable DSA, Control 2: unsensitised 
female.  For each experiment each condition was performed in triplicate, the mean +SD are 
shown in the figure.  The data shown are representative of three independent experiments. 
 
 
Symbol Responders vs Stimulators 
 Patient1 vs Donor PBMCs 
 Patient 2 vs Donor PBMCs 
 Patient 3 vs Donor PBMCs 
 Patient 4 vs Non-donor PBMCs 
 Control 1 (Positive) 
 Control 2 (Negative) 
Chapter 3 
 181
3.4.5.2.  Detection of HLA-specific antibodies using X-MAP technology 
Having established that three out of the four patients produced high levels of IgG and 
IgM in response to donor PBMCs, I next investigated the presence of HLA-specific 
antibodies in pre-transplant sera and culture supernatant from the four renal patients using 
the commercially available poly-antigenic beads kit, oligo-antigenic beads kit and IgG 
subclass-specific second layer modified kits (See Table 12 and Table 13).  
I used these kits:  
• To detect the presence of class I and II HLA-specific antibodies, 
• To identify the HLA-specific antibodies specificities for both class I and II HLA, and 
• To identify the IgG subclass for these antibodies.  
3.4.5.2.1.  Prevalence of Class I HLA-specific alloantibodies in transplant patients 
Table 12.  Specificities of IgG subclasses class I HLA-specific antibodies in culture 
supernatant and pre-transplant sera.  
DSA; indicates the presence of donor HLA-specific antibodies, neg; indicates the 
absence of HLA-specific antibodies, pos; indicates the presence of non-donor- HLA-
specific antibodies. 
  Detection of Class I HLA-specific antibodies using X-MAP technology 
 Pre-transplant Serum Culture  supernatant 
Assay: Screening Pan IgG IgG1 IgG2 IgG3 IgG4 Screening Pan IgG IgG1 IgG2 IgG3 IgG4
Controls 
                        
Negative  
controls 
neg neg neg neg neg neg neg neg neg Neg neg neg 
Normal  
volunteer 
neg neg neg neg neg neg neg neg neg Neg neg neg 
 Patient# 
            
1 
pos pos pos pos pos pos pos pos pos Pos DSA pos 
2 
neg neg neg Neg neg neg pos pos pos DSA DSA pos 
3 
pos pos DSA DSA DSA pos pos pos DSA Neg pos DSA 
4 
pos neg neg neg neg pos pos pos pos Pos pos pos 
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I detected the presence of HLA-specific IgG antibodies in all four pre-transplant sera 
samples and culture supernatants using poly-antigenic kit. I was also able to identify 
NDSA in all patients’ sera and culture supernatant using oligo-antigenic beads kit. To 
identify the IgG subclass, I used IgG subclass-specific second layer modified kits. For 
patient # 3, in pre-transplant serum and culture supernatant, I detected the presence of 
DSA and NDSA, complement-fixing (CFA) and non-complement fixing antibodies 
(NCFA). For patients #1, #2, and #4 in pre-transplant sera, I was able to detect only 
NDSA complement-fixing and non-complement-fixing antibodies but, interestingly, I 
identified the presence of DSA in patient #1 (IgG3) and #2 (IgG2 and IgG3) in culture 
supernatant.  
3.4.5.2.2.  Prevalence of Class II HLA-specific alloantibodies in transplant candidates 
Table 13.  Specificities of IgG subclasses class II HLA-specific antibodies in culture 
supernatant and pre-transplant sera.   DSA; indicates the presence of donor HLA-specific 
antibodies, neg; indicates the absence of HLA-specific antibodies, pos; indicates the presence of 
non-donor HLA-specific antibodies 
  Detection of Class II HLA-specific antibodies using X-MAP technology 
 Pre-transplant Serum Culture  supernatants 
Assay: Screening 
Pan 
IgG IgG1 IgG2 IgG3 IgG4 Screening
Pan 
 IgG IgG1 IgG2 IgG3 IgG4
Controls 
                       
Negative 
controls 
neg neg neg neg neg neg neg neg neg neg neg neg 
Normal 
volunteer 
neg neg neg neg neg neg neg neg neg neg neg neg 
 Patient  # 
                      
1 
pos pos pos neg neg neg pos pos DSA pos DSA neg 
2 
pos pos pos neg neg neg neg neg neg neg neg neg 
3 
pos pos pos neg neg neg pos pos DSA neg neg neg 
4 
pos pos pos neg neg neg pos pos pos neg pos neg 
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In all four pre-transplant patients’ sera, I was able to identify class II HLA-specific IgG 
antibodies using the poly-antigenic kit and oligo-antigenic kit. Moreover, for IgG 
subclass, I detected the presence of only IgG1 NDSA using IgG subclass-specific second 
layer modified kits. Interestingly, in culture supernatant, I was able to identify only 
complement-fixing DSA in patients #1 and #3.     
3.5.  Discussion 
The ELISpot assay is very useful for quantitatively assessing immune responses. In the 
context of the B cell compartment it has been used to determine the efficacy of 
vaccination and the longevity of B cell immunological memory to various vaccines or 
infectious diseases. For example, the ELISpot assay has been used to demonstrate that the 
anthrax vaccine elicits a substantial population of protective antigen (PA) specific 
memory B cells, and these B cells satisfy the canonical surface phenotype of human 
memory B cells: CD19+CD20+Ig+CD27+. These anti-PA antigen-specific memory B cells 
are IgG+ and represent up to 2% of circulating IgG+ B cells (Crotty et al. 2004).  In 
another area, researchers have developed an ELISpot method to characterize circulating 
memory B cells, specific to hepatitis B surface antigen (HBsAg), using CD40-CD40L 
polyclonal stimulation; an HBsAg-ELISpot enables enumeration of memory B cells 
differentiated into anti-HBsAg-secreting cells. Researchers using this assay concluded 
that the HBs-ELISpot assay is more reliable for tracking HBsAg-specific memory B cells 
than ELISA measurement of anti-HBs antibodies secreted in supernatants. In addition, 
the ELISpot assay can be used to explore the presence and the longevity of HBsAg-
specific memory B cells in vaccinated and immunized subjects, in chronic HBV infection 
and after liver transplantation for HBV-related disease (Tuaillon et al. 2006).  Long-term 
protection after hepatitis B vaccination is dependent on the persistence of strong 
immunological memory. Some investigators have studied the reactivity of vaccine-
induced HBsAg-specific T cells of both effector and memory phenotype: These cells 
were isolated, stimulated with HBsAg and tested for IFN-γ and IL-5-secretion by 
ELISpot assay. The results showed significant numbers of HBsAg-specific memory T 
and B cells present in all vaccine treated subjects, despite the absence of specific 
antibodies in serum samples. These results suggested that individuals who had lost their 
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anti-HBs antibodies in serum samples still showed immunologic T cell memory and that 
these T cells may be able to trigger anti-HB antibody production by B cells activated by 
revaccination (Bauer and Jilg 2006).  Finally, the ELISpot assay is one of the leading 
technologies used to measure cellular responses in HIV vaccine clinical trials; HIV-1-
specific effector T lymphocyte responses are considered necessary in the control of 
infection (Moodie et al. 2006). The interferon (IFN)-γ ELISpot assay has been widely 
used as a general screening method for the quantification and characterization of the 
human immunodeficiency virus (HIV)-specific CD8+ T cell responses (Streeck et al. 
2009).  
 
The presence of preformed donor HLA-specific antibodies serves as the major 
contraindication to transplantation (Patel and Terasaki 1969). However, the study of cells 
involved in solid organ rejection has mainly focused on the T cell compartment, not the B 
cell compartment. The work presented in the current chapter represents the beginning of 
the development of an assay to determine HLA-specific B cell precursor frequency and to 
use this to measure B cell immunity in actual and potential transplant recipients (in the 
same way as described above for microbial immunity).  The best assay before the 
development of the ELISpot and X-MAP Technology combined assay was to test the 
serum of patients for the presence of HLA-specific antibodies.  The ELISpot assay offers 
increased sensitivity over testing the serum because firstly, the culture of B cells and 
PBMCs prior to ELISpot stimulates all the B cells that can respond to the antigens (e.g. 
HLA on PBMCs) thus, when the stimulated cells are transferred to the ELISpot assay the 
number of B cells with reactivity to the antigens, can be detected.  Secondly, the 
stimulated B cells produce antibodies in the confined space of the ELISpot assay culture 
dish.  This produces a concentrated source of antibodies in the supernatant which is 
harvested for the X-MAP Technology bead assay.  In contrast, testing the serum of 
patients may miss the presence of some antibodies because they may be at very low 
concentrations in the serum.  Improving assays that allow the estimation of HLA-specific 
B cell precursor frequencies would improve donor-recipient matching and enhance the 
ability of clinicians to design better pre- and post-transplant medication regimes e.g. 
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using immunosorption before transplant and tailored immunosuppressive medication 
post-transplant.   
 
To develop the ELISpot assay, a number of parameters were optimised:  The PBMC 
numbers in each assay well were titrated over a range of responder to stimulator ratios of 
1:1, 1:2 and 1:4 per well. These titrations helped to establish the best conditions for 
culturing cells without interfering with their growth, proliferation and differentiation into 
antibody-secreting cells, as well as ensuring the detection of the highest spots number 
using the ELISpot assay. Responses by responder PBMCs (with the highest spots 
number) were detected well at ratios of 1:1 and 1:2 and started to decline at the 1:4 ratio. 
It was thought that because accessory cells play an important role in antigen processing 
and presentation for CD4+ T cells responses, reducing cell numbers in the assay (which 
will reduce the number of both responding cells and APC) may affect contact between 
the responder and stimulator populations and a critical level may be reached where the 
concentration of APC and CD4+ T cells is inadequate for a response.  
 
Analysis of PBMC-PBMC and PBMC-B cell co-cultures showed that in both cases, the 
highest frequency of IgG and IgM-secreting cells was detected on day 6 and 10, 
respectively. The presence of both responder and stimulator T cells in PBMC-PBMC co-
cultures provides maximum activation and proliferation of the responder B cells; 
activation of B cells to proliferate and secrete antibody is dependent on cytokines, 
secreted by activated T cells, such as IL-2, IL-4 and IL-6. This may explain the 
significant decrease in the frequency of plasma cells that secrete IgG and IgM when 
PBMCs are stimulated with B cells only.   
 
The main disadvantages of ELISpot technique are:  (1) it provides us with a way to 
quantify the immune response but it does not give qualitative information about the 
immune response involved. (2) Although it uses specialized imaging equipment to 
quantify the number of spots, there is a certain degree of subjectivity in the interpretation 
of results, for example, threshold for the size, intensity, and gradient of the spot. (3) It is 
very difficult to compare the results between different laboratories therefore; there is a 
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need to define standard parameters that define a positive spot which will be needed for 
reproducibility across laboratories and readers. But for all these disadvantages, the 
ELISpot is establishing a role in other diagnostic areas and may very well also have 
potential use in clinical transplantation medicine. 
 
3.5.1. In-vitro stimulation of patients’ PBMCs with donor PBMC or B 
cells 
Despite the absence of circulating antibody, the frequency of HLA-specific antibody-
producing B cells in sensitised individuals might reflect the actual immunisation status if 
the activation and proliferation of responder B cells is due to the presence of memory B 
cells against donor HLA antigens (resulting from previous transplants, pregnancies or 
blood transfusions) (Lobo et al. 2005). The present data demonstrate the ability of in vitro 
cultured B-lymphocytes of some individuals to stimulate DSA production in quantities 
that are detectable by X-MAP technology but not detectable in pre-transplant sera using 
CDC or FCXM. Applying this inducible B cell culture prior to kidney transplantation 
could better reflect the actual immunological status of sensitised individual and help in 
identifying high risk antigen. This might represent a level of sensitisation between 
‘sensitised, antibody-negative’ and ‘non-immunised’.  
 
One limitation of this study was not using third party cells for the stimulation of PBMCs 
and purified B cells. The third party donor acts as a negative control to help determine if 
the B cells’ proliferation and differentiation to antibody secreting cells, is donor specific 
or not. I only had limited numbers of cells available with which to do proliferation assays 
and was unable to do the third party condition.  However, I was still able to check for the 
specificity of the PBMC and B cell responses by detecting the presence of DSA in culture 
supernatant using the more sensitive X-MAP technology.  
 
The detection of HLA-specific DSA by ELISpot assay is a very sensitive method as it 
reflects the frequency of memory B cells that differentiate into ASC. As a result, this tool 
may give better indication of allograft outcome in some cases, such as historic positive 
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and current negative FCXM, which may lead to antibody mediated rejection. It also has 
the potential to predict early and late humoral rejection and to monitor the response to 
treatment. 
 
The titer of HLA-specific DSA in blood is primarily based on the presence of plasma 
cells that secret these antibodies. Therefore, in the resting state, plasma cells will secret 
low titer circulating antibody which may not reach clinical significance/be detectable by 
CDC and FCXM, at the time of transplantation. However, using the more sensitive 
ELISpot assay will give the chance to detect the frequency of memory B cells that can 
differentiate into ASC. In addition, culture supernatant can be used as a source of HLA-
specific antibodies that can be used to set up CDC and FCXM.  
 
After developing these assays and examining a small number of patients, the next step 
will be to expand patient numbers using live donor pre-transplant samples.  
 
3.6.  Potential Clinical Applications 
The B cell compartment (plasma cells, memory B cells and naïve B cells) may contribute 
to graft damage, albeit with different degrees of immediacy. The development of an assay 
to estimate the frequency of alloantigen-specific APC cells has potential clinical use to 
predict the outcome of a given donor-recipient combination. Assays could be applied 
both in advance of a proposed transplant and also as a monitoring tool following 
transplantation to guide the clinician to tailor immunosuppression to the immunological 
needs for a given donor-recipient combination.  
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4.1.  Introduction 
In kidney transplantation, long term survival of the graft depends on prolonged treatment 
with immunosuppressive drugs. However, current immunosuppressive drugs are not 
specific and they suppress all of the immune system, leaving the patient susceptible to a 
variety of infections and malignancies (Niethammer et al. 1999; Bustami et al. 2004). In 
addition, immunosuppressive drugs can cause hypertension, hyperlipidaemia, diabetes 
and osteoporosis amongst other complications (Lopez et al. 2006). However, a few 
patients who stop their immunosuppression do not develop rejection. This state is known 
as tolerance. In general, tolerance means the absence of immune responses to specific 
antigens (VanBuskirk et al. 2000). In the context of transplantation, tolerance can be 
operationally defined as the antigen-specific absence of a destructive immune response to 
a graft in a host in the complete absence of immunosuppressive therapy (Wieers et al. 
2007).  
 
Immunological monitoring can potentially contribute to identifying this state by 
quantitating pro-inflammatory and anti-inflammatory components of the anti-donor 
response. If reliable assays were available, then it would be possible to monitor the 
development of anti-donor responses, in individual patients, to determine the 
effectiveness of potentially tolerogenic therapeutic strategies. As new drugs and 
biological agents are introduced, such assays are important in determining whether they 
are tolerance-promoting or whether they impede the development of immune tolerance 
(Golshayan and Pascual 2006). 
 
The work described in this chapter represents my contribution to a wider consortium 
which was attempting to identify a “fingerprint of immunological tolerance” (Sagoo et al. 
2010). I will now briefly put my work on this into the broader context of the work of the 
consortium.  
 
A number of biomarkers and bioassays were applied to several groups of patients to 
determine if these assays could be used in combination to distinguish, tolerance to a 
kidney transplant in some patients, from a state of a suppressed, but active, immune 
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response in other transplant recipients. As controls, patients on a number of different 
regimens of immunosuppression were studied, alongside additional healthy controls. 
The assays used to analyse these patients were: 
1. Antigen-specific precursor cell frequency analysis using LDAs, ELISpot assays, and 
flowcytometric analysis of the division of carboxyfluorescein succinimidyl ester 
(CFSE)-labelled cells in proliferation assays (Hernandez-Fuentes and Salama 2006). 
The first two assays can also be adapted to the measurement of a variety of 
cytokines. Moreover, LDAs can reveal the presence of regulatory cells in responder 
populations (Dozmorov et al. 1996) and LDAs, ELISpot and CFSE assays can be 
used to assess the regulatory activity of such regulatory T cells (CD4+ CD25+). These 
assays can measure the frequency of T cells with a given specificity and they can 
also distinguish the direct and indirect recognition of allogeneic major 
histocompatibility complex (MHC) molecules (Baker et al. 2001; Sester et al. 2004). 
2. Detection of indirect alloresponses and regulatory cells by trans-vivo delayed-type 
hypersensitivity (DTH) assay. This assay has the ability to identify transplant 
patients who show specific hyporesponsiveness to donor alloantigens in an in vivo 
environment (VanBuskirk et al. 2000). In other words, it is used to detect donor-
specific delayed-type hypersensitivity responses mediated by sensitised or naïve 
lymphocytes in transplant recipients (Sebille et al. 2001).    
3. cDNA microarray analysis of donor antigen-stimulated peripheral blood and 
transplant-infiltrating leucocytes, to detect the transcription of mRNA coding for 
potentially tolerogenic proteins.  
4. Cytokine mRNA quantification by real-time reverse transcriptase polymerase chain 
reaction (RT-PCR). The technique has been adapted to the quantification of cytokine 
mRNA from peripheral blood. It was used to analyse genes suggested as being part 
of the expression profile signature of the tolerant state by the microarray analysis, 
described above, and on a number of tolerance-associated genes identified from 
animal models of transplantation tolerance (Sawitzki et al. 2002).   
5. X-MAP technology antibody screening: The presence of post-transplant, donor-
specific, HLA-specific antibodies has been identified as a risk factor for both acute 
and chronic rejection (discussed extensively in previous chapters). X-MAP 
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technology is known to be the most sensitive and specific method that detects de 
novo and low level HLA-specific antibodies usually missed by conventional CDC 
assays (Maccarone et al. 2005). The pattern of antibodies has been studied in these 
patients.  
 
Although many of these assays have been developed to understand the mechanisms 
behind the generation of tolerance and rejection, none of them alone was able, reliably, in 
a clinical setting, to differentiate those in whom tolerance had developed and, therefore, 
whose immunosuppression could be partially or completely stopped, from those who 
were not tolerant. We aimed to combine the results from the different assays performed 
on samples from the same patient. No previous study had compared these techniques with 
each other using cells or serum from the same patients.  Thus this project aimed to: 
1. Develop the concept of “fingerprint of tolerance”.  
2. Apply this prospectively to patients to identify those in whom discontinuation of 
immunosuppressive medication will not result in rejection. 
4.2.  Objectives 
1. To identify patients in Europe who have functioning renal allografts despite stopping 
their immunosuppressive treatment at the time of recruitment. 
2. To perform the above described assays on the specimens taken from these patients 
and compare these results with data from control patients. 
3. To determine if it is possible to develop a composite reliable index of tolerance using 
these assays. 
 
This work was done in collaboration with different laboratories throughout Europe. The 
Principal Investigator was Professor Robert Lechler and my supervisor, Professor 
Anthony Warrens, was a Co-Investigator. Our laboratory took responsibility for the 
antibody testing (point 5 above), which I developed and performed. All other assays were 
performed by other people in other laboratories and are included in this thesis solely to 
put my work in scientific context. Therefore, I shall describe only the methods of the 
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work I performed and present others’ data only to the extent as they are necessary to 
understand my work.  
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4.3.   Materials 
4.3.1. Study groups 
Peripheral blood was sampled from 71 kidney transplant recipients and 19 healthy 
controls (HC). Table 11, on page 178, illustrates the study groups, immunosuppressive 
treatment and renal function tests. Hammersmith and St Mary’s Hospitals Research 
Ethics Committee was assigned as the main study REC (application: 2002/6378) and 
REC approval from all other European recruitment sites was obtained.  The study was 
advertised, through various media internationally, in order to collect as many drug-free 
apparently tolerant recipients as possible.  When recruited, these patients were at very 
disparate times from transplantation.   
 
Samples from 71 kidney transplant recipients were collected from five different groups; 
the group of interest; operationally tolerant recipients (Group 1 – see below) and five 
control groups (Groups 2 – 6 below).  Please see below and Table 14, page 194, for full 
details.   
1. Operationally tolerant recipients:  Drug-free, apparently tolerant recipients who were 
functionally stable (no increase in serum creatinine (rise in creatinine <10%) in the 
last 12 months) in the absence of immunosuppression for more than one year (Tol-
DF). 
2. Stable patients maintained on low (<10 mg/d) prednisolone as the only 
immunosuppressive agent (s-LP).   
3. Stable patients maintained with calcineurin inhibitors (s-CNI). 
4. Stable patients maintained on CNI-free immunosuppression (s-nCNI) but more than 
just low-dose steroids. 
5. Patients with chronic rejection (CR). CR was confirmed by biopsy that demonstrated 
that the chronic damage was immunologically driven.   
6. Healthy controls  (HCs); age-matched and sex-matched healthy controls.  
 
Chapter 4 
 194
 
 
 
 
Table 14.  Study groups, immunosuppressive treatment and renal function 
HC: Healthy Control, Tol-DF: Tolerant Drug-Free s-LP: Stable on low dose Prednisolone snCNI: 
Stable and free of Calcineurin Inhibitors s-CNI: Stable on Calcineurin Inhibitors CR: Chronic 
Rejection N: Number of patients, eGFR: estimated Glomerular Filtration Rate at time blood 
taken, CRT: Creatinine CNI: Calcineurin Inhibitors, MMF: Mycophenolate mofetil, Aza: 
Azathioprine.  
 
A group of tolerant patients, collected by the Indices of Tolerance (IOT) consortium in 
Europe, was used to test bioassays and biomarkers for their ability to detect 
immunological parameters uniquely associated with the tolerant state. This group was 
used as a “training set” before the findings were validated by carrying out the same 
assays and looking for the same biomarkers on an independent test set of renal transplant 
recipients from similar clinical groups, recruited by the Immune Tolerance Network 
(ITN) in the United States.  In the IOT consortium group, a tolerance signature was 
identified: ten genes had significantly altered expression, there were elevated numbers of 
peripheral blood B and NK cells, reduced numbers of recently activated CD4+ T cells, 
Study 
groups N 
eGFR 
ml/min/ 
1.73m2 
CRT 
µmol/l CNI MMF Aza Steroid 
Antibody 
Induction 
HC 19        
Tol-DF 11 76.2   (58-69) 97   (88-119) 0 0 0 0 2 
s-LP 12 59.1   (41-70) 118.3 (107-41) 0 0 0 12 0 
s-nCNI 10 64.2   (59-74) 101.5 (87-121) 0 0 10 10 0 
s-CNI 29 56.3   (49-63) 115  (106-127) 29 10 14 11 5 
CR 9 19.0   (13-31) 312 (208-382) 6 5 3 6 5 
Total  71 58.1   (43-70) 117  (98-143) 35 15 27 39 12 
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CD4+ T cells showed donor-specific hyporesponsiveness and there was a high ratio of 
FoxP3/α-1,2-mannosidase gene expression in peripheral blood, in relation to the other 
renal transplant control groups.  My personal contribution was to analyse the HLA-
specific antibodies in these patients.  The methods for this analysis are shown below, 
followed by the results obtained.    
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4.4. Methods 
4.4.1.  Sample collection 
Peripheral blood was collected in clotting activator vacutainers (Becton Dickinson, San 
Jose, USA) and allowed to clot for at a minimum of 2 hours. Samples were centrifuged 
and collected serum aliquoted and stored at -80°C until use. Sera were tested using the 
Luminex100 platform (Luminex Corporation, Hammersmith Hospital) (referred to as X-
MAP technology in this thesis). 
4.4.2.  Screening for IgG HLA-specific antibodies using X-MAP 
Technology 
The filter plate wells were pre-wet with distilled water. Then, wash buffer was added, 
followed by patient serum or control. After that, HLA poly-antigenic beads were 
introduced. The plate was incubated at room temperature on a rotating platform. After 
incubation, wash buffer was added. Next, diluted goat anti-human IgG conjugated to PE 
was added, covered and incubated at room temperature on a rotating platform. Finally, 
the beads were resuspended in wash buffer (more details are provided in Chapter 2).   
4.4.3.  Identification of class I and class II HLA-specific antibodies 
The same method used for screening was applied for the identification of HLA 
specificities. The only difference between the two methods was the beads used. HLA 
class I oligo-antigenic beads are coated with HLA class I glycoproteins whereas class II 
oligo-antigenic beads are coated with HLA class II glycoproteins (more details are 
provided in the materials and methods section in Chapter 2).  
4.4.4.  HLA-specific IgG subclasses Identification 
I developed IgG subclass identification assays by replacing the anti-pan IgG second layer, 
supplied with the kit, with a series of biotinlyated IgG subclass-specific antibodies. The 
binding of these antibodies was identified by adding streptavidin- phycoerythrin (more 
details are provided in Chapter 2). 
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4.4.5.  Data analysis and statistics 
For collecting data, the Luminex100 instrument was used as recommended by the 
manufacturer. The signal intensity from each bead was compared to the signal intensity 
of a negative control bead included in the bead preparation to determine if each bead 
suspension was positive or negative for bound alloantibody. Cut off = mean of negative 
control x 1.5. Statistical differences were calculated using a two-tailed t-test. A value of 
p<0.05 was regarded as statistically significant. 
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4.5. Results 
4.5.1.  Screening for the presence of HLA-specific antibodies 
I started by looking for HLA-specific antibodies in the post-transplant sera in these 
patient groups - all of whom had received kidney transplant after a negative CDC 
crossmatch. I screened them using poly-antigenic beads to identify patients with either 
class I or class II HLA-specific antibodies or both. I detected the highest percentage 
(55%) for class I HLA-specific antibodies in the CR group and (32%) for class II HLA-
specific antibodies in s-LP and CR groups (Figure 49, page199) (See Table 14, page 194 
and section 4.3.1 for details of the study groups and explanations of the terminology and 
abbreviations used). Class I HLA-specific and class II HLA-specific antibodies were 
detected in all patient groups except for the s-nCNI group. For the latter, only the 
presence of class I HLA-specific antibodies was identified. The highest percentage of 
class I HLA-specific antibodies was detected in the CR group (55%), p< 0.0001 whereas 
for class II HLA-specific antibodies, the highest percentage was detected in s-LP (32%), 
p< 0.05.   
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Figure 49.  Screening for the presence of HLA-specific antibodies in post-transplant 
patients’ sera, using poly-antigenic beads. 
The presence of class I HLA-specific and class II HLA-specific antibodies was detected 
in patients’ sera using a poly-antigenic bead kit (Luminex). See also Table 14 for details 
of the study groups.  The highest percentage of class I HLA-specific antibodies was 
detected in the CR group (55%), p< 0.0001 whereas, for class II HLA-specific antibodies, 
the highest percentage was detected in s-LP (32%), p< 0.05.  Bars represent the mean ± 
standard deviation for each group.  
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4.5.2.  Detection of class I HLA-specific antibodies 
To confirm the results of the screening test and to identify the specificity for these class I 
HLA-specific antibodies, I used an oligo-antigenic bead kit (Luminex). This kit contains 
oligo-antigenic beads coated with different sets of HLA class-I or class-II antigens. Using 
the same post- transplant samples, I was able to identify the presence of both donor-
specific-antibodies (DSA) and non-donor-specific antibodies (NDSA) in all patient 
groups (Figure 50). As one might predict, the highest percentages of both HLA-specific  
DSA (33%) and NDSA (44%) were identified in the CR group, whereas only NDSA 
(26%) was detected in the Tol-DF group. The poly-antigenic and oligo-antigenic assays 
were consistent in detecting HLA-specific antibodies.  
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Figure 50.  Identification of class I HLA-specific antibodies specificities using oligo-
antigenic class I beads.   
The presence of DSA was detected in all patient groups except for Tol-DF, whereas the presence 
of NDSA (shaded column) was identified in all patient groups.  The highest percentages of both 
HLA DSA (33%) and NDSA (44%) were identified in the CR group, p <0.05.   
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4.5.3.  Detection of class II HLA-specific antibodies 
To confirm the presence of class II HLA-specific antibodies using the poly-antigenic 
beads kit and to identify the HLA class II specificities, I used an oligo-antigenic bead kit. 
Based on the identification kit, I was able to highlight the presence of both DSA and 
NDSA antibodies in all patient groups except s-nCNI group (Figure 51). Interestingly, the 
highest percentages of DSA were found in the s-LP (25%) and CR (22%) groups.   
Again, the poly-antigenic and oligo-antigenic assays were consistent in detecting HLA -
specific antibodies.  
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Figure 51.  Identification of class II HLA-specific antibodies specificities using class II oligo-
antigenic beads. 
The presence of DSAs and NDSAs was detected in all patient group except for s-nCNI. The 
highest percentage of DSA was detected in s-LP (25%) as well as CR (22%), p <0.05.   
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4.5.4.  Detection of donor-specific class I HLA-specific IgG subclasses 
After identifying the presence of DSAs using the oligo-antigenic kit, I was interested in 
defining the IgG subclass pattern for these specificities. Thus, I used the modified oligo-
antigenic IgG kits I developed and described in Chapter 2. Based on the class I IgG 
subclass assays, I was able to detect the presence of DSAs of both complement-fixing 
(IgG1 and IgG3) and non-complement-fixing subclasses (IgG2 and IgG4) in all patient 
groups except Tol-DF group (Figure 52. The highest percentage of DSA for both 
complement-fixing (33%) and non-complement-fixing antibodies (22%) was present in 
the CR group.  
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Figure 52.  Detection of donor-specific class I HLA-specific antibodies of both complement-
fixing and non-complement-fixing IgG subclasses using modified class I kit. 
The presence of CFAs and NCFAs was identified in all patients group except for Tol-DF. The 
highest percentage of both CF (33%) and NCF (22%) class I HLA-specific antibodies was 
identified in the CR group, p<0.0001.  
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4.5.5.  Identification of donor-specific class II HLA-specific IgG 
subclasses  
After I had developed the anti-class II IgG subclass assays, as described in chapter 2, I 
applied them to the patient groups post-transplant sera in this project. I was able to 
highlight the presence of IgG DSA subclasses in all groups except for the s-nCNI and 
Tol-DF groups (Figure 53). The highest percentage of class II DSA complement-fixing 
was present in s-LP (25%) whereas, for non-complement-fixing IgG antibodies, this was 
in CR patients (11%).  
 
Figure 53.  Detection of donor-specific class II HLA-specific antibodies of both complement 
fixing and non-complement-fixing subclasses using modified class II kit. 
The presence of CFAs as well as NCFAs was detected in all patients’ groups except Tol-DF and 
s-CNI. The highest percentage of CF antibodies was identified in s-LP (25%), p<0.005. However, 
for NCF the highest percentage was detected in CR (11%) p<0.005.  
 
I will now summarise the data obtained by the other groups in the consortia, before 
summarising my results in the context of this bigger project.  
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4.5.6.  Summary of results from other laboratories 
1. Tolerant patients displayed a relative expansion of B and NK lymphocyte 
compartments and a corresponding decrease in the percentage of T cell subsets. 
When expressing the percentages of B cells and T cells as a ratio, Tol-DF patients 
displayed the highest ratio compared to all other study groups including HC. 
Although this ratio could not be used as a biomarker of tolerance, it could aid in its 
identification. Tol-DF patients had significantly lower percentages of CD25int CD4+ 
T cells but similar percentages of CD25hi CD4+ T cells with respect to other patient 
groups. s-CNI patients had lower percentages of CD25hi CD4+ cells than s-LP 
patients or HC.  
2. Activated CD4+ T cells with intermediate CD25+ expression were decreased in Tol-
DF in the study. As above, this was insufficiently sensitive and specific to be used 
alone as a biomarker of tolerance, but it could contribute to its identification. 
3. Tolerant patients could be identified by gene expression using microarray and 
quantitative RT-PCR. Analysis of gene expression in Tol-DF patients revealed sets 
of 170, 37 and 56 genes with significantly altered expression when compared to s-
CNI, s-nCNI and s-LP, respectively. The analysis of gene expression in Tol-DF 
compared to CR group revealed 31 genes that showed altered expression specifically 
in Tol-DF patients, whereas, when compared to HC, 179 genes were differentially 
expressed. To generate a tolerant signature, a selection of genes, from a set of 170, 
37 and 56 genes, with significant differential expression, including those appearing 
twice or more, was used. A Receiver Operator Characteristic (ROC) curve with 
increasing number of genes included was built for 13 of the selected genes. The peak 
values generated by this signature of 13 genes, using a threshold of p=0.16, delivers a 
specificity of 0.833 and sensitivity of 0.93, with positive predictive value (PPV) of 
50% and a negative predictive value (NPV) of 98.65%. Increasing the number of 
genes in the analysis up to 23 did not improve the diagnostic capability of the 
signature.    
4. ELISpot assays determining the ratio of frequencies against donor cells and third 
party cells can help establish the donor-specific hyporesponsiveness and therefore 
provide an important parameter in the signature of tolerance. Tol-DF patients had the 
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lowest frequencies of direct pathway anti-donor responses by interferon-γ ELISpot 
assay. 
5. In the trans-vivo DTH assay, none of the tolerance drug free patients had positive 
responses to donor antigen. 
6. Renal  Function:   
 
Table 15 shows the creatinine level and eGFR measured in all patient groups. As  might 
have been predicted, the CR group had the worst renal function and the Tol- DF 
group had the best.  
 
 
 
 
Table 15.  Creatinine level and estimated Glomerular Filtration Rate in all patient 
groups.   
The highest creatinine level was detected in CR group.  eGFR: estimated Glomerular 
Filtration Rate at time blood taken, CRT: Creatinine, (a,b):  Median eGFR and CRT, 
respectively. The bracketed numbers mean Median eGFR and CRT, respectively in each 
study group 
 
 
 
Study groups N 
eGFR a 
ml/min/ 
1.73m2 
CRT b 
µmol/l 
HC 19   
Tol-DF 11 
76.2   
(58-69) 
97         
(88-119) 
s-LP 12 
59.1   
(41-70) 
118.3 
(107-41) 
s-nCNI 10 
64.2   
(59-74) 
101.5       
(87-121) 
s-CNI 29 
56.3   
(49-63) 
115       
(106-127) 
CR 9 
19.0   
(13-31) 
312     
(208-382) 
Total number 71 
58.1   
(43-70) 
117       
(98-143) 
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4.6.  Summary of results 
Various combinations of my data and that from all other partcipanting laboratories were 
studied to determine the combination with maximum sensitivity and specificity in 
identifying the Tol-DF group. When analysed in combination, it is possible to identify 
drug-free tolerant patients using: 
 
1. The signature of the top 9 most significant ‘tolerance signature’ genes, 
2. The ratio of B / T lymphocyte subsets, 
3. The percentage of CD25intCD4+, and 
4. The ratio of anti-donor to anti-third party ELISpot frequencies delivered a specificity 
of 0.964 and a sensitivity of 0.933. The positive predictive value (PPV) was 
increased to 82.4% band the negative predictive value (NPV) was 98.7%. 
 
While my data were very much in line with other data from this collaborative study they 
were not required for maximum sensitivity and specificity of tests to identify the Tol-DF 
group.   
4.7.  Discussion 
Kidney transplantation improves the survival of patients with renal failure. However, the 
use of immunosuppressive drugs causes an increased risk of both infection and 
malignancy plus a toll, mainly cardiovascular, related to other drug-specific adverse 
effects. Recent scientific advances hold out the prospect that the induction of tolerance, 
defined as state of donor-specific non-responsiveness in the absence of all 
immunosuppression, might be an achievable goal (Toungouz et al. 2003).  
Experimental animal studies have demonstrated that regulatory T cells, with the potential 
to suppress an anti-donor immune response, are present in both secondary lymphoid 
organs and the transplanted organ itself, indicating that immune regulation may occur at 
several sites. During immunological quiescence, regulatory T cells continuously 
recirculate among secondary lymphoid organs, blood, and the transplanted organ. In these 
compartments, the regulatory T cells may control both activation and expansion of donor-
reactive T cells, thereby preventing the induction of an immune response directed to the 
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donor antigens. However, when the anti-donor immune reactivity is escalating out of 
control and the recirculating regulatory T cells have failed to suppress the activation of 
effector T cells, a second line of regulation may be initiated: regulatory T cells migrate 
into the graft and adaptive regulators may develop in this compartment to control the 
damage of graft-destructive effector cells. (Dijke et al. 2008). The current view is that the 
‘functional’ state of immune responsiveness to an allograft represents a balance between 
the number of cells specific for alloantigens which have the intrinsic ability to proliferate 
in response to them and the number of regulatory cells holding them in check. 
Several approaches have been developed for measuring the frequency of T cells with a 
given specificity; the trans-vivo DTH assay (indirect pathway), ELISpot assays (direct 
pathway) and flowcytometry (Hernandez-Fuentes et al. 2003). These assays can be 
adapted to measure a variety of cytokines and can reveal the presence of regulatory cells 
in the responder population (Dozmorov et al. 1996). 
 
Donor-specific direct pathway hyporesponsiveness (CD4+ and CD8+ T cells) has been 
described in recipients of kidney (Mestre et al. 1996), heart (Hornick et al. 2000; Van 
Hoffen et al. 2000) or lung (de Haan et al. 2000) transplants. It has been found that this 
reduction in anti-donor frequency is most pronounced in memory cells due to their 
capacity to cross the vascular endothelium, and encounter the graft parenchyma (Baker et 
al. 2001). There have been several reports of raised frequencies of T cells with indirect 
allospecificity in patients with chronic rejection of heart (Liu et al. 1996; Suciu-Foca et 
al. 1998; Hornick et al. 2000), kidney (SivaSai et al. 1999; Hernandez-Fuentes et al. 
2003) and lung (Tugulea et al. 1997; Game and Lechler 2002) grafts. Some groups have 
measured direct and indirect responses in the same patients and it seems that direct 
pathway ant-donor responses diminish with time but raised frequencies of T cells with 
indirect anti-donor reactivity correlate with the presence of chronic transplant rejection. A 
population of T cells co-expressing CD4+ and CD25+ play a key role in the maintenance 
of experimental transplantation tolerance, and act as potent regulators of human 
alloresponses in vitro (Dijke et al. 2008). 
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None of these parameters have yet been found to have sufficient specificity and 
sensitivity for them to be of value in guiding the management of an individual patient. In 
the current study to which I have contributed, a set of biomarkers and bioassays were 
developed to distinguish between tolerant kidney transplant recipients from other patients 
with stable kidney function under different degrees of immunosuppression and other 
healthy controls. The goal of this study was to identify a pattern of immunological 
features which could define the tolerant state. 
 
By combining a number of parameters, outlined in the results section of this chapter, it 
has been possible to generate a combination of data that identify the “fingerprint of 
tolerance” with a reasonably high level of sensitivity and specificity.   
 
My contribution to this study was to ask if the detection of HLA-specific antibodies 
would help in generating an “immunological fingerprint” of drug-free kidney transplant 
recipients. Not surprisingly, patients in the CR group, who had the worst renal function, 
also had the highest prevalence of donor-specific anti-class I complement-fixing 
antibodies. Also as might be predicted, the Tol-DF group had the best function and the 
lowest association with DSA anti-class I and II. There appeared to be no association 
between the presence of non-donor-specific IgG subclass antibodies and graft function. 
Taken together, the data are compatible with the concept that the presence of 
complement-fixing DSA can contribute significantly to graft damage and possibly graft 
rejection even in the presence of immunosuppressive drugs. It also appears clear that in 
the Tol-DF group, the absence of DSA of complement-fixing type is a marker of better 
graft survival rate. These results may be used as an additional marker for tolerance and 
may help in identifying tolerant renal allograft recipients. This is an area of continuing 
investigation.  
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4.8.  Conclusion 
We now have a specific and sensitive set of reproducible laboratory assays which in 
combination appear to be capable of identifying tolerant renal allograft recipients. 
Validation of these biomarkers and bioassays can now be performed in a prospective 
study of drug weaning under careful supervision. 
  210
 
 
 
 
 
 
 
 
 
 
Chapter 5.   
Summary of Thesis 
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5.1. Discussion 
In this thesis I investigated the impact of the different IgG subclasses of HLA-specific  
antibodies and presence of memory B cells on transplant rejection/allograft survival.   
 
It is well established that there is a strong association between the production of HLA-
specific antibodies after transplantation and graft failure. For example, the presence of 
donor-specific complement-fixing HLA-specific IgG antibodies against donor HLA 
antigen class I or II, in pre-transplant serum, represents a contraindication for kidney 
transplantation and patients transplanted across this barrier are at high risk of graft 
rejection (Jordan et al. 2006). This indicates the importance of monitoring HLA-specific 
antibodies post-transplantation. Monitoring post-transplantation will improve the 
clinician’s ability to follow a patient’s ongoing humoral responses against an allograft 
and, more importantly, it may direct clinicians to optimize and/or minimize 
immunosuppressive drug therapy.  Previous studies showing a correlation between the 
IgG subclasses of HLA-specific antibodies and graft outcome, used ELISA and FCXM 
but, these assays have limited sensitivity.  X-MAP technology is now available to detect 
class I HLA- and class II HLA- specific antibodies present in pre-transplant patients’ sera 
at the time of transplantation.  I investigated the use and development of this technology 
in this thesis.  I found that using X-MAP technology was a more sensitive technique than 
FCXM or CDC assays for detecting low-level donor HLA-specific antibodies in pre-
transplant patients’ sera and I was able to extend the current scope of X-MAP technology 
assays to determine the IgG subclasses of HLA-specific  antibodies. 
 
Using X-MAP technology I analysed the significance of antibodies, undetectable using 
conventional techniques (CDC and FCXM assays) and found that patients with donor 
HLA-specific antibodies in pre-transplant sera had a higher incidence of rejection 
episodes and worse graft function than patients without donor HLA-specific antibodies.  
Consistent with this finding were the results I generated for the study of patients to define 
a state of tolerance (See section 4.3.1, page 193 for more details); most of the tolerant, 
drug-free recipients had no detectable levels of DSA (none of the training set tolerant 
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recipients, recruited by the IOT,  had DSA and only one recipient in the validation group, 
collected by the ITN, had DSA) whereas all other groups studied, had DSA, with the CR 
group showing the highest levels of DSA and the presence of DSA correlated with 
reduced graft function. 
 
Using the additional approaches outlined in this thesis it will potentially be possible to 
identify more clearly patients at increased risk of possible antibody-mediated rejection, 
patients who might previously have had unrecognised risk and therefore to act 
appropriately in therapeutic response.     
 
In addition to analysing antibodies in pre-transplant serum, recipient B cell responses are 
also important for determining graft rejection risk status.  It was previously known that 
the presence of memory B cells in transplant recipients may contribute to graft damage; 
pre-transplant B cell sensitization, in the absence of circulating antibody, represents a risk 
factor, since grafts transplanted into recipients with historical positive but current 
negative direct cross-match do less well than patients with no evidence of B cell 
sensitisation (no DSA in pre-transplant serum). These data suggest that even in the 
absence of low level antibodies, at the time of transplant, there may still be undetected B 
cell sensitization. However, this definition of ‘negative’ is based on conventional assays 
such as the LDA, haemolytic PFA and ELISpot assays, developed to quantitate B cell 
responses.  The IgM and IgG-detecting ELISpot assays that I developed, to determine the 
frequency of antibody-secreting cells, could be used in the clinic to improve the detection 
of patients with the potential to develop DSA; by testing, pre-transplant, for the presence 
of memory B cells with the ability to produce DSA in response to donor cells.  
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5.2. Future plans 
This thesis describes the development of ELISpot assays and X-MAP technology assays 
that improve the sensitivity of pre-transplant screening for recipients with HLA-specific  
antibodies.  It would be very useful to expand the patient numbers using live donor pre-
transplant and to study post-transplant samples to identify and follow humoral rejection.  
Furthermore, the scope of the investigation could be greatly increased to include studying 
the presence of DSA in pre-transplant and post-transplant sera (only pre-transplant was 
studied here), both CFA and NCFA, to correlate their presence with graft outcome.  It 
would also be interesting to look at patients who have had an antibody-mediated rejection 
episode in the first ten days following transplantation (I predict that donor specific 
memory B cells would be present), patients who have had their first  antibody-mediated 
rejection episode after the first three weeks following transplantation (I predict a high 
level of naïve antigen-specific B cells, implying a de novo B cell response) and patients 
who have never had an antibody-mediated rejection episode (I predict the detection of 
only very low levels of naïve, memory B cells and plasma cells) as this would give us 
more information about the temporal nature of the B cell response post transplant and 
how the response contributes to changes in graft function and survival and thus may 
reveal avenues for new therapies or improvements for current therapies. 
 
These assays could be added to the current arsenal of pre-transplant tests to enhance 
donor and recipient matching (which one would predict will improve transplant 
outcomes) and to improve the treatment of transplant recipients (improving monitoring of 
patients should allow optimisation of immunosuppressive drug regimes).  
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